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Abstract 
Introduction 
Intravenous thrombolysis in acute ischaemic stroke with alteplase improves clinical 
outcomes, but it has limited efficacy and is associated with increased risk of intracranial 
haemorrhage. An improved tissue plasminogen activator, tenecteplase, was evidenced to 
be at least equally effective with lower risk of haemorrhage in acute myocardial infarction 
thrombolysis. To date, two completed phase II randomised controlled studies comparing 
tenecteplase and alteplase in acute ischaemic strokes showed variable results. 
Methods 
A literature review of thrombolytic agents used in myocardial infarction and acute 
ischaemic stroke was performed, followed by a retrospective investigation of the bolus-
to- infusion delay of alteplase administration.  
The main focus of this thesis is the report of our single centre phase II randomised 
controlled trial that compared tenecteplase (0.25mg/kg, maximum 25mg) and alteplase 
(0.9mg/kg, maximum 90mg, 10% as the initial bolus, following by one hour infusion with 
the rest of the dose) in acute ischaemic stroke thrombolysis using advanced imaging as 
biomarkers. Imaging comprised baseline computed tomography (CT), CT perfusion (CTP) 
and CT angiography (CTA), and CT+CTA at 24-48 hours. The primary end-point was 
penumbral salvage (CTP-defined penumbra volume minus follow-up CT infarct volume). 
A sub-study of coagulation and fibrinolysis analysis of the two agents was performed by 
comparing a group of coagulation variables measured pre-treatment, 3-12 hours, and 
24±3 hours post thrombolysis. 
An individual patient data (IPD) meta-analysis was carried out using all three completed 
tenecteplase/alteplase comparison studies in stroke thrombolysis. We compared clinical 
outcomes including modified Rankin scale at 3 months, early neurological improvement 
at 24 hours, intracerebral haemorrhage rate and mortality at 3 months between all three 
tenecteplase doses (0.1mg/kg, 0.25 mg/kg, and 0.4mg/kg) examined and standard 
   
 
3 
 
alteplase.  Imaging outcomes including penumbra salvage, recanalisation rates were also 
compared using the data from the two studies that had advance imaging carried out. 
Results 
Delay between the initial bolus and the subsequent infusion in administration of alteplase 
is common. This may reduce the likelihood of achieving a good functional outcome. 
Among the 104 patients recruited in ATTEST trial, 71 contributed to the imaging primary 
outcome. No significant differences were observed for penumbral salvage [68 (SD 28) % 
tenecteplase vs 68 (SD 23) % alteplase], mean difference 1% (95% confidence interval -
10%, 12%, p=0·81) or for any secondary end-point. The SICH incidence (1/52, 2% vs 2/51, 
4%, by SITS-MOST definition, p=0·55; by ECASS-2 definition, 3/52, 6% tenecteplase vs 
4/51, 8% alteplase, p=0.59) did not differed significantly. There was a trend towards lower 
ICH risk in the tenecteplase group (8/52 tenecteplase, 15% vs 14/51 alteplase, 29%, 
p=0·091). 
Compared to baseline, alteplase caused significant hypofibrinogenaemia (p=0.002), 
prolonged Prothrombin Time (PT) (p=0.011), hypoplasminogenaemia (p=0.001) and lower 
Factor V (p=0.002) at 3-12 hours after administration with persistent 
hypofibrinogenaemia at 24h (p=0.011), while only minor hypoplasminogenaemia 
(P=0.029) was seen in the tenecteplase group. Tenecteplase consumed less plasminogen 
(p<0.001) and fibrinogen (p=0.002) compared with alteplase. 
In a pooled analysis, tenecteplase 0.25mg/kg had the greatest odds to achieve early 
neurological improvement (OR [95%CI] 3.3 [1.5, 7.2], p=0.093), excellent functional 
outcome (mRS 0-1) at three months (OR [95%CI] 1.9 [0.8, 4.4], p= 0.28), with reduced 
odds of ICH (OR [95%CI] 0.6 [0.2, 1.8], P=0.43) compared with alteplase. Only 19 patients 
were treated with tenecteplase 0.4mg/kg, which showed increased odds of SICH 
compared with alteplase (OR [95% CI] 6.2 [0.7, 56.3]). In the two studies where advanced 
imaging was performed, the imaging outcomes did not differ in the IPD analysis. 
Conclusion 
Tenecteplase 0.25 mg/kg has the potential to be a better alternative to alteplase. It can 
be given as a single bolus, does not cause disruption to systemic coagulation, and is 
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possibly safer and more effective in clot lysis. Further phase III study to compare 
tenecteplase and alteplase in acute ischaemic stroke is warranted. 
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Chapter 1 Introduction 
Traditionally, Stroke was defined as a syndrome characterised by rapidly developing 
neurological deficits attributed to an acute focal injury to the central nervous system 
secondary to a vascular cause that lasts more than 24 hours1, including ischaemic stroke, 
Intracerebral Haemorrhage (ICH) and Subarachnoid Haemorrhage (SAH). However, 
advances in imaging confirmed that permanent brain tissue damage can occur even when 
symptoms resolve fully in less than 24 hours. Driven by the development in hyperacute 
stroke management, an updated definition of ischaemic stroke has recently been 
published by the American Stroke Association, in which cerebral, spinal and retinal 
infarction based on imaging evidence were included, along with recognised clinical and 
pathology evidence2. 
1.1. Stroke epidemiology 
Stroke is the second leading cause of death worldwide in the adult population, and the 
fourth leading cause of disease burden (as measured in disability – adjusted life years)3. 
Ischaemic stroke comprises more than 80% of all strokes in Western countries4. Over the 
past four decades, age adjusted stroke incidence rates decreased by 42% in high-income 
countries, whereas it more than doubled in low to middle-income countries according to 
a recent systematic review5. However, this comparison was made with a relatively small 
proportion of all studies included from limited geographic regions and countries at 
different times. As an age dependent disease, it has been predicted that the number of 
strokes will increase in parallel with the increasingly aged population6. 
Risk factors for stroke are divided into two categories. Old age, male gender, family 
history of stroke, and low birth weight are non-modifiable risk factors. Although it is well 
known that ICH is more frequent in China7, and that SAH is more common in Finland and 
Sweden8, no particular ethnic pattern is observed in stroke mortality globally9. The 
traditional modifiable risk factors, such as diabetes, hypertension, smoking and atrial 
fibrillation account for 60-80% of population attributable risk for ischaemic strokes10. 
More recently identified risk factors including waist-to-hip ratio, ratio of apolipoprotein 
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(Apo) B to A1, diet, physical activity, psychosocial stress and depression, along with the 
traditional factors, account for more than 90% of all strokes11. 
1.2. Aetiology of ischaemic stroke 
The aetiology of ischaemic stroke can be largely classified into atherosclerosis, 
cardioembolic and lacunar syndrome resulting from small vessel occlusion12. In published 
large stroke registries, 25-39% of ischaemic strokes never had their definite causes 
identified13. This group of strokes is known as cryptogenic stroke. The proportion of this 
type of stroke is nevertheless decreasing due to the wide use of improved diagnostic 
tools, (e.g. Magnetic Resonance Angiography [MRA], Computed Tomography Angiography 
[CTA], Transoesophageal Echocardiogram [TOE]), and prolonged cardiac monitoring) and 
raised awareness of early investigation. Extracranial carotid and vertebral artery 
dissection account for only 2% of ischemic strokes overall, but in the less than 45 years 
old age group, dissection is responsible for approximately 20% of ischaemic strokes14. 
Other rare causes of ischaemic stroke such as vasculitis, and hypercoagulopathy account 
for less than 5% of strokes12. Positive anti-phospholipid antibodies, which can be present 
in more than 40% of ischaemic stroke patients may not have any clinical significance, and 
have not been shown to increase the risk of stroke reoccurrence15. 
Atherosclerosis is the most common pathology causing the occlusion of intra and 
extracranial arteries. The development of atherosclerosis is a chronic process which is 
caused, or at least accelerated partly by hypertension, smoking, diabetes and 
hyperlipidaemia16. The commonest sites affected by atherosclerosis that are relevant to 
stroke are the carotid bifurcation and the vertebral artery origins17. 
The risk of major thrombotic and thromboembolic complications of atherosclerosis is 
related to the stability of the plaque rather than the severity of stenosis18. Patients with 
irregular or ulcerated plaques on carotid angiography have higher risk of ischaemic stroke 
irrespective of the degree of stenosis of the vessel lumen19,20. The key feature of rupture-
prone unstable plaques are a thinned fibrous cap overlying a large necrotic core in the 
setting of active inflammatory infiltration21. Breakdown in the fibrous cap or plaque 
erosion, allows the intensely pro-coagulant lesion centre to contact the flowing blood, 
resulting in acute thrombosis22. 
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Atherosclerosis can lead to ischaemic stroke either via complete occlusion of intracranial 
carotid artery (ICA) with a thrombus resulting from the sluggish blood flow in the 
progressive narrowing of ICA (atherothrombosis), or “artery to artery” embolism – the 
thrombus embolises to block a more distal artery (atherothromboembolism)23. 
Emboli from cardiac sources are mainly from the left heart. The Trial of ORG 10172 in 
Acute Stroke Treatment (TOAST) classification12 grouped cardiac sources of embolism into 
high and medium risk. High risk groups included Atrial Fibrillation (AF), sick sinus 
syndrome and coronary artery disease related conditions, while Patent Foramen Ovale 
(PFO) was classified as in the medium risk group. PFO is found in approximately 50% of 
cryptogenic strokes, but one third of them may be incidental24. Furthermore, the risk of 
stroke recurrence may not be significantly higher for patients with PFO compared to 
those without PFO25. Besides, no study to date has demonstrated that percutaneous PFO 
closure is superior to medical management26,27. 
1.3. Cerebral Blood Flow (CBF) and pathophysiology of Acute Ischaemic 
Stroke (AIS) 
1.3.1. Physiology of CBF 
The human brain has a high energy demand, and uses glucose as the main substrate of 
energy supply. Unable to store energy, a constant supply of oxygenated blood is required 
to meet the high metabolic demand. A healthy adult’s CBF is about 50-55 mL/100g of 
brain/min, 800 mL/min for the whole brain. The values of CBF differ among different 
parts of the brain. Grey matter (75 mL/100g/min) has a higher rate of CBF than white 
matter (45 mL/100g/min). A well-developed intracranial collateral circulation and 
physiological response (cerebral autoregulation) constitutes the protective mechanism 
against cerebral ischaemia. 
1.3.2. Autoregulation 
In a physiological condition, CBF is determined by the Cerebral Perfusion Pressure (CPP) 
and by the Cerebrovascular Resistance (CVR) imposed by blood viscosity and the size of 
the intracranial vessels. When resting CPP is constant, CBF is closely matched to the 
metabolic demands of the brain tissue. Therefore, CBF, Cerebral Blood Volume (CBV), 
Cerebral Metabolic Rate of Oxygen (CMRO2) and Cerebral Metabolic Rate of Glucose 
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(CMRglu) are all coupled28. Under normal conditions, the brain has the ability to maintain 
CBF at a relatively constant level despite the change of CPP, which is termed  
“autoregulation”29. 
When AIS occurs, the occluded vessel causes a fall in CPP which can initially be 
compensated by autoregulation by dilatation of the collateral and distal vessels, increased 
CBV, and reduced CVR. When the mean arterial pressure falls below  40-50 mmHg (Figure 
1-1.), compensatory mechanisms become exhausted, CBF falls along with Blood Pressure 
(BP), and cerebral ischaemia occurs30. At this stage, oxygen supply to the brain is still 
adequate to maintain usual metabolic activities by increasing the oxygen extraction from 
blood, a stage termed “misery perfusion”31. Once CBF falls below 20 mL/100g brain/min, 
Oxygen Extraction Fraction (OEF) becomes maximal, and CMRO2 begins to fall32. 
 
Figure 1-1. Flow metabolism and perfusion pressure diagram under the 
physiological and pathological condition. Reproduced from “Pathophysiology 
of brain ischaemia as it related to the therapy of acute ischaemic stroke” 
Clinical Neuropharmacology 1990
33
 
The autoregulatory curve shifts to the right in chronic hypertension34. This population is 
therefore potentially more vulnerable to cerebral hypoperfusion if blood pressure is 
reduced aggressively. Similarly, an ischaemic brain with impaired autoregulation may be 
particularly vulnerable to hypoperfusion. If BP is aggressively controlled, it is potentially 
subject to further ischaemia. 
Many studies have examined the steady-state and dynamic components of cerebral 
autoregulation in acute ischaemic stroke settings using various imaging modalities 
(Transcranial Doppler [TCD], Single-Photon Emission Computer Tomography [SPECT] or 
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Positron Emission Tomography [PET]). None has shown clear evidence of global impaired 
autoregulation in acute ischaemic brains, except perhaps in infarcted tissue35,36. 
1.3.3. Mechanisms of neuronal injury and neuronal death in ischemic 
brains 
At the molecular level, the development of ischaemic neuronal injury is complex and 
heterogeneous. At the early stage of ischaemia, in the worst affected region with energy 
depletion, the process “excitotoxicity” is triggered to cause acute cell death (necrosis), 
and to initiate molecular events that lead to apoptosis, a delayed type of neuronal death 
which mainly occurs in penumbral tissue37. Glutamate that acts as a gateway for this 
complex cascade accumulates in the extracelluar space in energy depleted neurones, 
leading to the opening of the calcium channel and an influx of calcium, which is 
aggravated by the activation of N-methy1-D-asapartate (NMDA) and Alpha-amino-3-
hydroxy-5-methyl-4-isoxanolepropionic Acid (AMPA) receptors. Influx of sodium ions 
results in the passive increase of water intracellularly, which results in the subsequent 
cerebral oedema, a major factor which contributes to early death in AIS. 
The overload of neuronal calcium is related to a series of post-ischaemic inflammatory 
responses by releasing cytokines, such as Tumour Necrosis Factor Alpha (TNFα) and 
interleukin-1β; the expression of adhesion molecules on to endothelium; the migration of 
leucocytes, macrophages and monocytes into the ischaemic brain further contribute to 
ischaemia37. 
Repeat repolarisation and depolarisation is observed in the penumbral region, which is 
associated with infarct growth38. This phenomenon is called “peri-infarct 
depolarisations”39. 
Apoptosis, programed cell death, is linked with caspase activation37, that cleaves protein, 
and  modifies homeostasis and proteins which are directly responsible for cell death. 
1.3.4. The Neurovascular unit (NVU) 
The NVU has become an increasingly recognised concept in AIS pathophysiology. 
Comprising of neurones, interneurones, astrocytes, basal lamina covered with smooth 
muscular cells and pericytes, endothelial cells and extracellular matrix, it is considered the 
functional structure that interconnects neurones and the capillary vasculature, and that 
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plays an important role in the regulation of CBF40,41. Ischaemic injury to the brain can 
damage many components of the NVU42 (Figure 1-2.) 
 
Figure 1-2. Schematic model of neurovascular mechanism of postischemic 
reperfusion injury. Reproduction from “Revisiting cerebral postischaemic 
reperfusion injury: new insights in understanding reperfusion failure, 
haemorrhage, and oedema” International Journal of Stroke 2015
42
 
An animal study43 showed that the reperfusion of an ischaemic brain induced an 
excessive amount of autophagy accumulation within endothelial cells in the stroke rat 
model, which may result in cell death by degrading the normal cell component44. 
Pericytes are contractile cells that have functions similar to smooth muscle cells that can 
regulate CBF by constricting or dilating the capillaries45. Ischaemia leads to constriction 
and death of pericytes, which may irreversibly constrict capillaries and damage the Blood 
Brain Barrier (BBB)45. The role of astrocytes in acute ischaemia and stroke recovery 
differs. In the acute post ischaemia phase, astrocytes promote neuronal death by 
transporting and releasing inflammatory factors46, whereas in stroke recovery, they are 
cytoprotective by increasing cellular proliferation and facilitating the neurovascular 
remodelling47. Continuing efforts have been made to developed strategies targeting non-
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neuronal components of the NVU in AIS, but, in clinical studies, neuroprotection has not 
shown any benefit. 
1.3.5. Ischaemic Penumbra 
In the presence of an arterial occlusion, the downstream CPP falls below the capacity of 
cerebral autoregulation, and CBF continues to fall passively along with CPP as a result. 
Critical CBF thresholds were established in nonhuman primates and human studies48-50 to 
describe discrete stages of tissue ischaemia. These findings formed the basis for the 
concept “ischaemic penumbra”. Astrup and colleagues51 described “penumbra” as 
severely ischaemic, functionally impaired brain tissue that is at risk of infarction. Its fate 
depends on whether CBF is restored timeously, either to be salvaged or to progress to 
infarction. The original concept52 that the ischaemic area comprises of a central 
homogenous core tissue surrounded by a potentially salvageable penumbra provides the 
theoretical foundation for thrombolysis. This notion has been refined recently to the 
extent that what was believed to be the homogenous core probably contains pockets of 
“mini-cores” and “mini-penumbras” in the early minutes of ischaemia which evolve 
dynamically and heterogeneously depending on local differences in microvessel 
perfusion53. 
Ischaemic brain tissue is arbitrarily divided into three stages using physiological and 
metabolic parameters: an ischaemic core, penumbral tissue and an area of benign 
oligaemia (the area that is mildly hypoperfused , but not at risk of infarction)54,55. Except 
for CBF and electrophysiological parameters, characteristics of penumbra tissue can be 
described at the molecular level, and include decreased protein synthesis that can 
recover; preserved Adenosine Triphosphate (ATP) concentration; synthesis of heat-shock 
proteins; and possibly a successful unfolded protein response53. Clinically, the 
combination of core and penumbral volume correlates better with neurological deficits 
than do each of them individually56,57; the salvage of penumbra is highly correlated with 
neurological improvement56,58. 
The penumbra is dynamic; its fate is influenced by many factors: 
Time: Timely reperfusion is the crucial principle in AIS management. Without reperfusion, 
penumbra tissue will ultimately become irreversibly damaged, although exceptions exist 
in that some penumbra appears to be preserved for up to 24 hours or more54,59. In most 
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cases, the entire region of the penumbra is recruited into core within 6 hours. The natural 
history of AIS suggests that in each minute after a stroke, without treatment, 1.9 million 
neurones die60. The importance of time in AIS management is evidenced by the failure of 
early thrombolysis studies in which patients were treated late. Thrombolysis in stroke 
only became a success when the time issue was addressed in the National Institute of 
Neurological Disorders and Stroke (NINDS) study. The meta-analyses to date and the 
evolution of intra-arterial studies repeatedly proved time is the key. 
Collateral circulation: With intracranial or extracranial occlusion, collateral supply is the 
only way to perfuse the ischaemic tissue, which will be discussed in detail below. 
Temperature:  Hyperthermia is associated with worsening brain injury in the ischaemic 
brain61. In an animal model of Middle Cerebral Artery (MCA) occlusion, a rise of body 
temperature of three degrees increased infarct volume threefold histologically62. An 
experiment with hypothermia therapy63 as a neuroprotective strategy is underway in a 
phase III study. 
Hyperglycaemia: It is established by many studies that hyperglycaemia is associated with 
poor functional outcomes and infarct growth in AIS64-66. The risk of death and ICH is 
higher even with mildly raised serum glucose levels post stroke67. However, aggressive 
blood glucose control in AIS has not demonstrated any improvement in functional 
outcomes. On the contrary, it increases the risk of hypoglycaemia68. In a Magnetic 
Resonance Imaging (MRI) spectroscopy study65, acute hyperglycaemia was associated 
with greater lactate production irrespective of baseline diabetes status, which in turn, 
was independently associated with reduced salvage of penumbral tissue. 
Age: Age is one of the unmodifiable risks for stroke. Recent literature69,70 confirmed that 
elderly patients benefit at least as much as younger patients from IV rtPA. However, older 
patients do suffer from more severe strokes, and have poorer outcomes71. A recent 
study72 using whole brain CT perfusion to examine penumbra in acute ischaemic stroke 
suggested age is negatively correlated with penumbra volume despite similar 
haemodynamics and better recruitment of collaterals. Animal73 and human74 studies 
indicated the alternation of autoregulation with aging. There may be an intrinsic tissue 
process with aging that influences penumbra. 
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1.3.6. Brain oedema and reperfusion injury 
Both animal75 and human76 studies have now firmly established that reperfusion of the 
ischaemic but potentially salvageable region timeously, causes marked infarct volume 
reduction. Delayed reperfusion into the already infarcted area is considered to be harmful 
and  potentially fatal by inducing haemorrhagic transformation, and worsening cerebral 
oedema, a concept named “reperfusion injury”77. 
The mechanism involved in reperfusion injury is a complex process with multiple parallel 
and crosslinked pathways involved. During early ischaemic injury, cytotoxic oedema 
develops as the consequence of cellular dysfunction. The influx of calcium after the 
depolarisation of cell membrane results in an accumulation of intracellular calcium and 
lipolysis. Once delayed reperfusion occurs, the lipolytic break down products react with 
oxygen, producing large amounts of reactive oxygen species which are involved in 
mitochondrial mediated cell death42. In addition, protein synthesis is suppressed in 
vulnerable neurons. Post ischaemic reperfusion worsens the disruption of BBB 
permeability, possibly by reintroducing blood flow, increased production of free radicals, 
and matrix metalloproteinases mediated attack on the basal lamina in cerebral 
capillaries78, which results in vasogenic oedema. In addition, neurotoxicity, 
neuroinflammation and leucocyte recruitment also play a role in causing haemorrhagic 
transformation79 (Figure 1-3.). 
 
Figure 1-3. Simplified schematic representing the multiple cascades of tissue 
injury that are initiated after hemorrhage (Reproduction from “Triggers and 
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mediators of haemorrhagic transformation in cerebral ischemia” Molecular 
Neurobiology 2003
79
) 
 
1.3.7. Collateral circulation 
Leptomeningeal vessels provide alternative routes for CBF in acute arterial occlusions80. 
Good collateral status is associated with better clinical outcomes after acute ischaemic 
strokes, higher rates of recanalisation, better reperfusion and less infarct growth81-83. 
Patients with proximal MCA occlusion who had adequate collateral flow did as well as 
those with no visible occlusion, while patients with occlusion and absent collaterals had a 
10-fold increased risk of severe worsening measured with the National Institute of Health 
Stroke Scale (NIHSS) score, or death82. Poor pial collateral status is an independent 
predictor for post thrombolysis haemorrhage in intra-arterial therapy84. The effectiveness 
of collateral flow varies significantly in acute ischaemia. The mechanism of vasculogenesis 
remains unclear. Animal studies have suggested genetic and environmental factors may 
play a role85, as does vascular endothelial growth factor86. In humans, it was noted that 
elevated pre-treatment systolic blood pressure and a history of hypertension are 
associated with poor collateral status87; the use of Statins enhances collateral supply, 
possibly by increasing nitric oxide synthesis and endothelial progenitor cell growth88. 
Chronic progressive atherosclerotic disease affecting cerebral perfusion allows collateral 
recruitment over time89,90. Hyperglycaemia may also reduce collateral flow80. Collateral 
flow is dynamic. Following arterial occlusion, there seems to be a time-dependant 
recruitment of collateral flow, especially within the first hour of post-ictal, although the 
ability and speed varies considerably82. 
1.3.8. Imaging penumbra 
Penumbra is defined with neurophysiological and metabolic characters as discussed 
above. As the only non-invasive imaging modality that provides quantitative 
measurements of physiological and metabolic parameters including CBF, OEF, regional 
cerebral metabolic rate of oxygen and glucose, PET has been used initially to map the 
human penumbra and subsequently has become the gold-standard for verification of 
MRI-based Perfusion Weighted Imaging (PWI) and CT perfusion (CTP). The absolute flow 
values for thresholds established in humans vary among different research groups91, 
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partly because the determination of values requires arterial blood sampling, and partly 
because of the variability in measurements of tracer concentration. The time of the 
measurement post-ictus is another essential factor contributing to the variability54. 
Flumazenil, a central benzodiazepine receptor ligand that binds to the Gamma-
aminobutyric Acid (GABA) receptor is later used as a PET marker of neuronal integrity54 . 
It can identify ischaemic changes without invasive arterial sampling, and is not affected by 
time after itcus or variability in blood flow. The method can map the early ischaemic 
change more accurately if combined with the use of H2
15O to determine flow. In a study92 
which imaged 10 patients within 2-12 hours of stroke symptoms onset, flumazenil binding 
thresholds of 3.4 identified ischaemic core, and CBF <14.1mL/100g/min defined 
potentially salvageable tissue – the penumbra. The complexity and restrictions on the 
availability of PET nevertheless prevents its use in acute stroke management clinically. It 
remains a research tool. 
1.4. Advanced imaging in acute ischaemic stroke 
Current guidelines93 advise that decision making for Intravenous (IV) thrombolysis should 
be based on clinical diagnosis of acute ischaemic stroke and non-contrast Computed 
Tomography (NCCT) excluding ICH93, but diagnosis of stroke cannot always be achieved 
directly from clinical information. Advance multimodal imaging has been used in many 
centres to improve the sensitivity and specificity of stroke diagnoses and provide essential 
information to aid decision making and predict outcomes. Both multimodal MRI and CT 
are used as clinical and research tools; each has its advantages and limitations. In 
particular, there are unsolved issues in PWI-MRI and CT perfusion, and further validation 
is required94. The combination of NCCT/ Diffusion Weighted Imaging (DWI), angiogram 
and perfusion imaging addresses the crucial questions in IV thrombolysis decision-
making: the presence of haemorrhage, the occlusion site, and the extent of irreversible 
and reversible tissue injury. 
1.4.1. Magnetic resonance imaging 
1.4.1.1. Diffusion Weighted Imaging 
DWI measures the random Brownian motion of water molecules within a voxel of tissue. 
As a result of arterial occlusion, cytotoxic oedema develops due to the increase of 
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intracellular water causing a restriction of water molecule diffusion, which is evident as a 
reduced Apparent Diffusion Coefficient (ADC) on the ADC map, and a hyperintensity on 
DWI95,96. DWI is very sensitive in detecting early ischaemia (probably greater than 95% 
within the first hour). It is positive as early as two minutes after ischaemia in experimental 
animals and 40 minutes in humans97, and can readily discriminate acute ischaemia from 
chronic ischaemia. The DWI signal gradually decreases over 7-10 days post stroke, 
therefore needs to be performed quickly in order to identify acute stroke. DWI can also 
be positive in pathologies such as focal seizures, encephalitis and migraines, but only an 
acute infarction causes a bright signal on DWI and a dark area on the corresponding ADC 
map. 
The positive DWI lesion in AIS within the first few hours of symptoms onset is considered 
to represent ischaemic brain tissue that is irreversibly damaged (the ischaemic core). It is 
recognised that some DWI lesions may be reversible98, especially if CBF is restored 
timeously, but this is rare, the extent of tissue reversal is small, and rarely alters the 
DWI/PWI mismatch ratio99,100. 
1.4.1.2. Perfusion weighted imaging and Arterial Spin Labelling (ASL) 
Hypoperfused brain tissue can be imaged using PWI, which is obtained by bolus tracking 
the passage of IV gadolinium contrast. The DWI/PWI mismatch was hypothesised to 
represent core/penumbra101 mismatch. PWI identifies penumbra with high sensitivity, but 
tends to overestimate penumbra by including benign oligaemiac tissue102,103. The 
parameters proposed to identify an optimal threshold accurately defining PWI lesion 
remain variable, and most of them were not prospectively evaluated104. Currently, Time 
to Maximum (Tmax)>5-6 seconds defines “tissue at risk” most accurately105-107 . 
PWI is the most validated penumbra imaging method against PET. Many clinical studies 
use MRI to evaluate penumbra; however, about 10 – 15% of patients suspected of acute 
stroke cannot undergo MRI because of contraindications108. The duration of scanning is 
long, and may not be tolerated by those with severe symptoms; where scans are possible, 
the quality of imaging is often suboptimal. 
ASL imaging evaluates brain perfusion by using radiofrequency pulses labelling the 
protons in arterial blood as an endogenous contrast, and therefore does not require IV 
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contrast. It has the potential to replace PWI, but has the disadvantages109 of low signal to 
noise ratio, limited spatial resolution, and is a time consuming sequence to quantify tissue 
blood volume. Higher magnetic field MRI significantly improves the quality of ASL. As a 
relativly new technique, it lacks standardisation of acquisition, post-acquisition 
optimisation and automation. Compared with PWI, it overestimates hypoperfused 
tissue110,111 by underestimating CBF when there is a delay in contrast arrival. One study110 
suggested a threshold of CBF<40% for defining penumbra correlates well with Tmax>6s in 
PWI imaging. 
1.4.1.3. T2 Fluid-attenuated Inversion Recovery Imaging (FLAIR) 
T2 FLAIR reveals an infarcted area as a hyperintensity area by suppressing the Cerebro-
Spinal Fluid (CSF) signal, and is more sensitive to detecting small infarcts adjacent to CSF 
spaces compared to conventional T2 sequencing. In contrast to DWI, the bright signal on 
FlAIR in AIS appears 3-6 hours post stroke112, hence these signals are used as “a tissue 
clock” when the stroke onset time is unclear. The hyperintense vessel sign on FLAIR is an 
indicator of insufficient collateral circulation113, has a high specificity (86%) for predicting 
proximal vessel occlusion, and is associated with a larger ischaemic lesion and clinically 
more severe strokes113,114. 
1.4.1.4. Magnetic resonance angiography (MRA) 
MRA can be acquired as Time of Flight (TOF) imaging or post gadolinium contrast imaging 
including intracranial and extracranial vessels. Compared with CTA, 3 Dimensional (3D) 
TOF imaging has the advantage of being non-invasive, but the acquisition time is much 
more prolonged, resulting often therefore in suboptimal quality. It is flow dependent and 
signal loss due to turbulent flow (stenosis) or slow flow may overestimate degree of 
stenosis. Gadolinium contrast MRA can be acquired rapidly, but has poor spatial 
resolution compared to TOF. As with CTA, MRA is a reliable alternative for the provision 
of vessel assessment to Digital Subtraction Angiography (DSA). 
1.4.1.5. Gradient Echo (GRE) and Susceptibility Weighted Imaging (SWI) 
Gradient Echo and SWI sequences are both blood sensitive sequences that are used to 
detect haemorrhage. GRE is sensitive to blood break down products, such as 
deoxygenated haemoglobin, and intracellular methemoglobin, haemosiderin within 
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perivascular macrophages, due to their paramagnetic effect that results in signal loss115. 
GRE can therefore detect micro haemorrhages that are not visible on NCCT, and is 
possibly comparable to NCCT in detecting acute ICH116. 
SWI was designed with the aim of enhancing contrast in MRI imaging. It provides 
identification of tissue which has a different susceptibility to its surrounding structure, 
including blood break down products and minerals117. It has higher sensitivity in detecting 
blood than GRE and NCCT118. Systematic reviews119-121 did not find the presence of micro 
haemorrhage to significantly increase the risk of post rtPA haemorrhage, although in the 
case of people with severe micro haemorrhages, who may have a significant higher risk of 
ICH, the evidence is lacking. 
The susceptibility sign on GRE and SWI122 indicating the presence of a proximal arterial 
clot has a high sensitivity (87%) and specificity (100%), and is the equivalent of a 
hyperdense vessel on NCCT.  
1.4.2. Multimodal CT imaging in acute ischaemic stroke 
1.4.2.1. Non Contrast CT 
In many parts of the world, NCCT is the only imaging undertaken in AIS patients prior to 
administering IV recombinant tissue Plasminogen Activator (rtPA). It is sensitive in 
excluding haemorrhage, some tumours and established infarcts. It measures X-Ray beam 
attenuation proportional to tissue density quantified in Hounsfield Units (HU), which are a 
linear density scale with water valued zero123. 
A normal CT does not exclude AIS. Hyperdense vessels on the lesional side and early 
ischaemic changes on NCCT assist diagnosis of AIS. The hyperdense vessel sign is highly 
specific for AIS (90-100%), but it only presents in approximately 30% of patients124. The 
sensitivity of detecting hyperdense vessels increases with thin slice CT125. Early ischaemic 
changes on CT are present in 60-80% of patients within three hours from symptoms onset 
in MCA strokes in thrombolysis studies126,127, but in practice, the inter-observer 
agreements were low for detection of hypodensity of more than 1/3 MCA territory. Using 
the Alberta Stroke Program Early CT score (ASPECT score)128, a systematic approach to 
NCCT interpretation that deducts a point for abnormality in each of ten defined regions at 
two levels of a scan, the intraclass correlation coefficient improved to 0.69-0.86129,130 
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from 0.14-0.49, but to achieve this, training is required. In contrast, CTP and CTA have 
consistently higher inter-rater agreement in ASPECT score readings130. DWI sequences 
can detect acute ischaemic change with high sensitivity within less than 40 minutes post-
ictus97, with the advantages of differentiating acute and chronic lesions without contrast, 
and the inter-rater agreements for experienced radiologist (К=0.84) and novel readers 
were similar (К=0.76)131. 
1.4.2.2. CT perfusion 
CTP is the most convenient imaging modality currently available to image tissue status. It 
can typically be acquired in 60-90 seconds. The large majority of CT scanners currently in 
service are still the generation limiting CTP to 2-4 cm coverage of brain; but the new 
generation of 16cm detector (“320-slice” or similar) CT scanners can provide whole brain 
coverage132. 
Compared with MRI, multimodal CT is much more widely available, less time consuming, 
and better tolerated with fewer contraindications. The use of iodine contrast may be 
limited in patients with impaired renal function. The occurrence of contrast induced 
nephropathy is generally low, being approximately 2-7 % in the stroke population who 
underwent acute evaluation with CTA regardless of whether baseline renal function was 
known prior to contrast scan133. If contrast scan is necessary, the risk of iodine contrast is 
smaller than that of gadolinium in patients with borderline renal function (estimated 
Glomerular Filtration Rate [eGFR] 45-60)134. 
There has been concern that the use of iodine contrast may impair the effectiveness of 
thrombolysis, or that the interaction between the contrast and alteplase may increase the 
risk of ICH. Neither has been proven to date.135,136 Ischaemic core and penumbra are 
included in the same map in CTP. Mismatch can be visualised directly by readers. 
CTP provides quantifiable information due to the linear relationship between the contrast 
concentration and CT attenuation , which is not achievable with PWI that relies on the 
non-linear T2 effect induced in adjacent tissues by high concentrations of intravenous 
gadolinium.134 
The disadvantages of CTP over MRI-PWI include limited coverage for most current 
scanners, radiation exposure and more complex post-processing. Acute stroke MRI 
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sequences can also detect microbleeds with GRE sequence or SWI, which is not 
achievable with CTP. 
CTP post-processing 
CTP imaging raw data requires post-processing to generate interpretable parametric 
maps. A few algorithms have been developed for this purpose, but resulting quantitive 
maps differ significantly137. New evidence suggested that a delay-corrected Singular Value 
Decomposition (SVD) method probably provides the most accurate quantification of core 
and penumbra138. 
An Arterial Input Function (AIF) is required for the calculation of CBF. The choice of AIF 
and laterality was shown to have no significant impact on the calculation of the CBF and 
CBV values139. In practice, contralesional Anterior Cerebral Artery (ACA) is the common 
chosen AIF in order to minimise partial volume effects that can arise from use of arteries 
in the plane of section. 
The accuracy of CBF calculation is based on the assumption that there is no delay or 
dispersion. In reality, significant AIF delay exists in clinical situations such as AF, severe 
carotid stenosis, poor left ventricular function, or proximal intracranial occlusion with 
poor collateral circulation. The presence of these result in underestimation of CBF and 
overestimation of Mean Transit Time (MTT)140, and hence overestimate the volume of 
penumbra. The overestimation can be minimised by using a delay-insensitive 
algorithm137, which also appears to be less sensitive to the laterality of AIF selection 
compared with the use of standard processing software141. 
Parameters used to define tissue status 
Multiple parameters derived from various post-processing algorithms have been 
proposed to define the ischaemic core and penumbra post-processing. Using CTP to 
assess tissue status quantitatively is much less studied than using MRI, and many of the 
available studies are not of good quality, with limited numbers of patients104. 
Recent evidence has emerged that CBF may be the more accurate measurement of non-
viable tissue142. The physiology of haemodynamic changes occurring in acute stroke 
supports the view that CBF may be a more desirable parameter for estimating the 
ischaemic core across different times post-ictus and recanalisation status134. Relative 
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values performed better than absolute values  due to the variability in normal values on 
the contralesional side134. The actual CBF value to define ischaemic core varies depending 
on the post-processing algorithms138,143. The other widely used parameter to define 
irreversible tissue is CBV144. CBV has the advantage over CBF of being relatively delay-
invariant145, and is not influenced by AIF selection146. However, the normal CBV value 
varies in each individual, the difference between the CBV values defining irreversible 
tissue and the normal white matter is small. An absolute CBV value to define core may 
not represent the true ischaemic core. 
It has been demonstrated that Delay Time (DT) may be a more accurate parameter to 
define critical hypoperfused tissue147. DT, which is similar to Tmax –- the current 
preferred parameter to define penumbra in PWI-MRI,148 is derived from a vascular 
transport model correcting for delay and dispersion, and may identify tissue at risk more 
accurately than Tmax147. The previously preferred variable MTT, although relatively 
reliable as its value does not differ significantly between normal white and grey matter, 
and is less likely to be affected by extracranial factors, still overestimates penumbra by 
including “benign oligaemia”, especially under the circumstances of poor cardiac function 
or severe extracranial carotid stenosis145. DT is nevertheless not a commonly used 
parameter in most post-processing software. To increase the reliability of defining 
ischaemic core and penumbra, standardised post-processing software such as “Rapid 
Processing of PerfusIon and Diffusion (RAPID)” is the necessary next step to develop the 
utility of CT perfusion in respect of clinical and large scale research. 
1.4.2.3. CT angiography 
The current most widely used protocol for CTA allows visualisation of vessels from the 
aortic arch to the vertex. Alongside the advantages of availability, low cost and fewer 
contraindications, a modern Multi-detector CT (MDCT) can perform CTA in less than a 
minute, and is therefore better tolerated than MRA, and is a preferred choice by 
patients.149 CTA provides true anatomic, non-flow dependent data in assessing the 
severity of stenosis, residual lumen diameters, and calcification. This is not achievable 
with flow-dependent imaging, such as MRA and Doppler Ultrasound (DUS). 
DSA is considered the gold-standard imaging modality for vasculature assessment. Its 
invasive nature and availability have ensured that it is mainly reserved for patients who 
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undergo interventional procedures. CTA is an excellent non-invasive alternative that can 
provide similar information. 
Endarterectomy in patients who have symptomatic significant ipsilateral extracranial 
carotid stenosis is a standard practice to reduce the risk for recurrent stroke93. DUS is 
most commonly used in practice to identify candidates likely to benefit from this 
procedure. There is no sufficient direct evidence to suggest whether CTA is superior to 
DUS in the evaluation of carotid stenosis, but a recent study comparing DUS, CTA, and 
MRA against DSA suggested that CTA is the most accurate modality for evaluating carotid 
stenosis and is significantly more accurate than DUS (97% vs. 76%)150. A systematic review 
suggested that with MDCT, the sensitivity and specificity of CTA to diagnose significant 
carotid stenosis is close to 100%151. The inter-observer agreement is much higher in CTA 
interpretation, while DUS is more operator dependant, and the result is less 
reproducible152. CTA is also superior to DUS in detecting plaque ulceration and vessel wall 
abnormalities153. 
1.4.2.4. The use of multimodal CT in clinical settings 
Stratification for ischaemic stroke and stroke mimics 
In many centres, CT perfusion is used in routine work-up for hyperacute stroke patients. It 
has a higher sensitivity in detecting stroke than NCCT, (77.6% vs. 69.2%; P< 0.01), with an 
improved specificity (75.6-92.7% vs.65%; P<0.01) and a much better rate of inter-
observer agreement154. Multimodal CT ( NCCT, CTP and CTA) improved the sensitivity for 
stroke determination by 18.2% over NCCT alone155. Using NCCT and clinical information 
only to make therapeutic decision, 1-16% of stroke mimics received IV thrombolysis 
depending on the experience of centres156. The SICH risk of treating stroke mimics may be 
low (approximately 1%)156, but improving the diagnostic accuracy and treating fewer 
stroke mimics is nevertheless still desirable. 
A small percentage of clinically diagnosed stroke patients have normal multimodal CT,  
mainly accounted for by lacunar or infratentorial strokes157. Lacunar infarcts of less than 
1.5cm in diameter are not reliably detectable by CTP, probably due to poor signal to noise 
ratio, with accompanying low spatial resolution158. Although limited coverage of CTP is 
thought to be responsible for reducing the sensitivity of CTP in detecting stroke, after 
   
 
48 
 
excluding infratentorial and lacunar stroke, the sensitivity of CTP in detecting stroke is 
94%157. 
CTA is highly sensitive and specific in detecting thrombi especially those within proximal 
large vessels. Compared with good standard DSA, CTA has a sensitivity of 98.4%, and a 
specificity of 98.1% for the detection of large vessel occlusion159. It has a higher positive 
predictive value than that of MRA for detecting both stenosis and occlusion160. 
CTA and MRA are comparable in the diagnosis of cervical arterial dissection161. A wide 
range of sensitivities have been identified in studies (60-100%). Arterial luminal 
irregularities are more commonly identified by CTA, whilst intramural haematoma is 
better detected by MRI when a cervical axial fat-suppressed sequence is included162. 
Predicting clinical outcomes 
Both hyperdense vessel signs and early ischaemic changes on NCCT also have prognostic 
value. Clot lengths measuring more than 8mm163 are unlikely to be recanalised by IV rtPA, 
and are therefore associated with poor outcomes, and has been used as one of the 
selection criteria for intra-arterial therapy164. Hypodensity on a plain CT correlates with 
ischaemic core on CTP165, PET166 and MRI DWI lesion167. This is an independent predictor 
of poor outcomes168, and a risk factor for Symptomatic ICH (SICH) if it is more than 1/3 of 
MCA territory169,170. 
Baseline infarct core volumes have been shown to be strongly correlated to the clinical 
outcome by multiple studies using various imaging modalities134. A core volume of > 
70mls, measured by DWI on admission is a strong predictor for a poor outcome 
regardless of the application of reperfusion therapy171. Core size is also the best predictor 
for clinical outcomes at three months172. 
The baseline core volume, along with the Onset-to-treatment Time (OTT), systolic high 
blood pressure, admission glucose level, and the initial NIHSS score are independent 
predictors for risk of haemorrhage following IV rtPA173. In the absence of hypodensity on 
the plain CT, regions with very low CBF174 or very low CBV 175,176 were found to be at high 
risk of haemorrhage post reperfusion therapy. 
The location of thrombus is independently associated with the clinical outcome and 
recanalisation status following IV rtPA. Proximal occlusion (distal ICA, M1, M2 or basilar 
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artery) has been demonstrated to be a significant independent predictor for poor 
outcome177. In addition, the combination of the clinical assessment (NIHSS score) and the 
CTA score is highly predictive. 77.6% of patients with NIHSS>10 and proximal occlusion 
had a poor outcome, compared with only 21.5% of patients with NIHSS<10 and distal or 
no occlusion on CTA (p<0.0001) regardless of treatment. Clinical meaningful 
recanalisation is significantly less likely in patients with proximal occlusions (ICA, p=0.005; 
proximal M1, p=0.021)178. Proximal occlusion generates a larger CBV defect; more of the 
penumbra can be salvaged if the occlusion is located distally179. In basilar strokes180 
treated with IV thrombolysis, the frequency of recanalisation was also location-
dependent, with top-of-basilar only clot significantly correlating with recanalisation 
(p=0.004). Distal small branch or perforating artery occlusions can be difficult to visualise 
on CTA. In this group of patients, a good clinical outcome is expected after IV rtPA 
treatment, and the associated risk of haemorrhage is much lower181. 
Except for the location of the thrombus, the extent of the clot is another significant 
contributor to the outcome of revascularisation therapy. Several clot burden scores have 
been developed providing a combined assessment of clot location and extent, which are 
independently associated with final infarct volume, clinical outcomes, and the risk of 
haemorrhage.177,182,183 Measuring clot length/burden nevertheless remains problematic 
using either CTA or NCCT. The outline of thrombus on CTA is highly dependent on the 
degree of collateral flow. The current standard CTA  is a single phase study. The lack of 
contrast opacification in distal arteries may represent delayed filling rather than 
intraluminal thrombus182. Although the hyperdense vessel sign is highly specific, the 
prevalence is less than 30% of the stroke population124, and its value in measuring clot 
burden is very limited. Furthermore, measurement is only possible when there is a 
segment of proximal hyperdense artery, rather than a dot sign in the M2 region. 
Current decision making for IV rtPA is still based exclusively on non- contrast CT184. 
Whether multimodal CT can be advantageous remains to be answered by a well-designed 
study that examines this hypothesis. Some experts argue that the combination of non-
contrast CT and CT angiography can provide enough information about tissue fate and 
outcomes81,185. A newly published retrospective study186 emphasised that CT perfusion 
adds a unique evaluation on the determination of penumbra, which cannot be obtained 
from either non-contrast CT, CT angiography or clinical assessment. Others worry that 
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multimodal CT assessment in a hyperacute stroke setting will defer the thrombolysis 
treatment. Our centre’s experience187 was that multimodal CT takes approximately 15 
minutes to acquire. Whether the post-processing, interpretation and subsequent decision 
making will delay IV rtPA significantly, and whether the benefit of extra knowledge gained 
from multimodal CT will outweigh the delay is being examined in the ongoing  Penumbra 
and Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation 
(PRACTISE) trial. 
Imaging based selection for reperfusion therapy candidates 
Despite much exciting research exploring new technologies or drug treatments in acute 
stroke, the only approved management currently remains  intravenous rtPA within 4.5 
hour from the onset of symptoms188. Because of the narrow treatment time window, only 
3% of European stroke patients received thrombolysis in 2005189. Although the benefit of 
extending IV rtPA up to 6 hours is unclear70, it is known that core/penumbra mismatch 
can persist for up to 24 hours from symptoms onset190. 
Advanced imaging with MRI or CT using probabilistic perfusion thresholds allows 
assessment of the extent of viable (penumbral) and non-viable (core) tissue, and it has 
been hypothesised that this may allow individualised treatment decisions, including 
delayed intervention in individuals with favourable brain imaging features191. The pioneer 
studies testing this hypothesis were the Diffusion and Perfusion Imaging Evaluation for 
Understanding Stroke Evaluation (DEFUSE)192 and Echoplanar Imaging Thrombolytic 
Evaluation Trial (EPITHET)193 studies, which demonstrated that in patients presenting 
within 3-6 hours from symptoms onset who had a “DWI/PWI mismatch” (i.e. where 
penumbra volume exceeds core volume by an arbitrarily defined ratio), early reperfusion 
is significantly associated with favourable clinical response. 
A small number of completed studies 184,192-198 have used penumbral mismatch to select 
patients, predominantly in extended time windows between 3-9 hours. Early meta-
analyses199,200 found that baseline favourable imaging features were better associated 
than unfavourable imaging features with increased recanalisation, reperfusion and better 
outcomes. However, functional outcomes did not differ from control (non-thrombolysed) 
groups, and treatment was associated with increased mortality and ICH risk. More 
recently, the Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy 
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(MR RESCUE) 196 study found no interaction between imaging features and treatment 
effect from delayed Intra-arterial (IA) thrombectomy: outcomes were good in those with 
good scans, and poor in those with poor scans, regardless of intervention. In contrast, 
MRI profile and response to endovascular reperfusion in the non-randomised DEFUSE 2 
study195 found that MRI “target mismatch” was associated with better outcomes 
following IA treatment. The populations in these two studies had very different 
characteristics (e.g. median core volume in MR RESCUE was 60mL compared with 15mL in 
DEFUSE 2), indicating different selection biases. Imaging parameters to define core and 
penumbra remain highly heterogeneous in published literature104 and better validated 
and platform-independent software tools201 are not yet in widespread use, although 
current MRI-based trials will test one of these. The Extending the Time for Thrombolysis 
in Emergency Neurological Deficits Study (EXTEND) (NCT00887328)202 uses the RAPID 
201software package in a 4.5-8h window. 
The optimal mismatch ratio also remains uncertain. In one of the first studies testing the 
imaging selection hypothesis,the DEFUSE study192, mismatch was arbitrarily defined as a 
PWI lesion volume ≥120% accompanied with a DWI lesion volume with a minimum of 
10mL of mismatch. A subsequent sub-analysis203 showed that favourable clinical outcome 
rates associated with early reperfusion are related to the degree of mismatch. However, 
the greater the mismatch ratio applied in patient selection, the fewer patients will be 
eligible for treatment. A ratio of 1.8 (ie perfusion lesion >180% of DWI lesion) was 
considered a better ratio to be applied in future studies as only 15% of patients would be 
excluded, while the ratio for good clinical outcomes would still be doubled compared with 
the mismatch ratio of 1.2. Other ongoing studies however, use different mismatch ratios. 
The European Cooperative Acute Stroke Study (ECASS)-4 (Eudra-CT: 2012-003609080) 
uses a mismatch ratio of 1.6 in its patient selection, while the Tenecteplase versus 
Alteplase for Stroke Thrombolysis Evaluation trial (TASTE)204 still uses the 1.2 mismatch 
ratio. Further research and validation are required to reach a consensus on the most 
suitable mismatch ratio. 
In addition, the absolute volume of penumbra and core was suggested to be a better 
criterion for the selection of candidates. Patients with “malignant profile”192 (baseline 
DWI lesion ≥100mL, and/or PWI lesion≥100mL with Tmax delay≥8 seconds) were 
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associated with SICH or poor outcomes following reperfusion therapy, despite the fact 
that a large mismatch ratio was present in this population. 
A post-hoc analysis of DEFUSE 2 data205 suggested that the assessment of occlusion sites 
and ischaemic cores size are sufficient in providing information for patient selection. In 
patients who had ICA or M1 occlusion and DWI lesion <50mL, reperfusion was associated 
with good outcomes (Odds Ratio [OR] [95% Confidence Interval [CI]] 8.5 [2.3-31.3]). In 
recent completed endovascular studies197,198,206-208, the imaging selection criteria varied 
considerably. It is worth noting that although not included in the inclusion criteria, many 
patients in some of these studies had undergone perfusion imaging prior to the 
treatment, indicating a possible selection bias. This has also highlighted the urgent need 
for further work to define a unified advantageous imaging profile definition to be utilised 
in future studies, and more importantly clinical practice. 
In summary, using advance imaging to select patients for acute reperfusion therapy is 
probably the better way forward, especially in respect of endovascular therapy. 
Nevertheless, uncertainties exist in many aspects, including: the use of MRI or CT; the 
tissue status definition and mismatch ratio; whether the additional time involved is 
worthwhile; the post-processing and analysis of imaging; and what imaging is required for 
selection. 
Imaging selection for wake-up stroke 
Approximately one quarter of strokes are recognised on waking up. They are excluded 
from the current thrombolysis treatment protocols due to the unknown onset time. But 
“wake-up” stroke patients and conventional thrombolysis candidates are similar in clinical 
presentation and in imaging characteristics209,210. Evidence suggests that a large 
proportion of these strokes seem to have occurred shortly before waking up211. A 
systemic review212 of all available wake-up stroke reperfusion studies revealed that only a 
small number of patients are treated, and that the selection criteria and imaging modality 
used varied considerably. No evidence, to date, supports treating patients in this 
category. 
Advance imaging has been utilised as a tissue clock to identify those who presented with 
wake-up stroke, but who are within the potential treatment time window, and are eligible 
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for thrombolysis. Two main imaging criteria are used for this purpose. One is the 
traditional core/penumbra mismatch, which is used in ECASS 4213 and EXTEND214. Both 
studies are investigating IV rtPA in patients presenting 3-9 hours from symptoms onset. 
Wake-up strokes are also included, the onset time being defined as the midpoint of last 
known well and symptoms recognition. A large multicentre observational study215 found 
that DWI/FLAIR mismatch can identify stroke within 4.5 hour onset with 62% (95% CI 57-
67) sensitivity, 78% (72-84) specificity, and 83% (79-88) positive predictive value. This 
concept has subsequently been used in the Efficacy and Safety of MRI-based 
Thrombolysis in Wake-up Stroke study (WAKE-UP)216 and A Study of Intravenous 
Thrombolysis With Alteplase in MRI-Selected Patients (MR WITNESS)217, two studies 
which examine IV rtPA in wake-up strokes only. In both studies, patients have to receive 
treatment within 4.5 hours from symptoms recognition. 
Biomarkers in revasculisation studies 
Advanced imaging can quantify the consequences of thrombolysis by assessing 
reperfusion and recanalisation. It has been used as a biomarker in reperfusion studies as 
these are closely correlated to clinical outcomes192,193.  In DEFUSE192 and EPITHET193, early 
reperfusion and infarct growth were used as endpoints in assessing efficacy. Early 
reperfusion and reduced infarct growth were correlated with good clinical outcomes. 
Phase II studies have used this strategy to reduce sample size218. It is clear now that 
reperfusion is the better independent predictor for clinical outcomes219,220, while 
recanalisation does not necessarily lead to reperfusion221; reperfusion can occur without 
recanalisation220, and predicts penumbra salvage, less infarct growth, smaller final infarct 
volume and good clinical outcomes. 
Traditionally, studies have used PWI-MRI post-revascularisation therapy to quantify 
reperfusion192,193. CT perfusion studies have shown that neurological recovery in the early 
stage of stroke is predominantly driven by penumbral salvage58, hence the reperfusion of 
the ischaemic area. The proportion of penumbra salvaged representing reperfusion can 
be used as a biomarker for clinical outcomes. 
Recanalisation remains an important clinical outcome biomarker222, and is a commonly 
used imaging outcome measurement in acute stroke revasculisation studies. Several 
scoring systems have been developed for the assessment of vessel patency based on 
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different imaging modalities and have been used in various revascularisation therapy 
trials223. However, to date there is no consensus on what grading system is the best to 
describe the degree of recanalisation224. The commonly used and most validated 
scales225, such as the Thrombolysis in Cerebral Infarction (TICI) scale and the Thrombolysis 
in Myocardial Ischaemia (TIMI) scale were developed for conventional angiography. Both 
allow description for distal vessel reperfusion as well as vessel patency226. Without 
dynamic information available, these scales are difficult to apply in non-invasive studies 
using CTA to evaluate vessel status. Radiologists still use a simple grading system 
(complete, partial, and no recanalisation). Given that in most studies using imaging 
endpoints, recanalisation is usually dichotomised in data analysis227, the need for a 
complicated grading scale is questionable. 
Visualisation of collateral flow 
Various grading systems to describe the extent of collateral flow exist, but few have been 
validated. Studies using MRI to quantify collaterals have more diversity in sequences 
used, definitions and grading of collateral flow than do studies using CTA. None of them 
has been replicated. In comparison to MRA, leptomeningeal flow is better visualised by 
CTA using DSA as reference228, probably because it shows the anatomy of leptomeningeal 
vessels. 
The use of CTA, however, is inadequate because CTA only provides a snap shot in time, 
and does not give any dynamic information. It is difficult to differentiate antegrade flow 
resulting from an incomplete occlusion from retrograde flow acquired from collateral 
circulation with standard single phase CTA. CTA may also underestimate collaterals by not 
showing delayed contrast arrival. CT perfusion can complement CTA by providing dynamic 
“4 Dimensional” (4D) angiography81. Assessing collaterals with the combination of CTP 
and CTA is more accurate and reliable229. 
The combination of NCCT, CTP and CTA – multimodal CT – provides a complete 
assessment for acute ischaemic stroke patients, allowing the evaluation of the stroke 
severity, and prediction of the outcome of reperfusion therapy. It does take extra time, 
and there are many unresolved issue, in particular in CT perfusion, which prevent it 
becoming adopted widely as a valid clinical tool . In addition to ensuring continuing 
development in imaging technology, we still require a well-designed study to 
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demonstrate that decision-making based on multimodal CT is advantageous compared 
with the current CT only approach. 
1.5. Conclusion 
AIS causes significant disability. Research in its complicated pathophysiology has made 
important progress over the years. However, this has not translated into clinical 
treatment, except in respect of IV and IA reperfusion. 
The technology to assess and manage AIS continues to evolve. Advanced imaging 
comprises an important part of AIS evaluation, but with the expense of extra time. In 
clinical research, it is used increasingly to select potential responders to treatment. The 
concept nonetheless has not been validated in a clinical trial. Acute stroke MRI remains 
the most sensitive in detecting early infarct, and gives additional information of 
microbleeds, but multimodal CT has improved in coverage, and in defining tissue status. It 
remains the most time-efficient, well-tolerated with fewer contraindications. Its use in 
clinical and research setting has increased. 
Advanced imaging is used increasingly to select patients in research studies, although it 
has not itself been validated in a clinical trial. 
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Chapter 2 Bioproperties of 
thrombolytic agents and 
their use in acute ischaemic 
stroke 
Acute ischaemic stroke results from intracranial artery occlusion. Timely recanalisation by 
IV thrombolysis or endovascular treatment restores the CBF, limits the damage to brain 
tissue, and improves functional outcomes. In this chapter, I review the mechanism of 
thrombolysis, thrombolytic agents, their pharmacological properties and clinical use. 
2.1. Mechanism of thrombolysis 
In the event of endothelial injury, collagen in the subendothelial matrix becomes exposed 
to flowing blood, and triggers the accumulation and activation of platelets. 
Concomitantly, tissue factor initiates blood coagulation and generates thrombin. 
Thrombin plays a crucial role in clot formation. It not only converts fibrinogen to fibrin, 
which forms the scaffolding for the thrombus, but also activates platelets. In addition, 
platelet activation is necessary for thrombus formation under arterial flow conditions and 
accompanies thrombin-mediated fibrin formation 230. 
Recent research has suggested that two independent pathways of platelet activation exist 
231,232. In one pathway, platelet activation is initiated by the collagen exposed from the 
injured vessel wall. Platelets bind to collagen with collagen specific receptors – 
glycoprotein VI and glycoprotein Ib-V-IX. This adhesion is facilitated by the Von 
Willebrand factor (a marker of endothelial damage). In the other pathway, endothelial 
injury is not necessary. Tissue factor from the exposed vessel wall or present in flowing 
blood generates thrombin, which in turn activates platelets233. By cleaving to the surface 
of the platelet, thrombin initiates a positive feedback mechanism, which activates more 
platelets and leads to further fibrin network formation. The process of thrombus 
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formation is influenced by many other factors, such as shear stress, flow, turbulence and 
the number of platelets in circulation. 
The endogenous thrombolytic system comprises plasminogen, Plasminogen Activators 
(PAs) and their inhibitors. Figure 2-1 shows a simplified pathway of thrombolysis. When a 
thrombus is formed in the physical environment, thrombin, a key player in clot formation, 
is directly involved in the conversion of plasminogen to plasmin by inducing localised 
generation of PAs from endothelial cells, thereby activating the endogenous fibrinolysis 
system. Plasmin formation is essential to the lysis of thrombi. It occurs in two places; in 
the plasma or on reactive surfaces such as thrombi or cells. The fibrin network provides 
the scaffold for plasminogen activation.  
 
Figure 2-1. A simplified illustration demonstrates fibrinolysis from Wikipedia 
with blue arrows denoting stimulation, and red arrows inhibition. 
 
The activation of plasminogen follows two different pathways. One is as an activator-
catalysed conversion of Glu-plasminogen into Glu-plasmin followed by an autocatalytic 
conversion of Glu-plasmin into Lys-plasmin. The other is as a plasmin-catalysed 
conversion of Glu-plasminogen into Lys-Plasminogen followed by an activator-catalysed 
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conversion of Lys-plasminogen into Lys-plasmin234. Fibrin accelerates its own re-solution 
by serving as a cofactor for the activation of plasminogen235. Partial degradation of the 
fibrin network also provides a positive feedback mechanism to promote further local 
fibrinolysis by increasing the rate of conversion of activator-catalysed Glu-plasminogen to 
Glu-plasmin regardless of the activator type236. 
In the circulation, α2-Antiplasmin (α2-AP) is the main inhibitor of fibrinolysis by inhibiting 
plasmin directly, whereas Thrombin Activatable Fibrinolysis Inhibitor (TAFI) prevents 
further plasmin activation from forming a plasmin-fibrin complex237. Excess plasmin is 
inactivated by α2-Macroglobulin (α2-M). The most important inhibitor of tPA and 
Urokinase (UK) is Plasminogen Activator Inhibitor-1 (PAI-1), which is mainly synthesised 
by platelets, vascular endothelial cells and hepatocytes238. Its plasma concentration is 
low, but platelets are a reservoir of PAI-1, account for 93% circulating PAI-1239, and 
release large amount of PAI-1 during aggregation. Several animal studies have suggested 
that PAI-1 is the major determinant of the resistance of platelet-rich thrombi lysis by 
tPA240,241. Agents with a feature of PAI-1 resistance therefore may have advantages in the 
lysis of platelet-rich clots. 
Thrombolytic agents given at pharmacological dose significantly affect haemostasis by 
inducing hypofibrinogenaemia and increasing the amount of Fibrin(ogen) Degradation 
Products (FDPs) in circulation, inhibiting fibrin polymerization242, reducing factors V and 
VIII, and prolonging the Activated Partial Thromboplastin Time (APTT) and the thrombin 
time243. As a result, the newly formed fibrin is dissolved rapidly by the active fibrinolytic 
system, impairing the formation of new haemostatic plugs244, which may introduce the 
complication of bleeding. This disruption of haemostasis is most prominent in the first 
generation of PAs, such as Streptokinase (SK) and urokinase (UK). 
2.2. Thrombolytic agents, and their biochemical properties (Table 2-1) 
Plasminogen activators include both endogenous plasminogen activators, which are 
involved in physiological fibrinolysis, and exogenous plasminogen activators. Tissue type 
plasminogen activators and UK are considered to be endogenous PAs, whereas 
streptokinase (SK), Anisoylated Plasminogen-streptokinase Activator Complex (APSAC, 
Anistreplase), staphylokinase, desmoteplase and other variant tPAs are exogenous PAs. 
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So far, SK, UK, tPA, desmoteplase and tenecteplase have been examined in ischaemic 
stroke. 
Table 2-1. Biochemical properties of common plasminogen activators 
 Streptokinase Urokinase rtPA 
(Alteplase) 
Tenecteplase Desmoteplase 
Direct 
Plasminogen 
activator 
No Yes Yes Yes No 
Plasma half-
life 
8-25 mins 7-18 mins 4-9 mins 15-19 mins 2.8 hours 
Administration Infusion Infusion Bolus 
followed 
by infusion 
Bolus Bolus 
ß-amyloid 
stimulation 
No No Yes ?Yes No 
Fibrin 
specificity 
_ _ + ++ +++ 
Antigenicity +++ _ _ _ + 
Inhibition by 
PAI-1 
+ +++ +++ + + 
Pro-coagulant 
effect 
Yes Yes245 Yes No ? 
Neurotoxicity  Yes246 Yes ?Yes No 
 
2.2.1. Streptokinase 
Before the development of rtPA, streptokinase was the most widely used thrombolytic 
agent. It is a 47kDa single-chain polypeptide derived from group C β-Haemolytic 
streptococci247. When SK makes contact with human plasminogen, a 1:1 complex is 
formed which contains an active site allowing the conversion of circulating plasminogen 
to plasmin248. The complex itself is converted to a SK-plasmin complex via intramolecular 
activation249.The SK-plasmin complex is however 105 times less reactive towards α2-
antiplasmin than plasmin250. The uninhibited complex and free plasmin in circulation 
consume fibrinogen, fibrin and inactivate prothrombin, factors V and VIII, resulting in 
fibrinogen depletion (a systemic lytic state)251. 
The human body contains antistreptococcal antibodies, which probably form following 
previous infection with β-haemalytic streptococci. A sufficient amount of SK must be 
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infused to neutralise the antibodies before a thrombolytic activation is obtained252. The 
usual dose required to neutralise antibodies is at least 3.5x105 U SK. The anamnestic 
response is generally maximal 4-7 days following the initiation of the SK infusion230. 
Streptokinase has been shown to reduce mortality in acute Myocardial Infarction (MI)253 
by recanalising the coronary artery254. Its use in acute ischaemic stroke proved to be 
unsuccessful due to the high ICH rates and mortality255. 
2.2.2. Urokinase 
Urokinase is a trypsin-like serine protease composed of two polypeptide chains 
connected by a single disulfide bridge256. There are two molecular forms, High-molecular-
Weight (HMW) UK (54kDa) and Low-molecular Weight (LMW) UK (31kDa). Both forms 
demonstrate fibrinolytic activity. During thrombolysis, there is a continuous conversion of 
HMW-UK into LMW-UK257,258. The plasma half-life of both forms is 9-12 min230. Urokinase 
is secreted as a Single-chain Urokinase Plasminogen Activator (scu-PA) inactive 
proenzyme form by endothelial cells, renal cells, and certain malignant cells. It converts to 
fully active two-chain UK following limited digestion with plasmin259. Scu-PA has been 
demonstrated to possess more fibrin specificity than two-chain UK, as significant clot lysis 
can be obtained without the systemic activation of the fibrinolytic system with scu-Uk, 
while extensive fibrinolytic activation does occur with two-chain UK in order to achieve 
significant clot lysis260. Scu-UK is inactive in human plasma due to a competitive inhibitor. 
The inhibition is abolished however in the presence of fibrin, resulting in the formation of 
fibrin-associated plasmin. This demonstrates a different mechanism of fibrin-specificity 
from that of tPA, which seems to be due to the fact that fibrin neutralises the competitive 
inhibitor rather than the fibrin enhanced activation of tPA247. 
The clinical evidence in relation to scu-UK showed that after a short lag phase, substantial 
amounts of the substance are converted into UK, which results in significant fibrinogen 
break down261,262. As for UK, conclusions from limited evidence  are that it achieves 
similar efficacy and safety to tPA in treating acute MI patients, and that reocclusion 
during the first 24 hours may be less frequent263. 
2.2.3. Recombinant Tissue Plasminogen Activator 
2.2.3.1. Alteplase 
   
 
61 
 
rtPa is a 70kDa single-chain glycosylated serine protease264,265 (Figure 2-2). It consists of 
four domains, a finger (F-) domain, an Epidermal Growth Factor (EGF) domain, two kringle 
regions (K1&K2) and a serine protease domain266. The finger domain residues 4-50 and 
the K2 domain are responsible for fibrin affinity. The COOH-terminal serine protease 
domain contains the active site for plasminogen cleavage230. With limited plasmin action, 
the single-chain form can be converted to a double-chain form linked by disulfide 
bonds267,268. Both forms are enzymatically active and have relatively fibrin-selective 
properties268,269. It has been suggested that physiological fibrinolysis induced by native 
one-chain t-PA nevertheless occurs mainly via the two-chain derivative269. tPA is cleared 
by the liver270.  
 
Figure 2-2. Biochemical structure of alteplase (reproduction from “Review of 
stroke thrombolytics” Journal of Stroke 2013
271
)
 
Alteplase has a certain degree of fibrin affinity, a well-established character that results in 
less disruption to the haemostasis system, and is hence a safer option than the first 
generation thrombolytics272. It is a poor activator in plasma in the absence of fibrin. By 
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interacting with exposed lysine residues in partially degraded fibrin with lysine binding 
sites located in both tPA and plasminogen, its ability to activate plasminogen significantly 
increases273. 
Prolonged infusion of alteplase is required to maintain plasma concentration due to its 
short plasma half-life of 4-9 minutes270,274,275. As a result acute MI investigators have 
taken steps to identify the optimal infusion regime to lyse clot275. The paradoxical 
procoagulant effect276 of alteplase is undesirable in clinical practice. It is also susceptible 
to PAI-1 inhibitation277 by forming a stable complex with PAI-1. 
It has also been suggested that alteplase is linked to the development of cerebral oedema 
secondary to its property of increasing BBB permeability, and is associated with 
neurotoxicity leading to neuronal death278. These observations flowed from animal 
studies, and have not been replicated in human studies. 
Extensive clinical evidence supported the replacement of streptokinase with alteplase as 
the main thrombolytic agent in acute MI patients. The Global Utilisation of Streptokinase 
and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) study279 
compared four IV thrombolysis strategies in MI and showed that accelerated alteplase 
plus IV heparin reduced mortality at 30 days with a net clinical benefit in comparison to 
other groups. The haemorrhagic stroke rate in this group was nevertheless higher than 
the two streptokinase groups (2 more ICH in every 1000 patients treated). 
The initial ground-breaking NINDS study280, the results of which were confirmed by 
subsequent studies70, demonstrated that timely thrombolysis with a lower dose of 
alteplase in AIS improves functional outcomes. Alteplase is now the only approved 
treatment for AIS. 
2.2.3.2. Tenecteplase 
Tenecteplase is a third-generation thrombolytic agent that was specifically bioengineered 
to improve on a number of features compared with the native molecule. It is a 65kDa 
single chain glycoprotein with modification in three regions of alteplase: substitution of 
threonine to asparagine at amino acid 103 (T103N); replacement of asparagine at 
position 117 with glutamine (N117Q); and a tetra-alanine substitution at amino acids 296 
to 299 (KHRR296- 299AAAA)281 (Figure 2-3). This resultant agent has a 15-fold higher 
   
 
63 
 
fibrin specificity, an 80-fold reduced binding affinity to PAI-1 and a 4-fold prolonged 
plasma half-life (18 vs 4 minutes) in comparison to alteplase282. Fifteen minutes following 
injection, 50% of tenecteplase and 1% of alteplase respectively still remains in 
circulation283. Tenecteplase can be administrated as a single bolus and can potentially be 
more effective in platelet rich thrombi due to its high resistance to PAI-1. Theoretically, it 
should induce minimised systemic plasminogen activation while targeting the thrombi, 
and is therefore safer compared to other thrombolytic agents due to its high fibrin 
specificity. Animal experiments283 showed that tenecteplase induces 50% lysis in one-
third of the time required by alteplase when both drugs were given at the same dose 
(0.18mg/kg). It is 8- and 13-fold more potent in rabbits than alteplase towards whole 
blood clots and platelet-enriched clots respectively283. Compared with alteplase, time to 
reperfusion is significantly less with tenecteplase, and the duration of recanalisation is 
greater284. It also achieves more complete lysis of blood clots than alteplase with fewer 
overall bleeding complications. Evidence suggests that tenecteplase lacks the 
procoagulant effect, which may cause early reocclusion285 seen with other thrombolytic 
agents. In an acute MI study, there was no increase in Thrombin-antithrombin Complex 
(TAT) after administration of tenecteplase, in contrast to a four-fold increase following 
streptokinase and a doubling after tPA286. In addition, a rabbit model of carotid stenosis 
showed that tenecteplase does not generate collagen-induced aggregation of platelets in 
vitro as alteplase does284. 
Tenecteplase has been studied extensively in acute MI. The major studies are: TIMI 
10A287, and the Safety Assessment of Single-bolus Administration of tenecteplase Tissue-
Plasminogen Activator in Acute Myocardial Infarction (ASSENT) 1 study288, both phase I 
dose ranging trials; TIMI 10B289, a phase II non-blinded comparison of fixed doses of 
intravenous bolus tenecteplase and front-loaded infusion of alteplase; and ASSENT II290, a 
phase III comparison of body weight adjusted tenecteplase bolus and alteplase infusion 
(Table 2). Evidence from these studies suggested that there is no significant difference 
between the two agents in terms of the rate of achieving TIMI 3 flow. The ICH rates are 
similar in both agents, but the rate of overall bleeding complication was much lower in 
the tenecteplase group290. 
Two phase II studies have compared whether tenecteplase has advantages over alteplase 
in AIS thrombolysis, but the study population varied between studies. Currently, a few 
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phase III studies are investigating the use of tenecteplase in the treatment of acute 
ischaemic strokes. 
 
Figure 2-3. Biochemical structure of Tenecteplase (Reproduction from “Review 
of stroke thrombolytics” Journal of Stroke 2013
291
) 
2.2.4. Desmoteplase 
Saliva of the vampire bat (desmodus rotundus) contains a family of four plasminogen 
activators called Desmodus Salivary Plasminogen Activators (DSPAs). Of these, DSPAα1 
(Desmoteplase) has the most homologous structure to human tPA except that it only has 
one kringle structure and does not have the plasmin cleavage site which is necessary for 
conversion into a two-chain structure292. Desmoteplase is highly fibrin specific. It is almost 
inactive in the absence of fibrin, but with the presence of fibrin the activity of 
desmoteplase is 105,000 times higher than where fibrin is absent, whereas tPA’s activity 
is only 550 times higher293. Because fibrinogen, a co-factor of plasminogen activation by 
tPA, does not have an effect on desmoteplase, the factor of fibrin selectivity expressed as 
the quotient of activity in the presence of fibrin versus activity in the presence of 
fibrinogen is 12,900 for DSPA but only 72 for rtPA294. In comparison to rtPA, desmoteplase 
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is neither stimulated by the native nor aggregated amyloid β-peptide analogues295, which 
is thought to be a factor that contributes to rtPA induced intracranial haemorrhages293. 
Desmoteplase also lacks the neurotoxic effects of rtPA296 and has a significantly longer 
plasma half-life of 2.8 hours297. The thrombolytic efficacy is not affected by the presence 
of platelets or platelet-rich clots297. 
Like streptokinase, desmoteplase could potentially stimulate antibody formation due to 
its non-human origin. A study with healthy volunteers suggested that unlike 
streptokinase, the induction of antibodies is infrequent, dose-dependent, and only 
observed with a higher frequency after repetitive administrations.298 
Although the animal studies showed promising results compared to tPA, the use of 
desmoteplase in acute MI has been limited. A phase II open label dose finding study has 
taken place, but, any conclusions regarding safety and efficacy were limited  by the small 
patient number (26 patients)293. Investigation in AIS thrombolysis in an extended window 
of 3-9 hours299,300 has been very comprehensive, although the results were neutral301. 
2.2.5. Other tPAs 
Another agent, staphylokinase – a protein produced by a certain strain of staphycoccus 
aureus, is completely fibrin selective. Like streptokinase, it forms a 1:1 stoichiometric 
complex with plasminogen. Two clinical studies, the Collaborative Angiographic Patency 
Trial of Recombinant Staphylokinase (CAPTORS) study 302and CAPTORS II303 showed 
promising results, however, due to safety concerns, the dose (0.05mg/kg) that can 
achieve similar efficacy to tPA was not evaluated. 
Other third generation tPAs, such as reteplase and lanoteplase have been studied in acute 
MI patients. Reteplase has been shown to have an efficacy equal to alteplase, but there 
are concerns that it is associated with a greater incidence of reocclusion in comparison to 
alteplase292 and these have limited its clinical use. Lanoteplase was not approved for 
clinical use due to the evidence that there was an increased rate of haemorrhagic stroke 
in a lanoteplase treated group.304 Neither of these two agents has been studied in 
ischaemic stroke patients. 
The main thrombolysis studies in acute MI using the above agents are summarised in 
Table 2-2. Many of them are well-conducted studies with large sample sizes, using both 
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angiography and clinical endpoints. The accompanying pharmacokinetic study and 
coagulation assays provided robust evidence for dose selection and safety evaluation. 
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Table 2-2. Summary of major acute MI thrombolysis studies 
 Primary 
outcome 
Recanlisation 
rate (%) 
Bleeding 
/reocclusion rate  
(%) 
All-cause 
mortality 
(%) 
Percentage of 
Fibrinogen 
fall (%) 
TIMI I
305 
rtPA vs SK 
N=290 
TIMI 2/3 
flow at 90 
mins 
62% vs 31% 
(p<0.001) 
 
Comparable   4.9% vs 
8.2%  
33% vs 58% 
European Co-
operative 
Study
306 
rtPA vs SK 
N=129 
Vessel 
patency at 
75-90 mins 
70% vs 55% Comparable  4.7% vs 
4.6% 
39±65% vs 
92±89% 
GUSTO
307,308 
rtPA vs SK 
N=41021 
All-cause 
mortality at 
day 30 
81% vs 60%  Comparable  6.3% vs 
≥7.0% 
(p=0.001) 
 
TIMI 10B
289 
rtPA vs TNK 
N=837 
TIMI grade 
3 flow at 
90 mins 
62.8% vs 
62.7% 
Comparable. No 
significant 
difference 
40% vs 5-10% 
ASSENT II
290 
rtPA vs TNK 
n=16949 
All-cause 
mortality at 
30 days 
 ICH risk 
comparable; 
Overall 
bleeding: 28.95% 
vs 26.43%, 
p<0.001 
6.2 vs 
6.2% 
 
rtPA, recombinant tissue Plasminogen Activator; SK, Streptokinase; TNK: Tenecteplase; TIMI, 
Thrombolysis in Myocardial Infarction; ICH: Intracerebral haemorrhage. 
 
2.3. Revascularisation therapy in acute ischaemic stroke 
2.3.1. Intravenous thrombolysis 
Thrombolysis in ischaemic stroke differs from that in MI because of the difficulty in 
symptom recognition with associated delay in presentation, larger clot burden, and 
heterogeneity in thrombus composition. The risk of ICH is higher in ischaemic brain tissue. 
The three streptokinase studies255 terminated early because of higher mortality and ICH 
rates rate in the SK group, highlighted important lessons: minimising time to treatment is 
essential309; individualised dose adjustment by weight is safer; and the concomitant use 
of anti-platelet agents increases risk of ICH255. 
2.3.1.1. Alteplase 
The NINDS study280 in which alteplase was compared with placebo demonstrated that 
thrombolysis in acute ischaemic stroke can improve functional outcomes if it is given 
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within three hours from symptom onset. Other large studies (ECASS310, ECASS II311, 
Alteplase Thrombolysis for Acute Non-interventional Therapy in Ischemic Stroke 
[ATLANTIS] A312 & B313) nevertheless did not show that the treatment effect can be 
extended up to six hours from symptom onset, despite using similar methods and dose 
regimes (Table 2-3). The meta-analysis314 using the combined data from the above trials 
confirmed that time is the critical factor in revascularisation treatment. Treatment benefit 
diminishes as time elapses. The subsequent ECASS III study315 demonstrated that the 
treatment window can be extended up to 4.5 hours from symptoms onset. However the 
Number Needed To Treat (NNT) increases from 4.5 when treatment is within the the first 
90 minutes of symptoms onset to 14 if the OTT is between 180-270 minutes of symptom 
onset76. One can deduce that NNT increases by 1 with each 20 minutes delay in 
treatment. In addition, evidence316 suggests thrombus becomes more resistant to tPA 
with the increase of time. The benefit of treating patients who present beyond 4.5 hours 
but less than 6 hours remains unclear. The most updated meta-analysis70 including all the 
large IV thrombolysis studies to date demonstrated the time dependent efficacy of rtPA 
administration within 4.5 hours, but no strong evidence to support treatment beyond this 
time window. Patients aged over 80 or who have minor neurological deficits on 
presentation benefit from treatment with no increasing risk of ICH. 
The haemorrhagic complication rate related to IV alteplase was found to be from 2.7-
15.7% in IV thrombolysis trials317, which resulted from different definitions of 
symptomatic haemorrhage applied in different studies. It is understood now that 
haemorrhage on post thrombolysis CT is not always the culprit for neurological 
deterioration, which could be due to reasons such as extension of the infarction or 
cerebral oedema secondary to ischaemic infarction. Small haemorrhagic transformation 
within the infarction does not affect the clinical outcome. When stricter symptomatic ICH 
definition is applied (the ECASS III definition or the Safe Implementation of Thrombolysis 
in Stroke Monitoring Study [SIT-MOST] definition), symptomatic ICH prevalence was 
approximately 2% overall315,318. The most recent meta-analysis70 suggests that the relative 
risk of ICH may not be time dependent as was previously thought, nor is it related to age, 
but the absolute risk of alteplase related haemorrhage was higher among patients who 
had more severe strokes. 
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IV rtPA’s efficacy varies depending on the occlusion site319 and recanalization occurs more 
frequently in distal branches320. Early recanalisation (defined as recanalisation occurring 
within two hours from the start of treatment) can be achieved in 42.9% of patients with 
M2 occlusion, in 30.7% of patients with M1 occlusion, in 11.4% of patients with basilar 
occlusion, and in 12.9% of patients in terminus ICA or tandem ICA/M1 occlusion319,321. 
Reocclusion is relatively common within the first two hours322 with alteplase. 
The narrow 4.5 hour treatment window is one factor that has led to gross underuse of IV 
thrombolysis despite intensive efforts undertaken to raise public awareness and improve 
acute stroke facilities. Only 10.3% of acute ischaemic stroke patients received IV 
thrombolysis in 2011-2012 in the UK323. 
In 2014, Medicine and Healthcare Products regulatory Agency (MHRA) launched an 
investigation in response to the concern of the safety of alteplase in acute ischaemic 
stroke thrombolysis. However, it is evident from the individual study data and especially 
the most recent meta-analysis324, which was performed with individual patient data, that 
the benefit of thrombolysis outweighs  the risk of symptomatic ICH in patients presenting 
within 4.5 hours from symptoms onset.  
The main focus of research currently is to seek an alternative pharmacological agent or 
mechanical methods to reperfuse the brain more effectively in the current treatment 
time window, and investigate the potential of advanced imaging technology to identify 
suitable candidates to be treated in an extended time window. 
 
 
   
 
70 
 
Table 2-3. Main randomised controlled studies comparing rtPA with placebo (summarised from individual study data)
Study (year) Number rtPA Dose Time 
window 
(hours) 
Method Main results 
rtPA Placebo Functional outcomes (%) SICH (%) 
NINDS280 1995 312 312 0.9mg/kg (Max 
90mg) 
0-3 Double blind mRS 0-1 at 90 d: 43% vs 27% 13% vs 1% 
ECASS310 1995 313 307 1.1mg/kg (Max 
100mg) 
0-6 Double blind mRS 0-2 at 90 d: 29% vs 36% 6% vs 2% 
ECASS II311 
1998 
409 391 0.9mg/kg (Max 
90mg) 
0-6 Double blind mRS 0-1 at 90 d: 40% vs 37% 8.8% vs 3.4% 
ATLANTIS A312 
2000 
71 71 0.9mg/kg (Max 
90mg) 
0-6 Double blind mRS Median at 90 d: 5 vs 2 11% vs 0 
ATLANTIS B313 
1999 
272 275 0.9mg/kg 3-5 Double blind mRS 0-1 at 90 d: 41% vs 42% 6.7% vs 1.3% 
ECASS III315 
2008 
418 403 0.9mg/kg (Max 
90mg) 
3-4.5 Double blind mRS 0-1 at 90 d: 52% vs 45% 2.4% vs 0.2% 
EPITHET193 
2008 
52 49 0.9mg/kg (Max 
90mg) 
3-6 Double blind mRS 0-1 at 90 d: 36% vs 21% 7.7% vs 0 
IST369 
2012 
1515 1520 0.9mg/kg (Max 
90mg) 
0-6 Open label OHS 0-1 at 180 d: 22% vs 24% 7% vs 1% 
 SICH rates quoted use the individual study’s own definition; IST3 International Stroke Trial 3; mRS Modified Rankin Scale. 
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2.3.1.2. Tenecteplase 
Tenecteplase is an attractive alternative because of the theoretical advantages and the 
presence of extensive evidence from MI studies. All published and ongoing tenecteplase 
studies in AIS are shown in Table 2-4. After dose finding studies325,326, a randomised 
study327 comparing doses of 0.1, 0.25, and 0.4 mg/kg to standard alteplase within three 
hours discontinued recruitment to the 0.4 mg/kg dose due to a higher SICH incidence and 
less frequent major neurological improvements at 24 hours. Another randomised study194 
demonstrated that tenecteplase (0.1 mg/kg and 0.25 mg/kg) was superior to alteplase in 
achieving reperfusion, recanalisation and mean NIHSS score improvement at 24 hours in a 
selected group of patients with favourable perfusion lesion patterns and intracranial 
occlusions within six hours of onset. Since advanced imaging selection criteria were used 
in this study, the result is restricted to a highly selected population. To investigate 
tenecteplase’s efficacy in the general acute ischaemic stroke population, further study is 
required. 
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Table 2-4. Summary of all completed and ongoing tenecteplase studies in AIS
Study 
(year) n 
Design Number Time window 
(hour) 
Inclusion Efficacy 
Outcome (%) 
SICH (%) 
TNK Alteplase 
Haley et al
325
 
(2005) 
88 
Dose escalation 0.1mg/kg 25; 
0.2mg/kg 25; 
0.4mg/kg 25; 
0.5mg/kg 13 
Historical 
control in 
NINDS 
0-3 Conventional patient selection 0-1: 36% vs 32% 
vs 32% vs 46% vs 
13% 
0 vs 0 vs 0 vs 
15% vs 36% 
Parsons et al
326
 
(2009) 
20 
Controlled 0.1mg/kg 15 35 3-6 Target mismatch and intracranial 
occlusion 
0-1: 60% vs 35% 0 vs 2.9% 
Molina et al
328
 
(2008) 
122 
Controlled  0.4mg/kg 42 80 0-3 MCA occlusion 0-2: 66% vs 52% 2.1% vs 3.7% 
Haley et all
327
 
(2010) 
112 
Double blinded, 
Phase IIB/3 
0.1mg.kg 31; 
0.25mg/kg 31; 
0.4mg/kg 19; 
31 0-3 Conventional patient selection 0-1: 45% vs 48% 
vs 32% vs 39% 
0 vs 6.5% vs 
15.8% vs 3.2% 
Parsons et al
194
 
(2012) 
75 
PROBE, phase IIIB 0.1mg/kg 25; 
0.25mg/kg 25; 
5 0-6 Target mismatch and intracranial 
occlusion 
0-1: 36% vs 72% 
vs 40% 
4% vs 4% vs 
12% 
TEMPO-1
329
 
(2015) 
50 
Single arm cohort 0.1mg/kg 25; 
0.25mg/kg 25 
 0-12 NIHSS<5, and proximal occlusion 0-1: 76% vs 56; 4% vs 0% 
NOR-TEST
330
 
(ongoing) 
954 
PROBE Phase III 0.4mg/kg 
 
 0-4.5; 
0-4.5 from wake-up; 
0-6 for embolectomy 
Conventional patient selection, 
wake-up/embolectomy: target 
mismatch/proximal occlusion  
  
TASTE
204
 
(ongoing) 
1024 
PROBE Phase III 0.25mg/kg   0-4.5 Target mismatch and intracranial 
occlusion 
  
TEMPO-2
331
 
1274 
PROBE Phase III 0.25mg/kg  antiplatelets 0-12 NIHSS<6, ASPECT>5, and proximal 
occlusion 
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The appropriate dosage of tenecteplase that should be used in stroke thrombolysis 
remains unclear. An initial dose escalation study325 discarded doses of 0.5mg/kg and 
higher because of the high incidence of ICH. The subsequent phase II study327 comparing 
0.1, 0.25, 0.4mg/kg against standard alteplase (0.9 mg/kg) discarded a 0.4 mg/kg dose for 
failing to show superiority based on an adaptive sequential design with combined early 
neurological improvement and ICH rates. The ICH rate nevertheless was not significantly 
higher than for other dose groups. The study terminated before it could distinguish the 
efficacy between the 0.1 and 0.25 mg/kg doses. Parsons et al194 however did demonstrate 
the superiority of a 0.25 mg/kg dose to 0.1mg/kg in delivering reperfusion and clinical 
benefits. 
Two phase III studies are currently recruiting: the Tenecteplase versus Alteplase for 
Stroke Thrombolysis Evaluation (TASTE) trial204 (ACTRN12613000243718) uses imaging 
based patient selection examining 0.25mg/kg TNK, while the study of tenecteplase versus 
alteplase for thrombolysis in acute ischaemic stroke (NOR-TEST)330 (NCT01949948) 
compares 0.4mg/kg TNK with standard alteplase. 
2.3.1.3. Desmoteplase 
Desmoteplase studies pioneeered the use of imaging-based criteria in assisting patient 
selection with the application of the mismatch concept in a much later time window of 3-
9 hours after stroke. Two initial dose-escalation studies in a 3-9h window population 
selected using MRI mismatch criteria332,333 suggested a dose-response effect. However, a 
subsequent trial testing two doses against a placebo failed to confirm efficacy. An excess 
of less severe strokes, low rates of vessel occlusion at baseline, mixed imaging modalities 
for patient selection, and small sample sizes may explain the discordant findings334. 
Revised to select patients on the basis of arterial occlusion rather than MRI mismatch, 
desmoteplase did not appear to be superior to placebo in achieving good functional 
outcomes at three months in patients presenting between 3-9 hours from symptoms 
onset in DIAS 3301. 
2.3.2. Endovascular reperfusion therapy 
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Endovascular reperfusion therapy with devices or IA thrombolysis achieves much higher 
recanalisation rates in comparison with IV rtPA335. In 2012, the first three randomised 
trials196,336,337 comparing its efficacy against IV therapy disappointingly showed no benefit 
over IV therapy. A pooled analysis338 of earlier endovascular trials suggested that almost 
half of recanalisations were “futile” – ie not associated with favourable clinical outcome. 
A time to treatment stratum of 3-6 hours was associated with futile recanalisation. 
Compared with IV therapy, delays are common in endovascular therapy, such that the 
benefit of the high recanalisation rates may be cancelled336. Other factors that had a 
possible impact on the failed studies included the use of first and second generation 
devices, which have much lower recanalisation rates compared with the recent stent 
retriever. It has been suggested that if IV therapy is started within two hours from 
symptom onset, and IA therapy can be initiated within 90 minutes after the start of IV 
therapy, endovascular treatment may be beneficial337. Following the Multicenter 
Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands (MR CLEAN)206, the first successful RCT to compare modern endovascular 
treatment with standard care, similar studies around the world overwhelmingly showed 
the superiority of intra-arterial treatment. (Table 2-5). The common feature of these 
studies was that the median onset to femoral puncture times were all less than 4.5 hours, 
notwithstanding that some studies permitted inclusion of patients up to 12 hours from 
symptom onset. The patient selection methods varied among these studies. Some used 
vascular imaging and collaterals, some used additional tissue imaging. In MR CLEAN, 
target mismatch was not one of the selection criteria, but two-thirds of patients had 
perfusion imaging. 
It is evident that endovascular treatment is a highly effective therapy which is only 
suitable for a particular group of AIS patients, but the treatment time window that 
ensures benefit, and the patient selection criteria remain unclear. To apply intra-arterial 
therapy in clinical practice, in addition to the requirement of significant service 
reorganisation, it is crucial that we have solutions to these issues. Even so, it is likely to be 
only available in highly specialised stroke centres and in a highly selected populations. 
The search for a better pharmacological agent will remain relevant for a majority of 
ischaemic stroke patients. 
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Table 2-5. Randomised controlled studies for endovascular therapy to date 
 
Study 
N 
(IAT vs CTL) 
Selection criteria Treatment arms Device Onset to 
Puncture 
Time 
(mins)  
Results 
mRS 0-2 at 
90 day 
SICH 
IMS 3337 
656 (434 vs 222) 
NIHSS≥10, or intracranial 
occlusion with NIHSS≥8 
0-3 hours 
IV rtPA+ intervention vs IV 
rtPA alone 
1st & 2nd generation  43% vs 40% 6.2% vs 5.9% 
MR Rescue196 
127 (70 vs 57) 
Target mismatch 
0-8 hours 
Intervention vs standard care 1st & 2nd generation  41% vs 49% 9% vs 6% 
Synthesis336 
362 (181 vs 181) 
Eligible for IV rtPA 
0-4.5 hours 
Intervention vs Iv rtPA 1st & 2nd generation 225 42% vs 46% 6% vs 6% 
MR CLEAN206 
500 (233 vs 267) 
Proximal occlusion 
0-6 hours 
Intervention + standard care 
vs standard care alone 
Majority used stent 
retriever (86.1%) 
260 33% vs 19% 7.7% vs 6.4% 
ESCAPE207 
315 (165 vs 150) 
ASPECT 6-10, Proximal occlusion 
0-12 hours 
Intervention + standard care 
vs standard care alone 
Stent retriever  220 53% vs 29% 3.6% vs 2.7% 
SWIFT PRIME197 
196 (98 vs 98) 
Proximal occlusion, and target 
mismatch 
0-6 hours 
Intervention + IV rtPA vs IV 
rtPA 
solitaire 224 60% vs 36% 0 vs 3% 
EXTEND-IA198 
70 (35 vs 35) 
Proximal occlusion, and target 
mismatch 
0-6hours 
Intervention + IV rtPA vs IV 
rtPA 
solitaire 210 71% vs 40% 0 vs 6% 
REVASCAT208 
206 (103 vs 103) 
Proximal occlusion, ASPECT>7 on 
CT, or ASPECT>6 on DWI 
0-8 hours 
Intervention + standard care 
vs standard care alone 
solitaire 269 44% vs 28% 1.9% vs 1.9% 
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2.3.3. Other alternatives to standard IV thrombolysis, or adjunctive 
therapies 
2.3.3.1. Modified alteplase regimes 
While alteplase 0.9mg/kg is the RCT-supported dose, some Asian countries advocate a 
reduced dose of 0.6mg/kg, asserting ethnic differences and possibly lower haemorrhagic 
risk339, as well as greater affordability. Low dose alteplase (0.6mg/kg) is the only approved 
stroke thrombolysis treatment in Japan, but is supported only by small, non-randomised 
series340,341 and observational data342,343, and disagreement exists even within local 
medical communities344,345. The Enhanced Control of Hypertension and Thrombolysis 
Stroke study (ENCHANTED) trial is the first large RCT to address rtPA dose (as well as 
addressing BP lowering), which showed that the low dose alteplase is not inferior to the 
standard dose, but has significant lower risk of SICH346.The majority of the study 
recruitment was drawn from an Asian population, such that while the result will support 
the use of low dose alteplase in Asian country, it is unlikely to change the practice in the 
West. 
2.3.3.2. Liposomal tPA 
Drug delivery direct to the thrombus has the potential advantages of enhancing clot lysis 
and reducing adverse events by allowing smaller doses347. Liposome348-encapsulated PA 
has a longer half-life due to the avoidance of premature systemic release and inactivation 
by circulating inhibitors349, and in animal models liposomal PAs digested significantly 
more thrombi in a shorter time than their native forms350,351. Adjunctive transcranial 
doppler ultrasound, by disrupting liposomes, may offer targeted local drug release at the 
site of arterial occlusions. 
2.3.3.3. Sonothrombolysis 
Diagnostic frequency 2MHz TCD ultrasonography has microstructural effects on fibrin 
strands and agitates rtPA and blood at the thrombus surface, thereby enhancing 
thrombolysis by IV rtPA352. Adjunctive TCD was associated with higher recanalisation rates 
and a greater likelihood of functional independence in five clinical trials involving 233 
patients353,354. The recently completed phase III RCT Combined Lysis of Thrombus With 
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Ultrasound and Systemic Tissue Plasminogen Activator for Emergent Revascularization 
(CLOTBUST-ER) in Acute Ischemic Stroke study tested an ultrasound-delivery headset that 
is largely operator-independent as an adjunct to IV rtPA (NCT01098981), but was 
terminated on grounds of futility at a planned iterim analysis. In a small RCT, one dose of 
1.4 ml of microspheres, in addition to rt-PA, and insonation showed increased 
recanalisation compared to rt-PA alone, but 2.8mL of microspeheres was associated with 
higher ICH incidence355. 
2.4. Neuroprotective agents 
Aiming to “freeze the penumbra” or prevent reperfusion injury, neuroprotectants include 
a variety of antioxidants, anti-inflammatory drugs and other therapies. Despite success in 
animal models, none of the early neuroprotectives has demonstrated efficacy in human 
trials. Many reasons have been put forward for the failure to translate the success in 
preclinical experiments to humans356. Among those, the time window of drug 
administration is an essential factor. In an analysis of six large neuroprotectants studies, 
92% of patients were enrolled beyond three hours357, and animal studies indicated that 
most neuroprotectives are ineffective when administrated more than four hours after 
occlusion356. The Field Administration of Stroke Therapy – Magnesium (FAST-MAG) 
study358 addressed this issue by giving treatment in a pre-hospital setting within two 
hours from symptoms onset. It nonetheless did not show any benefits over placebo. High 
dose IV albumin359 was also shown not to be beneficial. Therapeutic hypothermia63 is 
currently under investigation. 
2.5. Other evidence based management for acute ischaemic stroke 
2.5.1. Stroke unit care 
Early admission to a specialist stroke unit reduces mortality, shortens the hospital stay 
and improves independence360. The recent updated systematic review indicated that a 
dedicated stroke ward is significantly better in all outcomes in comparison to a mobile 
stroke team or a mixed rehabilitation ward361. There is a suggestion362 that a 
comprehensive stroke unit (combining acute and rehabilitation units) may reduce the 
length of stay, mortality, and dependency compared to other forms of stroke unit. To 
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date, no randomised controlled trial has been conducted to demonstrate this. Patients 
with ICH benefit at least as much as ischaemic stroke patients363. 
2.5.2. Antiplatelets 
Early administration of aspirin in acute ischaemic stroke (≤48 hours) has been shown to 
significantly reduce the risk of recurrent strokes, improving survival and functional 
outcomes, with a small increased of risk of ICH (0.2%) compared with control364,365. Early 
anti-coagulation, on the other hand, compared with aspirin, is associated with a 
significant increase in mortality and a risk of haemorrhage, with no net benefit on long 
term functional outcome366.  A recently completed Chinese study367 suggested that short-
term use of dual anti-platelet agents (aspirin and clopidogrel) prevents early recurrent 
stroke in patients who had a minor stroke or a Transient Ischaemic Attack (TIA). An 
ongoing similar study368 elsewhere is examining the same question. 
2.6. Conclusions 
Among the many thrombolytic agents, tenecteplase and desmoteplase demonstrate the 
best pharmacological profile and theoretical advantages, but the current approved 
therapy is still IV alteplase within 4.5 hours from symptoms onset in AIS. Studies 
investigating tenecteplase are ongoing. Desmoteplase did not prove to be beneficial 
compared with placebo in AIS patients with evidence of vessel occlusion between 3-9 
hours from symptoms onset. 
Intra-arterial therapy is superior to IV therapy alone in treating severe stroke due to 
larger artery occlusion in the anterior circulation, but its application will be limited to a 
highly selected group of patients in specialised centres, and the selection criteria remain 
unclear from currently available studies. IV thrombolysis will remain a significant part of 
recanalisation therapy for majority of patients. Seeking a better alternative thrombolytic 
agent is worthwhile. 
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Chapter 3 Materials and 
methods 
3.1. Introduction 
This chapter provides a detailed description of the general methods used in the studies 
presented in this thesis. Methodology, protocol and endpoints relevant to individual 
studies are described in each study presented. 
Patient assessment, recruitment, follow-up, and clinical data collection was carried out by 
the stroke research team in the Southern General Hospital (now the Queen Elizabeth 
University Hospital), Glasgow, Scotland. Imaging data were collected with the assistance 
of radiographers. Imaging post-processing analysis was performed by the author of this 
thesis. Part of the analysis was repeated by a second clinical research fellow whose main 
project was based on CT based imaging analysis. Inter-observer agreement was calculated 
in these cases. 
3.2. The ATTEST study 
The Alteplase – Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) pilot 
phase is a Prospective Randomised Open label Blinded End-Point (PROBE) study that 
compares markers of biological activity to inform the design of a larger definitive trial 
comparing the efficacy and safety of alteplase and tenecteplase as thrombolytic agents in 
eligible patients with acute ischaemic stroke. 
The study was performed between January 2012 and September 2013. All patients were 
recruited from the Acute Stroke Unit, Southern General Hospital, Glasgow, Scotland. The 
study was funded by the Stroke Association. 
The primary and secondary outcomes are shown in Table 3-1. 
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Patients were eligible for recruitment into the study if they had a clinically diagnosed 
supratentorial acute ischaemic stroke with a measurable deficit on the NIHSS369, were 
within 4.5 hours of symptoms onset, were aged ≥18 years, were living independently pre-
stroke, and were considered eligible for IV thrombolysis according to clinical guidelines. 
Table 3-2 shows the full inclusion and exclusion criteria. Anticoagulant and antiplatelet 
drug treatments (including aspirin, clopidogrel, heparin and warfarin) should be avoided 
for at least 24 hours after thrombolytic drug treatment, and usually until after follow-up 
brain imaging. In lactating patients breast milk must be discarded and not used for 
feeding within the first 24 hours after thrombolytic therapy. 
Table 3-1. Primary and secondary outcomes for the ATTEST study 
Primary Endpoint 
 Percent penumbral salvage at 24-48 hours (initial CTP-defined penumbra volume 
versus 24-48 hour CT infarct volume) 
Secondary endpoints 
 Proportion of patients exhibiting recanalisation (measured by CTA) 24-48 hours post 
treatment 
 Early Clinical improvement (NIHSS score reduced by 8 points, or 0 or 1) 24 hours post 
treatment 
 Proportion of patients with symptomatic ICH (SICH) on 24-48h CT: 
 SITS-MOST definition - PH2/PHr2 + NIHSS deterioration by 3-4 points at 24h 
 Any ICH 
 Distribution of functional outcome scores (mRS) at Day 30 and Day 90 
 Proportion of patients with favourable clinical outcome (mRS 0-1) at Day 30 
 and Day 90 
 Average “home time” (number of nights spent in non-institutional private residence) 
by Day 90 
 Mortality at Day 90 
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Table 3-2.  Inclusion and exclusion criteria for the ATTEST study 
Inclusion Criteria 
1 Clinical diagnosis of supratentorial acute ischaemic stroke with score of ≥1 on the 
NIH Stroke Scale 
2 Male or non-pregnant female ≥18 years of age 
3 Within 4.5 hours of onset as defined by time since last known well 
4 CTP and CTA examinations acquired prior or immediate after  the initiation of 
treatment 
5 mRS ≤2 pre-admission 
Exclusion Criteria 
1 Contraindications to thrombolytic drug treatment for stroke 
 Evidence of intracranial haemorrhage or significant non-stroke intracranial 
pathology (including CNS neoplasm, aneurysm or Arteriovenous malformation) 
on pre-treatment CT 
 Established hypodensity on pre-treatment brain CT of more than one third of 
the MCA territory or ASPECT score <4 (sulcal effacement or loss of grey white 
differentiation in cortical territories alone are not counted towards ASPECT 
score) 
 Hypodensity consistent with recent cerebral ischaemia other than the 
presenting event 
 Very severe stroke (eg NIHSS>25) 
 Systolic blood pressure> 185 or diastolic BP> 110 mm Hg, or aggressive 
management (intravenous pharmacotherapy) necessary to reduce BP to these 
limits 
 If on warfarin, INR >1.4 
 Current prescription of non-warfarin oral anticoagulant drugs; 
 Significant abnormality of coagulation parameters pre-treatment (prolonged 
INR or APTT, or platelet count <100,000/mm3) 
 Administration of heparin within the previous 48 hours and a thromboplastin 
time exceeding the upper limit of normal for laboratory, or use of therapeutic 
dose low molecular weight heparin within 48h 
 Clinical history suggestive of subarachnoid haemorrhage even if no blood is 
evident on CT 
 Risk of bleeding (Major surgery within previous 1 month; intracranial or spinal 
surgery; recent trauma to the head or cranium; prolonged cardiopulmonary 
resuscitation (> 2minutes) within the past 2 weeks; acute pericarditis and/or 
subacute bacterial endocarditis; acute pancreatitis; severe hepatic dysfunction, 
including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) 
and active hepatitis; active peptic ulceration; any known history of 
haemorrhagic stroke or stroke of unknown origin; arterial aneurysm and known 
arteriovenous malformation) 
 Dependent (mRS 3-5) pre-stroke 
 Blood glucose <2 mmol/l or >18 mmol/l 
 Seizure at onset of symptoms unless brain imaging identifies positive; evidence 
of significant brain ischaemia (eg CTA confirmed arterial occlusion, early 
ischaemic change on plain CT, hypoperfusion on CTP) 
 Pregnancy 
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2 Known history of impaired renal function with an eGFR <30 mL/min pre-treatment 
precluding contrast CT 
3 Known allergy to radiological contrast 
4 History of allergies to active substances in either trial medication, or to excipients 
including Gentamicin 
5 Severe concurrent medical condition that would prevent participation in study 
procedures (e.g. cardiac failure with severe pulmonary oedema) or with life 
expectancy ≤ 3 months. 
CNS Central Nervous System; INR International Normalised Ratio 
 
Patients presenting with infratentorial ischaemic strokes were not included due to the 
limited coverage of CT perfusion. Our exclusion criteria reflected the current clinical 
interpretation of thrombolysis contraindication in stroke70,370, and the availability of 
extended imaging studies at the time of randomisation. We therefore allowed the 
inclusion of those aged over 80 years, with minor neurological deficits, a previous history 
of stroke and concomitant diabetes, or seizure at the onset of stroke if advanced imaging 
confirmed the presence of an ischaemic lesion. Patients with other standard 
contraindications for alteplase311,315 were excluded, as were those with contraindications 
for radiological iodinated contrast, including eGFR < 30 mL/min or with a previously 
identified allergy to contrast. The protocol was approved by the ethical committee 
responsible for trials involving adults with incapacity (Scotland A REC, Reference: 
11/SS/0039); this study’s clinical trial registration number is NCT01472926.  
All patients who were referred for possible thrombolysis to the acute stroke unit were 
screened by a member of the clinical research team. Once the decision in favour of 
thrombolysis was made by a clinician, patients or their representatives (if patients did not 
have the capacity to consent) were approached for study consent. Witnessed consent and 
consent by an independent physician was permitted if the patient could not write due to 
physical impairment or in the event of the patient lacking capacity and no representative 
being available. There was no restriction of time during the day for patient recruitment. 
During the study period, all patients suitable were approached for study inclusion. 
Patients were able to withdraw from the study at any time for any reason with an option 
of continuing clinical follow-up offered for those who were unwilling to undergo further 
imaging. Patients could also be withdrawn at the discretion of the clinical research staff if 
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they were found to have an alternative diagnosis to that required by the study protocol. 
All data collected prior to withdrawal were retained. 
All patients who arrived in the acute stroke unit received a full clinical assessment 
including the symptom onset time, past medical history, family history, and medication. 
The severity of the stroke was evaluated with the NIHSS. The pre-morbidity functional 
status was recorded using a modified Rankin Scale. Baseline blood pressure, pulse, 
temperature, capillary glucose and weight were measured. There was no study specific 
laboratory test. As determined by routine clinical procedures, all patients had a baseline 
electrocardiogram (ECG), urea and electrolytes, eGFR, blood glucose, full blood count, 
and coagulation. The study specific procedures included the assessments of the NIHSS 
scale at 24 hours, 72 hours and day-7 (or at discharge if earlier); modified Rankin Scale 
assessments were carried out at days 30 and 90. Capillary glucose was monitored every 
four hours in the first 48 hours from admission; vital signs were checked as per stroke unit 
protocol. The full study schedule is shown in Table 3-3. mRS assessment was performed 
at 30 days and 90 days via telephone interview. All clinical assessments were performed 
by trained observers. Whilst observers performing clinical assessments were not 
informed of treatment allocation at the time of follow-up, as a single-centre trial, blinding 
to treatment allocation for clinical end-points could not be guaranteed. 
Concomitant medications were recorded, as were all adverse events occurring from the 
point of study entry until 90 days post stroke, the defined study completion time. 
Treatment decisions were made by a clinician based on clinical judgement and the NCCT 
excluding ICH. Following written informed consent, a central computerised system which 
used a minimisation algorithm to balance allocation by age group (≤80, >80) and baseline 
NIHSS score (1-9, 10-15, ≥16) randomly assigned patients in a 1:1 ratio to standard dose 
alteplase (0·9mg per kilogram to a maximum 90mg, with 10% of dose as initial bolus, 
followed by 90% over one hour infusion) or tenecteplase (0·25mg per kilogram, to a 
maximum 25mg as a single bolus). Clinicians responsible for routine clinical care were 
aware of treatment assignment since additional infusion over 1 hour is required for 
alteplase administration. Patients were not informed of treatment allocation. The 
majority lacked capacity at the time of treatment, and would only have been aware of 
treatment allocation if they had prior knowledge of the different modes of drug 
administration (Figure 3-1) 
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Figure 3-1. ATTEST study flow chart 
 
 
Patient referred for IV thrombolysis
Clinical Evaluation deems patient eligible for IV alteplase pending CT 
Consent from patient or legal representative or independent clinician 
for ATTEST randomisation dependent on CT result
Routine CT confirms eligibility
IVRS system contacted
Additional CTP, CTA
R
Alteplase 0.9mg/kg (max 90mg)
10% bolus + 90% IVI over 1h
Tenecteplase 0.25mg/kg (max 25mg)
Bolus
Routine Clinical Monitoring
BP, HR, Neurological Status /15 mins for 2h; then hourly for 22h; then 4hrly for 24h
Capillary Blood Glucose 4 hourly for 48h
24 hours
CT, intracranial CTA
NIHSS
30 and 90 Day Follow-up
NIHSS, mRS, BI, Home Time
72h
NIHSS
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Table 3-3. Scheduled assessments for the ATTEST study 
Study Procedure  Pre- Randomisation Randomisation 0-2h 2-24h 24-48h 72 h Day 7 (2) Day 30 (5) Day 90 (7) 
Obtain Informed 
Consent or assent from 
next of kin 
√         
Review 
Inclusion/Exclusion 
Criteria 
√         
CT brain *    ×     
CT perfusion X         
CT Angiography X    √     
Vital Signs (temperature, 
blood pressure, pulse, 
respiration rate) 
*    √ √ √   
Post-thrombolysis 
observations (BP, pulse) 
  *1 *2      
Capillary Blood Glucose *  *3 *3      
Physical Examination- 
NIHSS 
*    × √ √   
Weight  *         
Bloods - Haematology 
and Biochemistry 
*         
IVRS  √        
Pregnancy Test (female 
patients of child bearing 
potential) 
√         
Trial Drug  √        
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Administration 
mRS √       √ √ 
Adverse Events 
Evaluation 
    √ √ √ √ √ 
Home time evaluation         √ 
√study-specific procedure; *clinically routine procedure (data captured for study); ×procedure clinically routine in some patients 
1 BP and pulse monitored every 15 minutes for 2h after starting IV thrombolysis 
2 BP and pulse monitored hourly from 2-24h after starting IV thrombolysis 
3 Capillary thrombolysis for 48 hours blood glucose monitored 4 hourly after starting IV  
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3.3. Definition of outcomes 
We defined the volumes of tissue fulfilling characteristics of the ischaemic penumbra 
(tissue that is hypoperfused but potentially salvageable) and core (hypoperfused tissue 
that will inevitably infarct) based on established probabilistic thresholds147 for CT 
perfusion. The primary outcome measure was the percentage of penumbral salvage at 
24-48 hours post treatment56,58 using the baseline CTP-defined penumbra plus core 
volume minus final infarct volume on follow-up NCCT. 
Recanalisation was defined as TIMI grade 2-3225 on follow-up CTA371; early clinical 
improvement was defined by a reduction of the NIHSS score of eight points or more, or 
an NIHSS score of zero or one at 24-48 hours post treatment; patients who achieved mRS 
0-1 at 30 and 90 days76,315 were deemed to have had an excellent outcome. Safety 
outcomes were the proportion of patients with Symptomatic Intracerebral Haemorrhage 
(SICH) at 24-48 hours post treatment defined by: i) the SITS-MOST318 criteria 
(Parenchymal haemorrhage [PH] type 2 or remote PH2 on 24-48h NCCT, plus neurological 
deterioration of ≥4 points NIHSS score); and ii) the ECASS II definition311 (any ICH on 
follow-up NCCT with clinical deterioration); and iii) any ICH. 
3.4. Study data recording and transfer 
All patients were identified by a study number in the form of 01-xxx, with 01 as the site 
number, and the subsequent three digits as the patient number. 
All clinical data were recorded on a paper based study workbook which was stored at our 
research office and subsequently transferred onto a web-based electronic data system. 
The electronic data system was designed and maintained by the Robertson centre for 
biostatistics, University of Glasgow, who oversaw the data management and was 
responsible for statistical analysis. 
3.5. Study imaging 
Baseline imaging comprised NCCT, and CT perfusion and CTA. Since CTP and CTA were 
study imaging only, treatment decisions were not made on the basis of this information. 
They can be acquired either before or immediately after the study drug administration. 
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Follow-up imaging included NCCT and an intracranial CTA at 24-48 hours post 
thrombolysis. Additional imaging could be carried out at the clinician’s discretion. 
All scans were carried out on a Philip 64 slice multidetector scanner. Whole brain NCCT 
was acquired first, (5mm slice thickness FOV 218 x 218mm, 120kv, 171mA or 0.9mm slice 
thickness, Field of View [FOV] 250x250mm, 120kV, 404mA) followed by CTP with 40mm 
slab coverage from the basal ganglia (8x5mm slices, FOV 25cm, 80kVp, 476mAs, 2 second 
cycle time, 30 cycles) using a 50mL contrast bolus administered at 5mLs/second (350 
Xenetix) via a large-gauge cannula. The subsequent CTA covering from the aortic arch to 
the top of the lateral ventricles (0.67mm slice thickness, 120kV, 475mA) was acquired 
during the first arterial pass of contrast (Xenetix 350, 60mLs, followed by 30mLs of saline 
bolus, both given at 5mL/sec). 
3.6. Imaging processing and analysis 
CT workstations were only used to undertake processing of CTP and CTA for clinical 
reporting and, if required, to inform clinical management. 
Study imaging records were transferred from clinical scanners or radiology archives after 
removal of individual identifiers from the Digital Imaging and Communications in 
Medicine (DICOM) file (patient name, date of birth, hospital number or similar unique 
identifier) and were identified with the study number. All imaging analysis was 
undertaken on separate secure computer workstations using a commercially available 
software package MIStar (Apollo Medical Imaging Technology, Melbourne, Australia). 
All imaging was analysed by two clinical research fellows (XH and BC) separately after the 
study was completed in order to minimise the likelihood of linking scans with treatment 
allocation. Inter-observer agreement was assessed for all parameters analysed. 
Volumetric analysis was carried out by each research fellow twice. The average of the 
four readings was taken as the final reading for analysis. Disagreements in categorical 
readings were resolved by the consensus of experienced neurologists or neuroradiologists 
who were also blinded to treatment allocation. The adjudication results of ICH on follow-
up NCCT according to the ECASS II radiological definition311 were used for the final safety 
outcome analysis. 
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Baseline NCCT was assessed for early ischaemic changes using the ASPECT score128 with 
5mm thickness slices imaging, and the presence or absence of hyperdense vessels with 
0.5mm thickness slices imaging. 
The MIStar software package provides four parameters when processing CTP: cerebral 
blood flow, cerebral blood volume, mean transit time, and delay time. Arterial input 
function and Venous Output Function (VOF) were manually selected from a Region of 
Interest (ROI) in the contralesional anterior cerebral artery and superior sagittal sinus 
respectively when possible. Motion correction was applied automatically using package 
provided options. A noise elimination technique “closing clustering” of <5mm2 was used 
to minimise the small artifactural pixels probably induced by noise142. After AIF and VOF 
selection, a Hounsfield Unit filter was applied in order to mask CSF (15) and bone (700), 
leaving only brain parenchyma as far as possible. Voxels with CBV values >90cm3/100g 
were then masked, as arterial voxels mimic tissue areas of high perfusion and their 
exclusion improves the accuracy of CTP relative to PET372 (Figure 3-2 to 3-4). 
 
Figure 3-2. CTP maps generated with MIStar software (Top four panels: CBV, 
CBF, MTT, Angiography; Lower four panels: penumbral map, DT, contrast CT, 
and time-attenuation curve for arterial input function [red], and venous 
output function [blue]). 
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Figure 3-3. After applying thresholds masking CSF and bone 
 
Figure 3-4. After applying thresholds masking voxels with CBV value 
>90cm
3
/100g) 
A modified SVD deconvolution was used to obtain the tissue enhancement curve and AIF 
with compensation for the effects of arterial delay and dispersion373. A series of delay 
time values, DTi ranging from 0 to Tmax were applied and for each delay time value a 
modelled arterial transport function was convolved with the measured global AIF to 
produce the AIFi which was used for SVD deconvolution of the tissue curve to produce an 
impulse residue function IRFi with its maximum appearing at Tmax (i). DT was determined 
as the minimal DTi value which produces Tmax (i) =0. CBF and CBV were calculated from 
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the peak height and area under the curve of the tissue enhancement curves respectively 
with MTT =CBV/CBF. 
Core volume was defined as tissue with reduced CBF (relative CBF < 40% that of the 
contralesional hemisphere) and prolonged DT (relative DT < 2 sec)147; penumbra volume 
was defined as tissue with prolonged DT only (relative DT > 2 sec). Total CTP lesion 
volume was calculated as the combination of core volume and penumbra volume (Figure 
3-5). 
The presence and location of arterial occlusions were determined using the baseline CTA. 
An occlusion visualised using CTA source images and 3D Maximum Intensity Projection 
(MIP) reconstructions was defined as the absence of contrast filling in a vessel separating 
the proximal and distal portions of the vessel81. The degree of carotid stenosis was 
collected as part of the clinical data from clinical radiological reports. 
The follow up NCCT was evaluated for the presence or absence of ICH, the degree of brain 
swelling (Table 3-4) and the ASPECT score for the quantification of infarction. 
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Table 3-4. The classification of the degree of brain swelling post thrombolysis 
(Adapted and modified from IST-3 imaging analysis protocol
374
) 
 
Brain swelling 
No Swelling (grade 0) 
 
Effacement of adjacent lateral ventricle 
(grade 1) 
 
Effacement of the lateral and the third 
ventricle (grade 2) 
 
Midline shift (grade 3) 
 
Because of the limited coverage of CTP, the co-registered infarct volume was used to 
calculate penumbral salvage. Both follow up NCCT and CTP scans were loaded side by side 
into a fusion tool function using MIStar. A rigid body 3D transformation was used to 
register the follow up structural imaging to the perfusion scan. Structural CT sequences 
were reformatted manually and visually verified to match the orientation of the original 
CTP (Figure 3-6). Reformatted structural CT slices resulting from co-registration were used 
to measure the final infarct volume with manually drawn ROIs using visual inspection 
(Figure 3-7 to 3-9). The combination of the co-registered infarct volume and the infarct 
volume beyond the co-registered slices produces the total infarct volume. 
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Figure 3-5. An example of Ischaemic core and penumbra measurement (The 
left panel showed penumbra region [green area], the right panel showed 
ischaemic core [red area], the yellow circle was region of interest). 
 
 
Figure 3-6. Co-registration (The top three panels: CT perfusion with 
superimposed [red] 24 hour CT following co-registration; middle three panels: 
24 hour CT at the same anatomical level; lower three panels: CT perfusion at 
the same anatomical level) 
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Figure 3-7. Reformatted 24 hours CT (with the red colour overlay − top left 
eight panels) presented in a same window as the original 24 hours CT (lower 
right eight panels) and baseline CTP (lower left eight panles). (CT perfusion 
angiography − top right eight panels). 
 
Figure 3-8. Reformatted 24 hours CT (with the red colour overlay turned off − 
top left eight panels) presented in a same window as the original 24 hours CT ( 
lower right eight panels) and baseline CTP (lower left eight panels). (CT 
perfusion angiography − top right eight panels). 
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Figure 3-9. The measurement of co-registered final infarct volume (left panel: 
manually drawed ROI [region within the yellow line] of final infarct volume; 
middle panel: the ROI transposed onto the corresponding penumbra map 
[core-red, penumbra-green]; right panel: core area was excluded by applying 
threshold, left with penumbra only. The penumbra volume infarcted is the 
green area within the ROI). 
To minimise the opportunity of including false positive pixels, ROIs drawn for final infarct 
volume measurement were transposed onto the corresponding CTP slice (Figure 3-9). 
Manual adjustment was applied when necessary in order to match to the same 
anatomical region. The penumbra volume that was infarcted was calculated from the ROI 
on the corresponding CTP slice. The following equations were used to determine relevant 
values: 
 Infarct Growth = Co-registered infarct volume - Core volume 
 Penumbra volume salvaged = penumbra volume – penumbra volume that 
infarcted; 
 Percentage of penumbra salvaged = (penumbra salvage/penumbra volume) x100 
Recanalisation was determined on follow up CTA using a TIMI scale371, a grading system 
adapted from cardiologists to describe recanalisation and reperfusion in revasculisation 
studies. We also used the TICI scale375, but found its application to be difficult due to the 
lack of dynamic information on the CTAs. 
   
 
96 
 
3.7. Statistics 
The statistical analysis presented in this thesis was performed mainly with IBM SPSS 
statistics (SPSS Chicago, Illinois, USA v.19) and SAS (SAS Software limited, United Kingdom 
v.9.3); StatsDirect 2.8 was used in inter-observer agreement calculation and meta-
analysis. 
3.8. Assessment and Scales 
3.8.1. NIH Stroke Scale 
The National Institute of Health Stroke Scale (Appendix 1) is a 42 point scale developed to 
provide quantitative objective measurements of neurological deficit caused by stroke. A 
score of zero indicates no neurological deficit, whilst a score of 42 indicates death. The 
NIHSS is probably the most frequently used scale in stroke studies and in clinical practice 
due to its simplicity and reasonable reliability across different professional groups. 
However, certain items assessed using the NIHSS such as facial palsy, gaze and ataxia 
were shown to demonstrate poor inter-rater reliability. Non-dominant hemisphere 
infarcts can be underscored due to its emphasis on language and the abililty to follow 
commands376. The severity of posterior circulation strokes is poorly represented using the 
NIHSS. The result of various factors is that the overall scale does not always reflect the 
severity of a stroke. Patients with isolated dysphasia or hemianopia are underestimated 
on the scale despite their significant functional disability. If only part of the limb is 
affected, motor deficits can be underestimated using the NIHSS. The baseline NIHSS score 
has been shown to be a strong predictor for clinical outcomes377. In reperfusion studies, 
NIHSS ≤ 1, or improvement in NIHSS ≥ 8 points at 24 hours post treatment are commonly 
considered as good clinical outcomes. This may however still represent a significant 
functional disability if the baseline NIHSS score is high. 
3.8.2. Modified Rankin Scale 
The modified Rankin scale is an ordinal hierarchical grading from zero (no symptoms) to 
six (death) for measuring the degree of disability or dependence in daily activity (Table 3-
5). It is the most used functional outcome measurement in stroke studies. However, the 
descriptions given for the categories of the mRS are too broad and leave ample spaces for 
subjective interpretation, which results in relatively lower inter-rater agreement 
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compared with other scales378. Inter-observer reliability improved moderately with the 
more recently developed structured mRS interview and video training system378,379. The 
more recent Rankin Focused Assessment provided a much clear criteria for scale 
assignment and requires much less time in assessment380, which may make it more 
popular in the future studies. 
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Table 3-5. Modified Rankin Scale 
Scale Description 
0 No symptoms at all. 
1 No significant disability despite symptoms; able to carry out all usual duties 
and activities. 
2 Slight disability; unable to carry out all previous activities, but able to look 
after own affairs without assistance. 
3 Moderate disability; requiring some help for more complex tasks (eg finances), 
but able to walk without assistance. Able to manage alone at home for at least 
1 week. 
4 Moderately severe disability; unable to walk without assistance and unable to 
attend to own bodily needs without assistance. Able to be left alone for at 
least a few hours during the day. 
5 Severe disability; bedridden, incontinent and requiring constant nursing care 
and attention. 
6 Dead. 
3.8.3. ASPECT Score128 
ASPECT score is a 10 points scoring system developed to quantify early ischaemic changes 
on presenting NCCT for MCA stroke. It segments the MCA vascular territory, and deducts 
one point if hypodensity or swelling is presented (Figure 3-10). The use of ASPECT 
improved the inter-rater agreement in the assessment of early ischaemic changes on 
NCCT with training, and is a commonly used score in AIS trial patient selection. 
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Figure 3-10.  Axial NCCT images showing the MCA territory regions as defined 
by ASPECTS. C −  Caudate, I −  Insularribbon, IC −  Internal Capsule, L −  
Lentiform nucleus, M1 −  Anterior MCAcortex, M2 −  MCA cortex lateral to the 
insular ribbon, M3 −  Posterior MCA cortex, M4, M5, M6 are the anterior, 
lateral and posterior MCA territories immediately superior to M1, M2 and M3, 
rostral to basal ganglia. Subcortical structures are allotted 3 points (C, L, and 
IC). MCA cortex is allotted 7 points (insular cortex, M1, M2, M3, M4, M5and 
M6). 
3.8.4. Scales to describe vessel patency (TIMI, TICI) (Table 3-6) 
The TIMI scale was initially used to grade the severity of vessel occlusion, ranging from 
zero (no flow) to three (normal flow), but was then subsequently used widely in 
cardiology revasculisation studies to describe vessel patency. Stroke physicians have 
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recognised that the TIMI scale does not give a description for distal branch perfusion. The 
TICI scale223 was subsequently developed to account for that, and has become popular in 
cerebral endovascular intervention studies. However, the TICI score was designed for 
conventional angiography, and dynamic information is crucial in order to use it 
accurately. Since most CTAs currently only provide a single-phased image, the TICI scale is 
unlikely to describe recanalisation more accurately than the TIMI scale. 
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Table 3-6.  TIMI and TICI scale 
Grade TIMI TICI 
0 No reperfusion No perfusion beyond the occlusion  
1 Penetration 
without perfusion 
Penetration but no perfusion, contrast penetration 
exists past the initial obstruction but with minimal 
filling of the normal territory  
2 Partial reperfusion a  Partial perfusion with incomplete distal branch 
filling of <50% of the expected territory  
b  Partial perfusion with incomplete distal branch 
filling of ≥50-99% of the expected territory  
c  Near complete perfusion without clearly visible 
thrombus but with delay in contrast run-off  
3 Complete 
reperfusion 
Full perfusion with normal filling of all distal 
branches of the expected territory in a normal 
haemodynamic fashion  
3.8.5. ECASS Classification of haemorrhagic transformation 
The haemorrhagic transformation following ischaemic strokes with or without 
reperfusion therapy is classified radiologically into four types381: Haemorrhagic Infarction 
(HI) 1 - Small petechiae along the margins of the infarct; HI2 - Confluent petechiae within 
the infarcted area but no space occupying effect; PH1 - Blood clots in ≤30% of the 
infarcted area with space occupying effect; PH2 - Blood clots in >30% of the infarcted area 
with space occupying effect (Figure 3-10). 
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Figure 3-11. Examples of ECASS 2 radiological classification of ICH from the 
ATTEST study imaging (from above left clockwise: HI1, HI2, PH1, PH2) 
3.8.6. The SITS-MOST definition of symptomatic intracerebral haemorrhage 
As discussed in Chapter 2, a number of definitions of symptomatic ICH have been used in 
stroke thrombolysis studies as safety outcomes. Among them, the SITS-MOST 
definition318 ensures the neurological deterioration is from the result of an ICH rather 
than from the extensive infarction or associated swelling. It uses the combination of the 
deterioration of the NIHSS scale of more than four from the baseline or the lowest 
subsequently recorded score within a time frame of less than 36 hours from treatment 
and the ECASS radiological criteria of PH2 to define symptomatic ICH. It is now widely 
used in stroke reperfusion studies. 
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Chapter 4 Does the delay 
between bolus and infusion 
in thrombolysis affect 
outcome? 
4.1. Introduction 
Timely recanalization is the goal in the management of acute ischaemic strokes. The odds 
of achieving functional independence diminishes the later the treatment is initiated70. The 
current approved therapy, the administration of IV rtPA within 4.5 hours from symptoms 
onset improves functional outcomes382, but its efficacy is limited to a small proportion of 
patients. 
rtPA has a very short half-life (4-9 minutes)274 requiring an hour-long continuous infusion 
following a front-loaded bolus to maintain therapeutic plasma concentration. Large 
randomised trials such as the NINDS study assumed no significant delays in the 
commencement of maintenance infusion dosing. 
Recanalization is achieved in only 50% or less of patients who receive IV rtPA319. Factors 
that contribute to this include patient factors such as the origin and the extent of the clot, 
the adequacy of collateral flow, and possibly blood glucose, but drug factors including 
pharmacokinetics may also be relevant. The emphasis of door-to-needle, or onset-to-
treatment times focuses on the delays in the start of treatment. However, delays 
between bolus and maintenance infusion, and interruptions of maintenance infusion, are 
common. We questioned whether delays in the completion of treatment affected 
functional outcomes. 
4.2. Methods 
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We performed a retrospective study in a single tertiary neurology referral centre. Patients 
included were those who received IV rtPA treatment in 2010, and patients who received 
thrombolysis between 2008 and 2011 from two local imaging study databases; the 
Multicentre Acute Stroke Imaging Study (MASIS) and the Post Stroke Hyperglycaemia 
(POSH) study,  two studies that performed CT or MRI angiography at baseline and 24-72 
hours. We collected information for stroke onset time, bolus time, infusion start and 
finish time, any interruption during the infusion, along with clinical information, such as 
baseline and 24 hours NIHSS scores, baseline occlusion, recanalisation status and day 90 
mRS. We compared clinical outcomes and recanalization rates in patients who had bolus-
infusion delay (BID) and those who had not. We defined BID as a delay between bolus and 
infusion start of more than nine minutes (based on one plasma half-life of rtPA). An early 
neurological improvement in 24 hours was defined as a reduction of NIHSS score of ≥ 8 
points, or an NIHSS score = 0 or 1 at 24 hours; a favourable functional outcome was 
defined as mRS 0 – 1 at day 90. 
Imaging assessment comprised pre-treatment CTs, with CTA covering from the aortic arch 
to the top of the lateral ventricles, with follow-up CT at 24 hours, and intracranial CTA at 
24-72 hours. The detailed procedure of acquiring imaging is described in Chapter 3 above. 
CTA occlusion and recanalization were determined by a single reader (FM). The vessel 
patency on follow-up CTA was defined as none, partial, or complete recanalization. SICH 
was defined as any intracerebral haemorrhage on follow-up non-contrast CT with clinical 
deterioration using the ECASS II definition311. 
Baseline characteristics in the two groups were compared using the independent t test, 
the Mann-Whitney U test for continuous variables, Chi-square, and Fisher’s test for 
categorical variables. Binary logistic regression was used to investigate whether there was 
an association between the BID, clinical outcomes and recanalization rates. mRS 
distribution (“ordinal shift”) analysis was carried out with ordinal logistical regression. 
All statistical analysis was carried out with SPSS 19 and SAS 9.3. 
4.3. Results: 
   
 
105 
 
118 patients with documented bolus times and infusion start times were included in this 
study, of which 63 patients had CTA assessments: 49 of these had occlusion on pre-
treatment CTA (Figure 4-1). The baseline demographic information is shown in Table 4-1. 
    
Figure 4-1. Study CONSORT chart 
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Table 4-1. Baseline demographics for all patients in the study 
 
 
 
 
 
 
 
 
 Group with BID Group without BID p Value 
 N=90 N=28  
Age year Mean (SD) 70 (17) 68.5 (17) 0.47 
Sex male no. (%) 50 (55.6) 21 (75) 0.07 
Baseline NIHSS 
Median (IQR®) 
14 (8-19) 13 (7-18) 0.74 
Basline mRS 
Median (IQR) 
0 (0-1) 0 (0-1) 0.74 
OTT (minutes) Mean 
(SD) 
170 (70) 173 (77) 0.92 
Co-morbidities 
Hypertension no. 
(%) 
59 (66%) 15 (54%) 0.25 
Diabetes no. (%) 13 (14%) 6 (21%) 0.38 
Previous MI no. (%) 10 (11%) 2 (7%) 0.54 
Atrial Fibrillation 
no. (%) 
20 (22%) 7 (25%) 0.76 
Previous stroke or 
T.I.A., no. (%) 
19 (21%) 5(18%) 0.71 
Hyperglycaemia 
(Random glucose 
>7.0mmol/l) no. (%) 
24 (27%) 9 (32%) 0.57 
Hyperlipidaemia 
no. (%) 
20 (23%) 4 (14%) 0.43 
Peripheral vascular 
disease n. (%) 
3 (3%) 1 (3%) 1 
SD Standard Deviation; ®IQR Interquartile Range 
   
 
107 
 
 
 
Figure 4-2. Distribution of all 118 patients with/without bolus infusion delay 
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Figure 4-3. Distribution of  infusion time of 76 patients who completed 
infusion and had documented infusion start and finish time. 
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Figure 4-4. Distribution of total treatment time from initial bolus to the 
completion of infusion in 76 patients who completed infusion and had 
documented infusion start and finish time. 
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Figure 4-5. Change of NIHSS in 24 hours in the group with BID and the group 
without BID. 
 
 
 
 
Figure 4-6. mRS at day 90 between the two groups. 
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Figure 4-7. The comparison of Recanalization rates between the group with 
BID and the group without BID. 
 
There were only four patients who had no documented bolus infusion delay. The range of 
delays between bolus and infusion was 2 to 65 minutes (median [IQR] 15 [10- 20]) (Figure 
4-2). Using our definition of BID, 89 (75%) patients had a delay. In 79 patients who had 
documented infusion start and finish times, 58 (73%) completed the infusion within 60 
minutes (Range 30 – 100 minutes, median [IQR] 60 [60-60]) (Figure 4-3); 3 (4%) infusions 
were discontinued prematurely due to clinical deterioration. One patient’s infusion 
finished in 30 minutes, and another’s completed in 40 mintues. No reason was 
documented in the clinical notes for the shortened infusion.  There were 8 (10%) patients 
whose infusion duration ≥ 65 minutes, of which one was due to the interruption of scan, 
one due to clinical deterioration, and another one due to delayed blood results. For the 
remaining five patients, no reason was documented for the extended infusion time. Total 
treatment times ranged between 60 to 125 minutes (median [IQR] 75 [69-80]) (Figure 4-
4). The differences in outcome measures including early neurological improvement, mRS 
at day 90 and recanalization rates between the two groups are shown in Figures 4-5 to 4-
7. The 90 day mRS distributions show higher mortality and reduced proportions of 
patients with favourable outcomes in the group with BID. However the mRS shift analysis 
adjusted for the baseline NIHSS score and age showed no significant statistical shift of day 
90 mRS between the two groups (P=0.92). 
In a binary logistic regression model adjusted for known predictors of outcome (age, 
initial NIHSS score, OTT and baseline glucose), no significant association between early 
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neurological improvement (P=0.73), day 90 favourable clinical outcomes (P=0.9) and BID 
was found. In those 49 patients who had vessel occlusion on the initial CTA, no significant 
association was found between the recanalization rate and BID (P=0.92). The same 
analysis was performed between the group who had BID of more than 15 minutes, and 
the group with BID<15minutes. No significant association was demonstrated between the 
early neurological improvement (p=0.3), favourable clinical outcomes at day 90 (p=0.34), 
recanalisation (p=0.83) and BID of more than 15 minutes.  
15 (13%) out of the total 118 patients had intracerebral haemorrhages on the 24 hour CT 
scan. Three (10%) were from the group without BID, none had SICH; 12 (13%) were from 
the BID group, of whom three (3%) who were PH type 2 also fulfilled the SICH criteria, but 
no significant difference in SICH rates was demonstrated between the two groups 
(P=1.00). 
4.4. Discussion: 
This retrospective study of tPA administration showed that, in practice, the extended 
administration of tPA is common, mainly due to delays between the initial bolus and 
subsequent infusion commencement. In some cases, the delays were quite prolonged. 
Experiments in rabbits showed that the rate of elimination of tPA in vivo is rapid 
(16.1ml/min/kg), especially within the first hour (plasma half-life in rabbits is three 
minutes). 15 minutes after IV bolus administration, only 1% of the tPA still remained in 
circulation283. In humans, an early pharmacokinetic study of a large single bolus dose 
(50mg over 2 minutes) compared with a front-loading dose regime (10mg as bolus, 
followed by 50mg infusion in 1 hour, and 30mg in 1.5 hour—60mg given within the first 
60 minutes) in acute MI thrombolysis showed that 10 minutes after the bolus, less than 
50% remained in the system383,384 . It is worth noting that the purpose of this study was to 
compare a high single bolus regime with the conventional infusion regime. In this study, 
the initial recanalization rates at 60 minutes determined by angiography were similar in 
the two groups, with a higher rate of recurrent ischaemic events and reocclusions in the 
former group. It is thought that the initial high plasma concentration was probably 
responsible for the higher recanalization rate; whereas the principal function of the 
maintenance infusions was probably the prevention of reooclusion385. 
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The pharmacokinetic studies of IV alteplase carried out in healthy populations and MI 
patients demonstrated that the front-loading regime with an initial bolus followed by an 
infusion led to much quicker attainment of steady state concentration (4 minutes)386, 
rather than about 20 minutes for infusion only dosing387. A study388 which simulated the 
effect of rtPA bolus-infusion delays using a mathematic model showed a significant drop 
of plasma concentration to 25% with a bolus infusion delay of 15 minutes (the 
approximate mean delay time in our sample). As expected, it also affected the speed of 
achieving therapeutic plasma concentration (which took about 36 minutes in the model, 
as opposed to 3 minutes in the situation with no delay). 
No pharmacokinetic study has been performed in which tPA has been studied in relation 
to acute ischaemic stroke. The front-loading regime we currently use was presumably 
adapted from cardiology studies. However, fundamental differences between acute MIs 
and ischaemic strokes exist. Coronary arteries are of smaller diameter than the major 
intracranial vessels (the average diameter of the left main stem of the coronary artery is 
0.004-0.005cm389; the average diameter of the middle cerebral artery ranges from 0.3-
0.5cm390) and the pathological process of MI is one of in-situ plaque rupture and 
thrombosis; most strokes arise from the embolism of clots formed more proximally, and 
of varying composition, and in many instances the clot volume is much larger. The total 
dosage of rt-PA used in the treatment of acute ischaemic strokes is smaller compared 
with that used in acute MIs, with 10% of dose as initial bolus and 90% of dose infused 
within one hour, defined by ascending dose studies in stroke that escalated dose until ICH 
was encountered. The initial plasma concentration is lower in comparison with the 
standard accelerated infusion regime used in acute MIs275. If there is a delay between 
bolus and the subsequent infusion, the speed of recanalisation and subsequent attempts 
to prevent reocclusion can both be affected. In our sample, we did not demonstrate any 
difference in clinical, imaging or safety outcomes between the two groups. 
The strength of the present study is that both clinical outcomes and imaging outcomes 
were assessed. We confirmed significant BID in our routine clinical practice. A clinical 
focus on shortening onset-to-treatment time emphasises the initiation of treatment but 
perhaps at the expense of timely commencement of the maintenance infusion. Systemic 
delays include relative ease of bolus injection in the CT scanning environment compared 
   
 
114 
 
to set-up of an infusion pump; the need to transfer patients from CT to the stroke unit 
environment; and competing nursing priorities once in the stroke unit. 
This study was retrospective and reflects a single centre experience. The sample size was 
small, although the stroke characteristics were well-balanced and similar to most general 
acute stroke patients; only around half of the subjects had a CTA assessment, and even 
fewer contributed useful data on the basis of having an initial occlusion identified. In the 
statistic model we used, established factors which correlated with outcomes, such as 
OTT391, the initial NIHSS score391, and high serum glucose 392 (defined as glucose > 7.0 
mmol/l) did not show any significant association with outcomes, except for the initial 
NHISS, which was significantly correlated with day 90 favourable clinical outcomes 
(P<0.001). However, another similar study393 with a larger sample size (n=229) failed to 
show any significant difference in functional outcomes in patients who were treated with 
BID and those who did not have BID. The complexity of pathophysiology in ischaemic 
strokes ensures that the determination of successful recanalisation is multifactorial. To 
demonstrate a significant difference in clinical or imaging outcomes influenced by bolus 
infusion delay alone may require a very large sample size. 
Given that a zero delay between bolus and infusion is difficult to achieve, newer 
thrombolytic agents with a longer plasma half-life which enable single bolus injection may 
be a solution in clinical practice. 
4.5. Conclusion: 
Extended IV tPA treatment is common in clinical practice, mainly due to delays between 
initial bolus and following infusion. This may affect clinical and imaging outcomes, but this 
has not been demonstrated in the present sample. Further study in this area is 
warranted. 
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Chapter 5 The ATTEST study, 
demographics and main 
outcomes 
5.1. Introduction 
As discussed in Chapter 2, alteplase significantly improves the likelihood of disability-free 
recovery, but it has limited fibrinolytic efficacy, achieving arterial recanalisation in fewer 
than 50% of patients319. Among those who recanalise, only about half do so within two 
hours of drug administration394. Clinically, the most recent meta-analysis70 included all 
major thrombolysis studies using alteplase showed that only 33.8% (1145/3391) treated 
within six hours achieved independence (mRS 0-1) at three months; in practice, if treated 
within three hours, 38.9% (2386/6136) of patients recovered completely at three months 
in the SIT-MOST database318. Tenecteplase is purposely modified to improve efficacy283 
through higher affinity binding to fibrin, greater resistance to inactivation by PAI-1, lack of 
procoagulant effects, and longer free plasma half-life. 
In animal models, tenecteplase took significantly less time to reperfuse compared with 
alteplase, with greater recanalisation rates and reduction of thrombus burden, and 
significantly less blood loss from existing wounds284. In acute MI, tenecteplase 
demonstrated a similar therapeutic efficacy and lower overall bleeding risk than 
alteplase290, the ICH rates were not different in the two groups probably due to the small 
number of occurrence of ICH in MI. There was a suggestion that tenecteplase treated 
patients might have a greater likelihood of early recanalisation than was the case with the 
alteplase group at 60 minutes, although this was not statistically significant395. 
Investigation of new thrombolytic agents in acute stroke has, until recently, concentrated 
on time periods beyond the 4.5 hour time window from symptom onset established for 
alteplase in order to treat more patients. However, given that more than 60% alteplase 
treated patients according to the current guideline93 still remained disabled, seeking a 
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better, alternative, thrombolysis agent is an essential element of the search to improve 
outcomes of stroke patients. Dose-ranging studies of tenecteplase in acute stroke have 
been reported325,326. Parsons and colleagues194 reported superiority of tenecteplase over 
alteplase in terms of both imaging-defined reperfusion and clinical outcomes in a selected 
group of patients with large artery occlusions and favourable brain perfusion patterns 
defined on CT. However, it is unclear how the effect sizes observed in a highly selected 
population will translate into more general populations. We undertook a phase II 
randomised, controlled clinical trial comparing alteplase with tenecteplase in a 
thrombolysis-eligible acute ischaemic stroke population, using imaging criteria as an 
exploratory outcome measure rather than as a selection criteria, in order to define 
possible effect sizes in a general stroke population eligible for intravenous thrombolysis. 
5.2. Methods 
The detailed methodology of the ATTEST study was described in Chapter 3. The trial was 
conducted at a regional neurosciences centre providing a comprehensive stroke service 
to a population of approximately 450,000, with some additional secondary transfers for 
thrombolysis assessment from seven regional stroke services. Total admissions are 
approximately 900 per annum, of whom approximately 600 are confirmed to have had 
ischaemic strokes. Thrombolysis numbers average 100 per annum. Clinical research staff 
recruited to the trial and additionally supervised multimodal CT acquisitions, including out 
of hours. 
All eligible patients were screened and approached for consent to the study once the 
treating physician deemed they were candidates for thrombolysis. All patients were 
weighed when they arrived in the unit. The patient or the relatives were given the study 
information sheet, and the study was discussed by the research team with the 
patient/relative. Immediately following the NCCT confirming eligibility for thrombolysis, 
consent was taken. All efforts were  made to avoid delaying treatment by recruiting 
patients into the study. In the rare situation (on two occations during the whole study) 
when thepatient had no capacity, and there was no relative available, an independent 
clinician’s consent was sought. The whole process from screening to consent typically 
took approximately 15 minutes.  
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5.2.1. Inter-rater agreements 
The methods of imaging analysis to derive the primary and secondary imaging outcomes 
were detailed in Chapter 3. All imaging parameters were analysed by two research 
fellows (XH and BC). The inter-rater agreements were assessed initially in a test set of 
scans and then evaluated in the full set of the ATTEST study scans. 
5.2.1.1. Agreement in test scans 
The test scan set (n=18) was randomly taken from our imaging archive including the 
ATTEST study and other studies which have used advanced CT imaging at our site. 
The inter-rater agreements for continuous variables were assessed with an intra-class 
correlation coefficient, and categorical variables were examined with weighted kappa 
using StatsDirect. 
For the ischaemic core, the intra-class correlation coefficient was 0.87 (95% limits of 
agreement -9.95-23mL) (Figure 5-1). 
 
Figure 5-1. Bland-Altman agreement plot for inter-rater agreement in baseline 
core volume (test scan set) (mean[green]±1.96SD[black]). 
 
For penumbral volume, the intra-class correlation coefficient was 0.92 with 95% limits of 
agreement of -20.8-11.3mL (Figure 5-2). 
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Figure 5-2. Bland-Altman agreement plot for inter-rater agreement in baseline 
penumbra volume (test scan set) (mean[green]±1.96SD[black]). 
The correlation coefficient for co-registered infarct volume was 0.8 (95% limits of 
agreement -31-73.4mL) (Figure 5-3). 
 
Figure 5-3. Bland-Altman agreement plot for inter-rater agreement in co-
registered infarct volume at 24-48 hours (test scan set) 
(mean[green]±1.96SD[black]). 
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The correlation coefficient for total infarct volume was 0.94 (95% limits of agreement -
22.2- 70.2mL) (Figure 5-4). 
 
Figure 5-4. Bland-Altman agreement plot for inter-rater agreement in total 
infarct volume at 24-48 hours (test scan set) (mean[green]±1.96SD[black]). 
Overall, one of the raters consistently measured the volume as being larger than did the 
other rater. 
The weighted kappa for arterial patency (n=20) was 0.46 (95% CI 0.2-0.7). 
5.2.1.2. Inter-rater agreement in the ATTEST study scans 
For baseline irreversible tissue volume, the correlation coefficient was 0.96 (95% limits of 
agreement -16.2-19.9mL) (Figure 5-5). 
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Figure 5-5. Bland-Altman agreement plot for inter-rater agreement in baseline 
core volume (mean[green]±1.96SD[black]). 
For penumbra volumes, the correlation coefficient was 0.91 with 95% limits of agreement 
of -30.3-30.1mL (Figure 5-6). 
 
Figure 5-6. Bland-Altman agreement plot for inter-rater agreement in baseline 
penumbra volume(mean[green]±1.96SD[black]).  
The correlation coefficient for the co-registered infarct volume was 0.91 (95% limits of 
agreement -57.3-26.4mL) (Figure 5-7).  
Agreement Plot (95% l imits of agreement)
0 50 100 150
-30
0
30
60
mean
difference
Agreement Plot (95% l imits of agreement)
0 30 60 90 120
-100
-50
0
50
mean
difference
Average of the two measures (mL) 
D
if
fe
re
n
ce
 in
 t
h
e 
tw
o
 m
ea
su
re
s 
(m
L)
 
Average of the two measures (mL) 
D
if
fe
re
n
ce
 in
 t
h
e 
tw
o
 m
ea
su
re
s 
(m
L)
 
   
 
121 
 
 
Figure 5-7. Bland-Altman agreement plot for inter-rater agreement in co-
registered infarct volume at 24-48 hours (mean[green]±1.96SD[black]). 
For total infarct volumes, the correlation coefficient was 0.91 with 95% limits of 
agreement of -92.9-47.3mL (Figure 5-8). 
 
 
Figure 5-8. Bland-Altman agreement plot for inter-rater agreement in total 
infarct volume at 24-48 hours (mean[green]±1.96SD[black]). 
Again, one of the raters consistently produced higher measures than did the other rater.  
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The weighted kappa for baseline occlusion sites was 0.63 (95%CI 0.49-0.77); for arterial 
potency at 24-48 hours, kappa=0.68 (95%CI 0.48-0.89) using the TIMI scale, and 0.7 (95% 
0.5-0.89) using the TICI scale. 
Other imaging parameters assessed included brain swelling at 24-48 hours (k=0.5, 95% CI 
0.36-0.65), the radiological classification of ICH according to ECASS 2311 (k=0.75, 95% CI 
0.6-0.91), hyperdense vessel sign on baseline NCCT (k=0.61, 95% CI 0.42-0.8), the ASPECT 
score on baseline NCCT (k=0.41, 95% CI 0.29-0.53) and on follow-up CT (k=0.69, 95% CI 
0.57-0.81). 
Given the low agreement in categorical variables, the discrepancies in baseline occlusion 
and recanalisation were resolved by referencing the reports of radiologists who were not 
aware of the treatment allocation. The ICH classification was adjudicated by experienced 
external readers from the University of Calgary. Any remaining categorical parameters 
disagreements were settled by readings from Professor. Muir. 
5.2.2. Statistical analysis 
The trial was primarily intended to inform the design of a larger definitive study by 
yielding information on potential recruitment rates, incidence of relevant imaging 
abnormalities, and the distribution of outcome events; however, a sample size based on 
imaging parameters was determined, assuming that tenecteplase would exhibit a 15% 
absolute superior recanalisation rate compared to alteplase326,327 with quicker 
recanalisation. We estimated a potential 25% reduction in mean infarct volume (38 mL vs 
49 mL, standard deviation 20mL)396, equating to 52 subjects per group for 80% power at a 
5% level of significance. The findings were expected to assist in deciding whether a 
definitive trial based on imaging selection criteria or clinical features alone would be 
preferable. 
The primary outcome and other continuous variables were analysed with a linear 
regression model adjusted for the stratification variables of age and baseline NIHSS scale. 
Binary variables were tested using logistic regression models, adjusted for the same 
stratification variables. P values for differences between treatment groups have been 
extracted from these models. In the subgroup analyses, when the numbers were small, 
univariate regression was used. The results presented below use per protocol analysis 
population comprising all patients who were randomised and had a final diagnosis of 
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stroke, as pre-specified in the statistical plan. This was selected as appropriate for a phase 
II exploratory study reliant on a primary imaging end-point. Normally distributed variables 
are described as mean and standard deviation (SD), ordinal variables as median and 
interquartile range (IQR) and categorical variables as number and percentage per 
category. 
The primary outcomes and secondary outcomes listed in the study protocol were 
analysed by the study statistician from the Robertson centre for Biostatistics in the 
University of Glasgow, the rest of the analysis was performed by the author of this thesis. 
5.3. Results 
Between January 2012 and September 2013, 355 patients were screened (Figure 5-9), of 
whom 157 were eligible for IV thrombolysis and 104 patients were enrolled, 52 being 
assigned to each treatment group. The study recruitment completed earlier than 
scheduled (Figure 5-10). Reasons for exclusion are detailed in Figure 5-9. Eight patients 
ultimately had a diagnosis of non-stroke conditions and were excluded from the protocol-
defined analysis. Groups were well-balanced for clinical baseline characteristics and co-
morbidities (Table 5-1), had moderate stroke severity (median NIHSS score 11 to 12), and 
similar onset-to-treatment time at just over three hours. Participants randomised to 
tenecteplase had a larger median core volume (20 mL [IQR 2-55] vs 15 mL [IQR 3-40]), 
and a higher proportion presented with large artery occlusion (internal carotid artery or 
proximal middle cerebral artery occlusion in 26/35 [75%] tenecteplase-treated vs 23/38 
[61%] alteplase treated) on baseline CTA, although these differences were not statistically 
significant. 
One patient assigned to alteplase did not receive the study drug after randomisation, 
following a clinician review of the baseline CT querying minor ICH; all other participants 
received the full dose of the study treatment. Excluding those with no baseline perfusion 
lesion or vessel occlusion, 71 had technically satisfactory imaging for the primary 
outcome analysis, and 67 were suitable for recanalisation assessment. Patients who did 
not contribute to the primary imaging analysis (n=33) were younger (mean age 66 years, 
SD 13) and had less severe strokes (median NIHSS score 9, IQR 6-12) than those with 
analysable imaging. 
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All patients with a confirmed stroke were followed-up for three months after entry into 
the study. 
 
Figure 5-9. Study CONSORT chart 
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Figure 5-10. Graph of study recruitment progress 
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Table 5-1. Demography, risk factors and stroke characteristics in the per 
protocol population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Tenecteplase 
(n=47) 
Alteplase 
(n=49) 
Clinical 
Age years mean(SD*) 71 (13) 71 (12) 
Male (n, %) 30, 64% 31, 63% 
Dominant hemisphere stroke (n, %) 24, 51% 26, 53% 
Baseline NIHSS (Median, IQR)[min-max] 12 (9-18)[2-26] 11 (8-16)[3-27] 
Onset-to-treatment 
Time min  
mean(SD) 184 (44) 
 
192 (45) 
Median (IQR) 180 (156, 215) 200 (160, 220) 
Time between Initial and Follow-
up Imaging (hours) 
mean (SD) 
28.5 (7.1) 27.3 (7.5) 
Door to Needle Time min mean(SD) 42(17) 38 (19) 
Previous stroke/TIA (n, %) 12, 26% 11, 22% 
Hypertension (n, %) 20, 43% 28, 57% 
Diabetes (n, %) 7, 15% 7, 14% 
Blood glucose mmol/L mean (SD) 7 (1) 7 (2) 
Atrial Fibrillation (n, %) 19, 40% 15,31% 
Hyperlipidaemia (n, %) 4, 9% 7, 14% 
Smoker (n,% ) 13, 28% 10,20% 
Stroke clinical syndrome 
TACS (n, %) 27, 57% 28, 57% 
PACS (n, %) 16, 34% 16, 33% 
LACS (n, %) 2, 4% 3, 6% 
POCS (n, %) 2, 4% 2, 4% 
ASPECT score mean (SD) 7 (2) 7 (2) 
Imaging  
Penumbra 
Volume ml  
Median (IQR) 40 (4-62) 37 (9-69) 
Mean (SD) 53 (31) 49 (30) 
Core Volume ml  Median (IQR) 20 (2-55) 15 (3-40) 
Mean (SD) 32 (36) 24 (29) 
Occlusion (n,% ) 35/47, 74% 38/49, 78% 
Tandem/ICA 10/35,29% 8/38, 21% 
M1§ 16/35, 46% 15/38, 40% 
M2§ 6/35, 17% 11/38, 29% 
M3§ 1/35, 3% 3/38, 8% 
ACA/PCA 2/35, 6% 1/38, 3% 
*SD, standard deviation; NIHSS: National Institute of Health Stroke Scale; IQR: 
Interquartile Range; TIA: Transient Ischaemic Attack; TACS; Total Anterior Circulation 
Syndrome; PACS: Partial Anterior Circulation Syndrome; LACS: Lacunar Syndrome; 
POCS: Posterior Circulation Syndrome; ASPECT score: Alberta Stroke Program Early CT 
score; ICA: Internal Carotid Artery; § Middle Cerebral Artery M1, M2, M3 segment; 
ACA: Anterior Cerebral Artery; PCA: Posterior Cerebral Artery. 
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5.3.1. Efficacy 
There were no significant differences in the primary endpoints of the percentage of 
penumbra salvaged (mean difference 1%, 95%CI -10% to 12%, p=0.81), or of secondary 
endpoints, either for imaging or for clinical outcomes (Table 5-2, Figure 5-11 to 5-12). 
 
Figure 5-11. Baseline CT perfusion lesion segmented into core and penumbra 
and co-registered final infarct volumes at 24-48 hours. Error bars show 
standard deviation. 
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Figure 5-12. Distribution of Modified Rankin scale at 90 days 
Adding core volumes and occlusion sites to the regression models as a post-hoc analysis, 
did not affect either the primary outcomes (mean difference 2.5%, 95%CI -8%-13%, 
p=0.65) or recanalisation rates (OR 0.7, 95%CI 0.2-2.2, p=0.65) (Figure 5-13). 
 
Figure 5-13. Recanalisation rates according to treatment groups and occlusion 
sites (percentage within each treatment group shown). 
4 
11 
9 
2 
4 
11 
5 
1 
2 
4 
1 
1 
1 
5 
5 
1 
0%
10%
20%
30%
40%
50%
IC
A
M
1
M
2
M
3
A
C
A
/P
C
A
IC
A
M
1
M
2
M
3
A
C
A
/P
C
A
Alteplase Tenecteplase
Not recanalised
Recanalised
   
 
129 
 
The volume of infarct growth (mean difference -6mL, 95% CI -21-9, p= 0.43), and the 
volume of penumbra salvage (mean difference 5mL, 95% CI -7-17, p=0.43) at 24-48 hours 
did not differ between the two groups. When core volumes and occlusion sites were 
added as adjusted variables, the results were still similar (mean difference -7mL, 95% CI -
21-7, p=0.33; and mean difference 1mL, 95% CI -10-11, p=0.88 respectively). 
5.3.2. Safety 
The safety population included 52 patients treated with tenecteplase and 51 treated with 
alteplase. ICH of any kind was seen in eight patients in the tenecteplase group and 14 in 
the alteplase group (OR 0.4, 95%CI 0.2-1.2, p=0.091); only one incidence of PH311 
occurred in the tenecteplase group, compared to five in the alteplase group. The 
symptomatic ICH incidence, using either the SITS-MOST definition or the ECASS II 
definition, did not differ (Table 5-2). 
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Table 5-2. Study outcomes in the protocol-defined population.  
 
 
Tenecteplase 
(n=47) 
Alteplase 
(n=49) 
p value¢ Mean difference 
(95%CI) 
Odds ratio 
(95%CI) 
Primary outcome  
Percent penumbral salvage at 24-48 h 
mean (SD)* 
68% (28) 68% (23) 0.81 1.3% (-9.6, 12.1) - 
Secondary imaging outcomes   
Co-registered final infarct volume at 24-
48 h mL mean (SD )# 
50 (62) 47 (62) 1.00 0.1 (-20, 20) - 
Total infarct volume at 24-48 h mL 
mean (SD )║ 
75 (101) 66 (91) 0.75 5 (-26, 35) - 
Volume of infarct growth at 24-48 h mL 
mean (SD) 
18 (39) 22 (42) 0.43 -6 (-21, 9) - 
Volume of penumbra salvaged at 24-48 
h mL mean (SD) 
36 (27) 32 (22) 0.43 5 (-7, 17) - 
Recanalisation at 24-48 h (n, %)§ 21/32, 66%¤ 26/35, 
74%¤ 
0.38 - 0.6 (0.2-1.8) 
Secondary clinical outcomes  
Early neurological improvement at 24 h 
(n, %) ¶ 
19/47, 40% 12/49, 
24% 
0·10 - 2.1 (0.9-5.2) 
Improvement in NIHSS between 
baseline and 24 h mean (SD) 
3 (6) 2 (6) 0.74 -0.4 (-3.1-2.2) - 
mRS 0-1 at 30 days (n, %) 7/47, 15% 7/49, 14% 0.89 - 1.1 (0.3-3.5) 
mRS 0-1 at 90 days (n, %) 13/47, 28% 10/49, 0.28 - 1.8 (0.6-5.5) 
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20% 
Home by 90 days (n, %) 30/47, 64% 36/49, 
73% 
0.36 - 0.6 (0.2-1.8) 
Days at home by 90 days mean (SD ) 45 (39) 50 (36) 0.64 -3.1 (-15.8-9.7) - 
Mortality at 90 days (n, %) 8/47, 17% 6/49, 12% 0.51 - 1.3 (0.4-3.7) 
Safety outcomes (A=51, T=52)  
Any ICH (n, %) 8/52, 15% 14/51, 
27% 
0.09 - 0.4 (0.2-1.2) 
Any parenchymal haemorrhage (n, %) 1/52, 2% 5/51, 10% 0.12   
Parenchymal haemorrhage type 2 (n, %) 0/52, 0% 3/51, 6% 0.94   
Symptomatic ICH (ECASS II311 definition) 
(n, %) 
3/52, 6% 4/51, 8% 0.59 - 0.6 (0.1-3.2) 
Symptomatic ICH (SITS-MOST318 
definition) (n, %) 
1/52, 2% 2/51, 4% 0.50 - 0.4 (0.04-5.1) 
*SD, standard deviation; NIHSS: National Institute of Health Stroke Scale; IQR: Interquartile Range; ICH: Intracerebral 
haemorrhage; mRS: Modified Rankin Scale; 
¢ p-values were calculated from linear of logistic regression models that adjust for stratification variables and are a test 
for difference between groups. 
# Co-registered infarct volume was defined as infarct volume measured on 24-48 h CT slices co-registered to baseline CT 
perfusion; 
║Total infarct volume was defined as total infarct volume measured on follow-up CT at 24-48 h; 
§ Recanalisation was defined as TIMI371 2-3; 
¤ The percentages for recanalisation were derived from the number of subjects with an occlusion. 
¶ Early neurological improvement at 24 h was defined as NIHSS reduction ≥ 8 points or 24 h NIHSS 0-1. 
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There were 32 Serious Adverse Events (SAEs) in 22 (42%) patients given tenecteplase and 
16 SAEs in 16 (31%) patients given alteplase, including ICH events fulfilling the criteria for 
seriousness. Within seven days of randomisation, six SAEs were documented in the 
tenecteplase group and four in the alteplase group (excluding SICHs, shown in detail in 
Table 5-3). Full details of all SAEs are shown in Tables 5-3 to 5-4 splitting into prior to day 
seven and post day seven of treatment, a brief summary of non-serious AEs is given Table 
5-5. Probable treatment-related SAEs other than ICH were anaphylactoid reactions (one 
case in the tenecteplase group), and epistaxis resulting in hypotension (one case in the 
tenecteplase group). Three other cases of bleeding in the tenecteplase group (one each of 
post-menopausal bleeding [53 days after treatment], rectal bleeding [70 days after 
treatment] and upper gastrointestinal bleeding [60 days after treatment]) all occurred 
beyond the first month after study drug administration, and were therefore deemed to 
be unrelated. 
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Table 5-3. Summary of serious adverse events occurring on or prior to Day 7 (subjects with at least one event) 
System Organ Class 
Preferred Term 
Tenecteplase 
(N=52) 
Alteplase 
(N=51) 
All 
(N=103) 
Total number of events on or prior to Day 7 8 9 17 
    
No. subjects with at least one adverse event on or prior to 
Day 7 
8 (15%) 9 (18%) 17 (17%) 
    
General disorders and administration site conditions 1 (2%) 1 (2%) 2 (2%) 
Chest pain 1 (2%) 0 (0%) 1 (1%) 
General physical health deterioration 0 (0%) 1 (2%) 1 (1%) 
Infections and infestations 1 (2%) 0 (0%) 1 (1%) 
Pulmonary sepsis 1 (2%) 0 (0%) 1 (1%) 
Neoplasms benign, malignant and unspecified (incl cysts and 
polyps) 
0 (0%) 1 (2%) 1 (1%) 
Malignant glioma 0 (0%) 1 (2%) 1 (1%) 
Nervous system disorders 4 (8%) 5 (10%) 9 (9%) 
Cerebral haemorrhage 0 (0%) 5 (10%) 5 (5%) 
Embolic stroke 1 (2%) 0 (0%) 1 (1%) 
Haemorrhage intracranial 1 (2%) 0 (0%) 1 (1%) 
Ischaemic stroke 1 (2%) 0 (0%) 1 (1%) 
Subarachnoid haemorrhage 1 (2%) 0 (0%) 1 (1%) 
Respiratory, thoracic and mediastinal disorders 2 (4%) 2 (4%) 4 (4%) 
Epistaxis 1 (2%) 0 (0%) 1 (1%) 
Pneumonia aspiration 1 (2%) 2 (4%) 3 (3%) 
Skin and subcutaneous tissue disorders 1 (2%) 0 (0%) 1 (1%) 
Angioedema 1 (2%) 0 (0%) 1(1%) 
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Table 5-4. Summary of serious adverse events occuring after Day 7 (subjects with at least one event) 
System Organ Class 
Preferred Term 
Tenecteplase 
(N=52) 
Alteplase 
(N=51) 
All 
(N=103) 
Total number of events after Day 7 24 7 31 
    
No. subjects with at least one adverse event after Day 7 18 (35%) 7 (14%) 25 (24%) 
    
Cardiac disorders 3 (6%) 1 (2%) 4 (4%) 
Atrial fibrillation 3 (6%) 1 (2%) 4 (4%) 
Gastrointestinal disorders 3 (6%) 0 (0%) 3 (3%) 
Abdominal pain 1 (2%) 0 (0%) 1 (1%) 
Constipation 1 (2%) 0 (0%) 1 (1%) 
Diarrhoea 1 (2%) 0 (0%) 1 (1%) 
Rectal haemorrhage 1 (2%) 0 (0%) 1 (1%) 
Upper gastrointestinal haemorrhage 1 (2%) 0 (0%) 1 (1%) 
General disorders and administration site conditions 2 (4%) 0 (0%) 2 (2%) 
Chest pain 2 (4%) 0 (0%) 2 (2%) 
Non-cardiac chest pain 1 (2%) 0 (0%) 1 (1%) 
Infections and infestations 2 (4%) 1 (2%) 3 (3%) 
Bronchopneumonia 1 (2%) 0 (0%) 1 (1%) 
Gastroenteritis viral 0 (0%) 1 (2%) 1 (1%) 
Urosepsis 1 (2%) 0 (0%) 1 (1%) 
Injury, poisoning and procedural complications 1 (2%) 1 (2%) 2 (2%) 
Fall 1 (2%) 1 (2%) 2 (2%) 
Investigations 1 (2%) 0 (0%) 1 (1%) 
Biopsy uterus 1 (2%) 0 (0%) 1 (1%) 
Hysteroscopy 1 (2%) 0 (0%) 1 (1%) 
Metabolism and nutrition disorders 1 (2%) 0 (0%) 1 (1%) 
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System Organ Class 
Preferred Term 
Tenecteplase 
(N=52) 
Alteplase 
(N=51) 
All 
(N=103) 
Dehydration 1 (2%) 0 (0%) 1 (1%) 
Musculoskeletal and connective tissue disorders 0 (0%) 1 (2%) 1 (1%) 
Mobility decreased 0 (0%) 1 (2%) 1 (1%) 
Nervous system disorders 4 (8%) 2 (4%) 6 (6%) 
Cerebrovascular accident 2 (4%) 1 (2%) 3 (3%) 
Ischaemic stroke 2 (4%) 1 (2%) 3 (3%) 
Psychiatric disorders 0 (0%) 1 (2%) 1 (1%) 
Depression 0 (0%) 1 (2%) 1 (1%) 
Intentional self-injury 0 (0%) 1 (2%) 1 (1%) 
Renal and urinary disorders 3 (6%) 0 (0%) 3 (3%) 
Renal failure acute 1 (2%) 0 (0%) 1 (1%) 
Renal impairment 2 (4%) 0 (0%) 2 (2%) 
Reproductive system and breast disorders 1 (2%) 0 (0%) 1 (1%) 
Postmenopausal haemorrhage 1 (2%) 0 (0%) 1 (1%) 
Respiratory, thoracic and mediastinal disorders 3 (6%) 0 (0%) 3 (3%) 
Epistaxis 1 (2%) 0 (0%) 1 (1%) 
Pneumonia aspiration 1 (2%) 0 (0%) 1 (1%) 
Pulmonary embolism 1 (2%) 0 (0%) 1 (1%) 
Surgical and medical procedures 3 (6%) 1 (2%) 4 (4%) 
Endarterectomy 1 (2%) 1 (2%) 2 (2%) 
Gastrointestinal tube insertion 1 (2%) 0 (0%) 1 (1%) 
Hospitalisation 1 (2%) 0 (0%) 1 (1%) 
Joint resurfacing surgery 1 (2%) 0 (0%) 1 (1%) 
Vascular disorders 2 (4%) 0 (0%) 2 (2%) 
Circulatory collapse 1 (2%) 0 (0%) 1 (1%) 
Orthostatic hypotension 1 (2%) 0 (0%) 1 (1%) 
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Table 5-5. Total Adverse Events (AE) (including serious) 
 
 
  
 Tenecteplase Alteplase 
All AEs to day 90 110 76 
Probably or definitely related to 
study drug 
3 7 
Subjects with at least one AE n 
(%) 
42 (81%) 36 (71%) 
MEDDRA classification Incidence (n AEs) 
Blood 1 0 
Cardiac 6 6 
Congenital (ASD) 1 0 
Eye 0 1 
GI 8 6 
General Disorders 3 5 
Hepatobiliary 0 1 
Infections 13 7 
Injury 5 5 
Investigations 3 0 
Metabolic/ Nutritional 3 0 
Musculoskeletal 3 5 
Neoplasms 0 1 
CNS 17 17 
Psychiatric 4 2 
Renal & Urinary 5 1 
Respiratory 11 9 
Skin 1 1 
Procedures 4 2 
Vascular 7 2 
MEDDRA Medical Dictionary for Regulatory Activities; ASD Atrial septal Defect; GI 
Gastrointestinal. 
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5.3.3. Correlations between baseline variables and outcomes 
The baseline NIHSS score was significantly associated with the baseline penumbra volume 
(p=0.002, 95% CI [0.6-2.8]. Itwas found to be significantly inversely associated with excellent 
functional outcomes at 90 days (OR [95%CI] 0.7 [0.6-0.9], p<0.001) in this sample, but there 
was no association with early neurological improvement (p=0.59). The baseline NIHSS score 
was correlated with the proportion of penumbra salvaged (p<0.001, 95%CI [-2.7-- -0.9]) 
(Figure 5-14), and infarct growth (p<0.001, 95%CI [1.5-4.1]) (Figure 5-15), but not with the 
volume of penumbra salvaged (p=0.4). No significant association was found between the 
baseline NIHSS score and recanalisation (p=0.7). More severe strokes were associated with a 
higher risk of ICH (OR [95%CI] 1.1 [1-1.2], p=0.014), but not with SICH (SITS-MOST definition).
 
Figure 5-14. The association between the baseline NIHSS score and the proportion 
of penumbra salvaged 
%
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Figure 5-15. The association between the baseline NIHSS score and Infarct growth 
There was no association shown between age or OTT and any of the main outcomes. 
Baseline glucose levels on admission were significantly associated with the volume of the 
penumbra salvaged (p=0.006, 95%CI [-6.6- -1.2]) (Figure 5-16), but not with the percentage 
of penumbral salvage (p=0.45) or infarct growth (p=0.62). The baseline glucose level has no 
correlation with recanalisation (p=0.24), haemorrhage (p=0.25), functional outcomes at 90 
days (p=0.3) or early neurological improvement (p=0.89). 
m
L 
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Figure 5-16. The association between the baseline glucose and volume of 
penumbra salvaged 
Baseline systolic BP was shown to be associated with the change of the NIHSS score at 24 
hours (p=0.047, 95%CI [0-0.1]) (Figure 5-17), and there was a near-significant association 
with early neurological improvement (OR 95%CI 0.98 [0.96-1], p=0.073). It had no correlation 
with excellent functional outcomes at day 90 (p=0.26), penumbral salvage (p=0.4), infarct 
growth (p=0.47) or recanalisation (p=0.41). High baseline BP was associated with higher ICH 
risk (OR [95%CI] 1.03 [1-1.1], p=0.043), but not with SICH (SITS-MOST) (p=0.14). 
m
L 
mmol/L 
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Figure 5-17. The association between baseline systolic blood pressure and change of the 
NIHSS score in the first 24 hours post thrombolysis26 out of 96 (27.1%) patients had 
confirmed cardioembolic stroke, 18 (18.8%) had confirmed artherosclerotic stroke. The 
proportion of patients who had hypersense vessel sign on baseline NCCT did not differ 
between the two groups [17(65.4%) vs 11(61.1%), p=0.77]. Compared with artherosclerotic 
stroke, with thein regression model adjusted for age, baseline NIHSS and OTT, cardioembolic 
stroke was associated with significantly more early neurological improvement at 24 hours 
(p=0.031, 95%CI[1.2-21.7]), but not mRS 0-1 at 90 days (p=0.77), nor any ICH (p=0.58). None 
of these 44 patients had SICH according to the SITS-MOST criteria. No difference was found 
in the percentage of penumbra salvaged (p=0.73), the volume of penumbra salvaged 
(p=0.36), infarct growth (p=0.95), or recanalisation (p=0.94) at 24 hours. 
mmHg 
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5.3.4. Sub-group analysis 
5.3.4.1. Oxford stroke classification 
Of the 96 patients included, 55 (57%) presented with total anterior circulation syndromes, 32 
(33%) with partial anterior circulation syndromes, 5 (5%) with lacunar syndromes, and 4 (4%) 
with posterior circulation syndromes. This sample provided minimal information for IV 
thrombolysis in lacunar stroke. 
5.3.4.2. Age 
71 (74%) out of 96 patients were aged less than 80, and 25 (26%) were aged 80 or over. 
Between the tenecteplase- and alteplase-treated groups, the imaging outcomes including the 
percentage of penumbra salvaged, the volume of penumbra salvaged, infarct growth and 
recanalisation rates at 24 hours did not differ. No differences were found in early 
neurological improvement, in excellent functional outcomes at 90 days, or in any ICH or SICH 
between tenecteplase- and alteplase-treated patients (Table 5-6). 
5.3.4.3. Stroke severity 
14 (15%) out of 96 patients had a baseline NIHSS score of 1-5, 48 (50%) of the subjects’ NIHSS 
scores were between 6-14, 29 (30%) between 15-24, and 5 (5%) were 25 and above. The 
main outcomes following IV thrombolysis in these groups are shown in Table 5-7. In the 
subgroup of moderate severe stroke (NIHSS score 6-14), significantly more patients who 
received tenecteplase achieved early neurological improvement at 24 hours (p=0.048). All 
other clinical and imaging outcomes were similar. In the severe stroke group (NIHSS score 15-
24), no difference was demonstrated in any outcomes. In the groups of patients with mild 
stroke (NIHSS score 1-5) and very severe stroke (NIHSS score ≥25), the numbers were too 
small to provide any useful comparison. 
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Table 5-6. Comparison of the main imaging and clinical outcomes between tenecteplase and alteplase treated patients in subgroups 
of patients<80 or ≥80 years of age 
 
Age 
TNK vs 
Alteplase 
Percentage of 
penumbra 
salvaged % 
mean difference 
(95%CI) 
Volume of 
penumbra 
salvaged mL 
mean 
difference (95% 
CI) 
Infarct 
growth mL 
mean 
difference 
(95%CI) 
Recanalisation n 
(%), OR (95%CI)  
Early 
neurological 
improvement n 
(%), OR (95%CI) 
mRS 0-1 at 90 
days n, %, OR 
(95%CI) 
Any ICH n (%), OR 
(95%CI) 
SICH (SITS-MOST) n 
(%), OR (95%CI) 
<80 
34 vs 37 
5% (-4, 17), 
p=0.22 
10 (-5,25), 
p=0.2 
-12 (-30, 
5),p=0.17 
 13 (38%) vs 19 
(51%), 0.7 (0.2, 
2.4), p=0.56 
14 (41%) vs 9 
(25%), 2 (0.7, 
5.6), p=0.2 
9 (27%) vs 8 
(22%), 1.8 (0.5, 
6.7), p=0.39 
5 (15%) vs 9 
(24%), 0.4 (0.1, 
1.5), p=0.4 
1 (3%) vs 1 (3%), 0.7 
(0.03, 14.1), p=0.66 
≥80 
13 vs 12 
-12% (-45-20), 
p=0.44 
-7 (-29-14), 
p=0.48 
20 (-72-58), 
p=0.83 
8 (62%) vs 7 
(58%) 
5 (38%) vs 3 
(25%), 1.9 (0.3-
10.4), p=0.47 
4 (31%) vs 2 
(17%), 2.2 (0.3-
15.2), p=0.42 
2 (15%) vs 5 
(42%), 0.2 (0.03-
1.5), p=0.12 
0 vs 1 (8%) 
 Univariate regression model used due to small sample size.  
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Table 5-7. Comparison of main outcomes between tenecteplase and alteplase treated patients in stroke severity subgroup 
Stroke 
severity 
(NIHSS) 
TNK vs 
Alteplase 
Percentage of 
penumbra 
salvaged % mean 
difference (95%CI) 
Volume of 
penumbra 
salvaged mL 
mean 
difference (95% 
CI) 
Infarct 
growth mL 
mean 
difference 
(95%CI) 
Recanalisation, 
n (%), OR (95%CI)  
Early 
neurological 
improvement 
n (%), OR (95%CI) 
mRS 0-1 at 90 
days n, %, OR 
(95%CI) 
Any ICH n 
(%), OR (95%CI) 
SICH (SITS-
MOST) n (%), 
OR (95%CI) 
1-5 
7 vs 7 
-3% (-39-45), 
p=0.85 
0.3 (-32-31), 
p=0.98 
-0.7 (-4-
6),p=0.67 
1(14%) vs 2 
(29%) 
4 (57%) vs 3 
(43%), 4.6 
(0.8-87.7), 
p=0.35 
6 (86%) vs 5 
(71%), 11.8 
(0.8-744), 
p=0.24 
1 (14%) vs 1 
(14%) 
0 vs 0 
6-14 
27 vs 21 
7% (-9-21), 
p=0.4 
7 (-13-
26),p=0.49 
-7 (-26-
10),p=0.39 
10 (48%) vs 
27(52%), 0.2 
(0.02-1.6), 
p=0.13 
9 (43%) vs 5 
(19%), 11.8 (1-
20.5), p=0.048 
5 (24%) vs 5 
(19%), 1.4 
(0.3-6,3), 
p=0.63 
1 (5%) vs 6 
(22%), 0.1 
(0.01-1.2), 
p=0.07 
0 vs 1(4%), 
p=1 
15-24 
13 vs 16 
3% (-29-15), 
p=0.51 
3 (-23-21), 
p=0.92 
-5 (-33-56), 
p=0.59 
9 (56%) vs 8 
(62%), 0.5 
(0.03-9.5), 
p=0.66 
4 (25%) vs 3 
(23%), 1.1 
(0.2-6.2), 
p=0.9 
2 (13%) vs 0, 
p=1 
5 (31%) vs 5 
(38%), 0.6 
(0.1-3), 
p=0.57 
1 (6%) vs 1 
(8%), 0.7 
(0.04-13), 
p=0.83 
≥25 
3 vs 2 
11 (-116-138), 
p=0.8 
-5 (-69-59), 
p=0.83 
-25 (-292-
243), p=0.8 
1 (33%) vs 2 
(100%) 
2 (67%) vs 1 
(50%) 
0 vs 0 0 vs 2 
(100%) 
0 vs 0 
 Univariate regression model used due to small sample size. 
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5.3.4.4. Onset-to-treatment time 
No patients were treated less than 90 minutes from the onset of symptoms. 44 (46%) 
were treated within 180 minutes, and 52 (54%) were treated between 181-270 minutes. 
In the group treated within 180 minutes, all clinical and imaging outcomes were similar 
between the tenecteplase and the alteplase groups. In the subgroup of patients who 
were treated between 181- 270 minutes, those who had tenecteplase had a significantly 
higher rate of early neurological improvement (p=0.014), and a near-significant trend of 
lower proportion of ICH rate (p=0.053) (Table 5-8). 
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Table 5-8. Comparison of main outcomes between tenecteplase and alteplase treated patients in OTT subgroup 
OTT 
TNK vs 
Alteplase 
Percentage of 
penumbra 
salvaged % mean 
difference (95%CI) 
Volume of 
penumbra 
salvaged mL 
mean 
difference (95% 
CI) 
Infarct 
growth mL 
mean 
difference 
(95%CI) 
Recanalisation, 
n (%), OR (95%CI)  
Early 
neurological 
improvement 
n (%), OR (95%CI) 
mRS 0-1 at 90 
days n, %, OR 
(95%CI) 
Any ICH n 
(%), OR (95%CI) 
SICH (SITS-
MOST) n (%), 
OR (95%CI) 
<180 
24 vs 20 
12 (-25-19), 
p=0.78 
-2 (-25-20), 
p=0.8 
12 (-24-33), 
p=0.77 
11 (46%) vs 10 
(50%), 0.7 
(0.08-5.3), 
p=0.69 
8 (33%) vs 8 
(40%), 0.7 
(0.2-2.6), 
p=0.55 
6 (25%) vs 6 
(30%), 2.8 
(0.5-16.6), 
p=0.27 
6 (25%) vs 6 
(30%), 0.4 
(0.07-2), 
p=0.25 
1 (4%) vs 0, 
p=1 
181-270 
23 vs 29 
8 (-11-17), 
p=0.67 
10 (-7-24), 
p=0.26 
-16 (-29-14), 
p=0.35 
10 (43%) vs 16 
(55%), 0.4 
(0.09-1.6), 
p=0.19 
11 (48%) vs 4 
(14%), 5.7 
(1.4-22.7), 
p=0.014 
7 (30%) vs 4 
(14%), 2 (0.4-
10.9), p=0.41 
1 (4%) vs 8 
(28%), 0.1 
(0.01-1), 
p=0.053 
0 vs 2 (7%), 
p=1 
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5.3.5. Comparative study using different definitions for imaging analysis 
5.3.5.1. Volumetric analysis for CT perfusion using two definitions 
As previously discussed, the definition of tissue status in perfusion imaging varies 
depending on the analysis methods and processing algorithms used104,137. When the 
ATTEST study was planned, the most recognised thresholds to define irreversible and 
potential reversible tissue were from Wintermark’s group144. When the study started in 
2011, further evidence emerged that delay-corrected SVD with DT>2 seconds most 
accurately defined the penumbra, and a double core threshold with DT>2 seconds and CBF< 
40% provided the most accurate definition of the infarct core among all the available post-
processing algorithm and viability thresholds138. Since we used both definitions in our 
analysis, we compared the results generated. 
Intra-observer agreement for volume measurements using the two definitions 
During the volumetric analysis, although there appeared to be a greater variability in the 
volumes measured using Wintermark’s (MW) definition compared with those using 
Bivard’s (AB) definition, the intra-observer agreements between the two measurements 
for each definition were both excellent with AB’s definition faring slightly better. 
Ischaemic core: 
The intra-class correlation coefficient for MW definition was 0.96 (95% limits of 
agreement -24-20mL) (Figure 5-18). 
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Figure 5-18. Intra-observer Bland-Altman agreement plot for ischaemic core 
volume using Wintermark’s definition (mean[green]±1.96SD[black]). 
The intra-class correlation coefficient for AB definition was 0.99 (95% limits of agreement 
-9-11mL) (Figure 5-19).  
 
Figure 5-19. Intra-observer Bland-Altman agreement plot for ischaemic core 
volume using Bivard’s definition (mean[green]±1.96SD[black]). 
Penumbra: 
The intra-class correlation coefficient for MW definition was 0.91 (95% limits of 
agreement -23-21mL) (Figure 5-20). 
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Figure 5-20. Intra-observer Bland-Altman agreement plot for penumbra 
volume using Wintermark’s definition (mean[green]±1.96SD[black]). 
 
The intra-class correlation coefficient for AB definition was 0.98 (95% limits of agreement 
-13-13mL) (Figure 5-21). 
 
Figure 5-21. Intra-observer Bland-Altman agreement plot for penumbra 
volume using Bivard’s definition (mean[green]±1.96SD[black]). 
The comparison of CT perfusion lesion volumes measured using the two definitions was 
shown in Table 5-9. The core sizes measured with the two definitions (mean 26mL vs 
33mL, p<0.001) were significantly different, the penumbra volumes (mean 38mL vs 33mL, 
p=0.058) were not significantly different. The absolute volumes of penumbra salvaged 
(mean 34mL vs 29mL, p=0.043) were significantly different, but the proportion of 
penumbra salvaged was not different (mean 68% vs 70%, p=0.2). However, the mismatch 
ratio calculated using the two definitions (mean 4.2 vs 2.5, p<0.001) were significantly 
different. 
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Table 5-9. The comparison of the perfusion lesion volume measured with two 
widely used definitions 
 
 
 
 
 
 
 
 
 
 
 AB definition147 MW definition144 P Value 
Ischaemic core mL Mean (SD) 26 (32) 33 (37) P<0.001 
Median (IQR) 14 (0-41) 25 (0-47) P<0.001 
Penumbra mL Mean (SD) 38 (34) 33 (30) P=0.058 
Median (IQR) 37 (0-62) 31 (0-59) P=0.091 
Volume of 
penumbra salvaged 
mL 
Mean (SD) 34 (25) 29 (19) P=0.043 
Median (IQR) 31 (12-49) 17 (0-36) P=0.094 
Percentage of 
penumbra salvaged 
% 
Mean (SD) 68 (25) 70 (25) P=0.2 
Median (IQR) 75 (50-88) 78 (51-85) P=0.32 
Mismatch Ratio Mean (SD) 4.2 (3.7) 2.5 (0.9) P<0.001 
Median (IQR) 2.9 (1.9-5) 2.3 (1.8-2.9) P<0.001 
 p Value was calculated using paired T tests for mean and related-samples Wilcoxon 
Singed rank tests. 
 150 
5.3.5.2. Recanalisation status using TIMI371 and TICI375 
Both the TIMI and the TICI scales are popular in acute ischaemic stroke recanalisation 
studies for describing the reperfusion status. As discussed previously, both scales were 
designed for endovascular study, where reperfusion can be observed directly during the 
procedure in a 4D manner. CTA, on the other hand, can only provide a snapshot of the 
contrast passing through a vessel, in which case delayed perfusion can be missed. Neither 
the TIMI nor the TICI scales is ideal to describe vessel patency or reperfusion on CTA. TICI, 
which categorises reperfusion in a more detailed fashion, did not show any benefit over 
TIMI on CTA reading during our analysis. 
In 5.2.1, I have discussed the inter-observer agreement for TIMI and TICI between the two 
readers for the ATTEST study, which were similar (0.68 vs 0.7). The percentage of patients 
that recanalised according to the TIMI definition (47%) was similar to that using TICI (53%) 
(p=0.55) using a Chi-Square test. 
5.4. Discussion 
Despite baseline imbalances such that the tenecteplase group included a higher 
proportion of patients with large artery occlusion (and therefore a lower probability of 
favourable response to treatment319) and a larger ischaemic core (and therefore a higher 
risk of haemorrhagic complications173), neither radiological nor clinical outcomes were 
significantly different with IV tenecteplase 0·25 mg/kg compared to alteplase 0·9 mg/kg, 
the current standard of care. In addition, there was a trend towards fewer intracerebral 
haemorrhages of all kinds in the tenecteplase group, and, notably, fewer parenchymal 
haematomas, a complication most strongly associated with treatment-related 
neurological deterioration397. In two subgroups (NIHSS score 6-14 and OTT 181-270), 
tenecteplase-treated patients had significantly higher rates of early neurological 
improvement. This nevertheless was not a pre-specified analysis, numbers were small, 
and needs to be interpreted with caution. Because of the modest sample size, some of 
the known predictors for stroke outcomes, such as OTT and age, were not shown to be 
associated with any outcome in this sample. Even if efficacy does not differ, the greater 
ease of administration alone may offer a significant advantage for tenecteplase over 
alteplase, for which delays in respect of the latter between the initial bolus and the 
initiation of maintenance infusion are common and may compromise effectiveness; the 
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possibility of improved safety with respect to fewer intracerebral haemorrhages is 
promising, meriting further investigation of tenecteplase for acute ischaemic stroke. 
The study population in the ATTEST study is similar to that of previous alteplase trials, 
with respect to age, comorbidities and stroke severity.70  Except for the treatment time 
window (4.5 hours compared to 3 hours), our inclusion criteria were similar to those of 
the phase IIB tenecteplase study conducted by Haley and colleagues327. In contrast to the 
ECASS trials, we applied no upper age limit or minimal baseline NIHSS score. Patients with 
history of previous stroke and concomitant diabetes (four patients), or seizure at onset of 
stroke (although none were recruited in this study) were not excluded from our study 
based on current clinical practice and the availability of advanced imaging to support a 
clinical diagnosis of stroke70,370. 
We selected a dose of tenecteplase of 0·25 mg/kg based on available data194,325-327 
although numbers of randomised subjects in previous studies were small. One previous 
study327 terminated investigation of a higher dose (0·4 mg/kg) due to possible increased 
SICH incidence (3 in 19 patients). The same study suggested more frequent good 
outcomes with 0·25 mg/kg compared to 0·1 mg/kg, and Parsons and colleagues194 also 
found superior efficacy of 0·25 mg/kg compared to 0·1 mg/kg, with no additional 
haemorrhagic risk. 
We used advanced CT imaging for outcome analysis to offer insights into biological 
efficacy with a modest sample size, but did not use imaging for patient selection. This 
differs from the approach of Parsons and colleagues194, who demonstrated the 
superiority of tenecteplase over alteplase for both reperfusion and clinical outcomes in a 
small randomised controlled trial that compared two different tenecteplase doses to 
standard alteplase. Their study used multimodal CT imaging to identify what is widely 
considered to be the optimal “responder” population in acute stroke, with favourable 
core/penumbra “mismatch” ratios, small ischaemic cores, and intracranial vessel 
occlusions, a strategy that has been expected to reduce sample size in phase II trials218, 
but which is likely to have limited general application. In contrast, our patients had larger 
core (median [IQR] 14 mL [0-41] compared to 10 mL [5-17] and smaller penumbra 
volumes (median [IQR] 53 mL [0-110] compared to 79 mL [56-100], with only 64% 
(67/104) with baseline vessel occlusion. In our study, 14% of patients had either acute ICA 
occlusion or a thrombus involving the terminal ICA extending to the proximal MCA 
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segment, while these patients were excluded from the Parsons study. These factors will 
certainly contribute to the difference in outcomes between these two studies. However, 
it is notable that both studies identified a trend towards lower ICH risk with tenecteplase. 
The application of advanced imaging in acute stroke trials has strengths and limitations. 
Limitations of this study included the use of non-contrast CT to quantify final infarct, 
restricted brain coverage for CT perfusion imaging, and reliance on probabilistic 
thresholds to define core and penumbra that have only limited validation104,398. The 
analysis in our study using the two widely accepted thresholds demonstrated that the 
results generated using different definitions can be significantly different. Although it 
would not have affected our primary outcome (the percentage of penumbra salvaged). 
The core/penumbra mismatch ratio was significantly different. Perfusion mismatch has 
been used widely as an essential criterion for trial entry in trials examining thrombolysis 
in extended time windows213,299,300, or in identifying potential responders194-196,204 within 
the current treatment time window. The optimal mismatch ratio remains controversial. 
The additional variability in the mismatch ratios generated with different thresholds adds 
the uncertainty of the quantitive analysis of perfusion imaging. 
Various deconvolution algorithms have been used in different post-processing 
commercial software packages145, an approach which may require different tissue status 
thresholds to be validated. We used the same software from which AB’s thresholds were 
derived and additionally had derived similar thresholds using a different imaging dataset 
independently399. The algorithm used in MIStar is a modified SVD with compensation for 
the effects of arterial delay and dispersion373, whereas the MW thresholds were derived 
with software based on the central volume principle144. It is possible that MIStar is not 
optimised to process perfusion imaging using the MW definition. Further literature138 has 
suggested that AB’s threshold using delay-corrected SVD is the most accurate one among 
all those thresholds used in currently available post-processing algorithms, which again 
emphasises the importance of standardising the post-processing of perfusion imaging, 
and caution is required in utilising perfusion imaging in clinical settings. 
MRI has a high sensitivity in defining the extent of infarction400, and greater lesion 
conspicuity at early time points than CT, but this advantage is at the expense of lower 
follow-up rates, and the introduction of additional bias in patient selection. Large 
detector CT systems which are able to acquire entire brain volumes for perfusion studies 
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remain largely confined to research environments. While we did not utilise advanced 
imaging for patient selection, studies that do so may introduce delay in treatment 
initiation to allow for acquisition, processing and interpretation of additional scans, and 
thus may compromise treatment efficacy. However, when used as a biomarker for 
relevant outcomes (reperfusion, recanalisation, and tissue salvage) additional imaging 
offers valuable insights in phase II evaluation. In our study, imaging identified baseline 
imbalance in important markers of potential treatment response and haemorrhagic risk 
between groups that was not evident using clinical criteria alone. This in itself is a 
powerful argument in favour of acquiring additional imaging at this stage of research. 
With respect to definitive trial design, additional imaging analyses may lead to significant 
loss of evaluable subjects from a trial. Even with a single centre study familiar with the 
techniques, 30% of per protocol recruited patients did not contribute to imaging analyses, 
the great majority of these being due to the absence of an initial perfusion lesion or 
vessel occlusion. In any multicentre trial, the proportion of non-evaluable subjects is likely 
to be increased further. While baseline imaging characteristics offered additional insights 
into stroke severity beyond clinical criteria, the potential detriment of delaying treatment 
initiation in order to review imaging findings as a selection criterion pre-randomisation 
needs to be considered. 
5.5. Conclusions 
The non-inferiority in efficacy and improved safety compared to standard thrombolytic 
treatment, despite imaging features indicative of greater baseline severity, support the 
further investigation of IV tenecteplase in acute ischaemic stroke. 
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Chapter 6 Secondary imaging 
analyses of the ATTEST study 
data 
6.1. Introduction 
In Chapter 5, the main results of the ATTEST study were presented, along with the sub-
group analyses of age, stroke severity and OTT. In this chapter, I will discuss further 
findings from the imaging analysis. 
It was noted in the main analysis that some of the imaging characteristics identified 
imbalances that were not reflected by clinical scales. Furthermore, well recognised 
imaging parameters that influence outcomes such as collateral flow and the length of 
thrombus were not taken into account. In this chapter, these two variables are included 
in further analysis of the data, and the association between them is explored. In addition 
baseline known confounders and clinical and imaging outcomes are investigated. 
Brain oedema in acute ischaemic stroke is a poor prognostic predictor. There have been 
suggestions that alteplase exacerbates cerebral oedema post thrombolysis278 by 
augmenting blood brain barrier permeability. To date only sparse data examining post 
thrombolysis brain swelling are available. We assessed the presence and the severity of 
cerebral oedema post thrombolysis in the ATTEST study patients, and compared the 
occurrence of brain swelling in patients who received the two different thrombolytic 
agents. 
The Australian tenecteplase study194 which used imaging selection is the the only study 
among the three completed RCTs that compared tenecteplase and alteplase in AIS to 
show the superiority of tenecteplase. In this chapter, a sub-group of the ATTEST study 
patients who fulfilled the inclusion criteria of Parsons et al194 was examined to determine 
whether tenecteplase is superior to alteplase in this population. 
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6.2. Methods 
6.2.1. Additional imaging variables 
6.2.1.1. Measurement of clot length 
Clot length was derived from non-contrast CT. We used a method that was modified from 
Riedel and colleagues125 to measure the clot length. 
All baseline non-contrast CTs and corresponding CTAs were processed offline on a 
university computer as described in Chapter 3, using MIStar. NCCT was reformatted with 
a slice thickness of 2.5mm. Hyperdense vessels were identified by two research fellows 
(XH and BC). Disagreements were resolved by an experienced neurologist (KM). The 
occlusion was confirmed with a concurrent CTA. All hyperdense vessels with confirmed 
occlusions including intracranial ICA, M1 and M2 sections were included as long as the 
length was measurable. 
To measure the clot length, a region of interest was drawn around the hyperdense vessel 
area. MIP was applied (with a slice thickness between 2.5-10mm depending on the extent 
of clot) to include the whole length of the clot. Hounsfield unit thresholds were 
subsequently applied to segment the clot, starting with 55-80, followed by including all 
imaging pixels in the ROI with a threshold of 45-80 (Figure 6-1 to 6-2). Clot length was 
then measured using the segmented pixels. To reduce measurement error, two 
measurements were taken on two separate occasions by XH. Intra-observer agreement 
was assessed, and the average of the two measurements was used in the final analysis. 
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Figure 6-1. ROI (yellow circle) with hyperdense vessel on the lesional side 
(Arrow: hyperdense vessel) 
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Figure 6-2. Same ROI after applying HU threshold (45-80) (Arrow: hyperdense 
vessel) 
6.2.1.2. Assessment of collateral status 
Collateral flow was assessed using a modified method derived from the one used by 
Miteff and colleagues81. Baseline CTP and CTA were required for the assessment. First of 
all, CTA imaging was reviewed to determine the presence of terminal ICA, M1 or M2 
occlusions using a MIP with a slice thickness of between 10-20mm. Once the occlusion 
was confirmed, we used CT perfusion to assess the direction of the downstream flow 
beyond the occlusion site. CT perfusion was processed with the method described in 
Chapter 3 producing CBF, CBV, DT, and MTT maps. A 4D angiography MIP image of the 
4cm CTP slab was viewed in cine mode in order to evaluate the flow direction. Those with 
antegrade flow were considered as partial occlusions and were excluded from the 
analysis. Only those with retrograde flow were deemed as being supplied by 
leptomeningeal collateral flow and proceeded to collateral status evaluation. The 
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intracranial baseline CTA imaging was subsequently displayed as axial MIP imaging with 
40mm slab thickness. Depending on the downstream flow, the collaterals were 
catogorised into three grades: good, moderate and poor. The definitions of the three 
categories are as follows81: 
Good: showed the entire M1 or M2 distal to the occluded segment reconstituting with 
contrast. CTA MIP reconstructions clearly demonstrated the MCA branches, with abrupt 
termination of the reconstituted vessels at the distal end of the occlusion within the M1 
or M2 segments (Figure 6-3). M3 occlusions were not included as all of them had good 
collaterals. The original Miteff method did not include M2, but we noticed frequent poor 
regional collaterals in the ischaemic territory. 
 
 
Figure 6-3. Examples of collateral supply with three grade respectively 
(Arrowed area: occlusion site). Left panel: contrast can be visualised distal to 
the occlusion; middle panel: some contrast can be seen distal  to the occlusion 
partially in M2 branch ; right panel: No contrast seen distal to the occlusion 
site and the downstream perfusion area. 
Moderate: the distal M1/M2 reconstituted only partially to ischaemic territory, but not 
distal to occlusion (Figure 6-3). 
Poor: only the distal superficial MCA branches reconstituted (Figure 6-3). 
6.2.1.3. The severity of brain swelling 
Good Moderate Poor 
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The methods of assessing cerebral oedema and the scales used were detailed in Chapter 
3. 
6.2.2. Subgroup analyses using all patients who fulfilled Parsons and 
colleagues’194 imaging selection criteria 
We applied the inclusion criteria of Parsons’ group in all of the ATTEST study patients: 
baseline NIHSS scores >4; the presence of intracranial occlusion in ACA, MCA or Posterior 
Cerebral Artery (PCA) (ICA or basilar artery occlusions are excluded); infarct core <1/3 of 
MCA or ½ of ACA/PCA territory; Penumbral volume>20mL with a mismatch ratio >1.2. 
In our centre, CTP has a limited coverage of 4cm, and a single CTP study was undertaken 
in order to minimise radiation exposure, whereas Parsons and colleagues used two 
contiguous CTP acquisitions to cover most of the brain. To account for the difference, the 
minimal core and penumbral volume for study entry were reduced proportionately. The 
proportion was derived as follow: 
The proportion = the mean co-registered final infarct volume (non-recanalised 
patients)/the mean total infarct volume = 0.715 
The CTP lesion covered by a 4cm Z axis is therefore approximately 70% of the whole brain 
coverage. 
The corrected core and penumbral volume criteria are: infarct core <70mL in MCA 
territory (1/3 of MCA territory is approximately 100mL), <50mL in ACA/PCA territory; 
penumbra volume>14mL. 
Patients who had good or moderate collateral gradings were considered to have good 
collateral status, and those had poor collateral grading were deemed to have poor 
collateral status. 
Other definitions of imaging and clinical outcomes are as described in Chapter 3, as are 
the calculations of the percentage of penumbra salvaged, and infarct growth. 
6.2.3. Statistical methods 
The continuous variables are compared using the independent t test, the Mann-Whitney 
U test, and categorical variables with Chi – square and Fisher’s test. We used a 
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generalised linear model, and linear and logistic regressions to assess the association 
between imaging and clinical variables, and the comparison of imaging and clinical 
outcomes was adjusted for variables including age, OTT and the baseline NIHSS score. All 
statistical analyses were carried out with SPSS 21. 
6.3. Results 
6.3.1. Clot length 
63(66%) (T=35, A=28) out of 96 patients had hyperdense vessel signs on the baseline CT 
brain, of which 47/96 (49%) (T=26, A=21) were measurable. No significant difference was 
found in the mean clot length between the two groups (13±11mm vs 14±11mm, p=0.63). 
25 patients had a clot length of more than 8mm (T=14 [54%], A=11 [52%], p=1). 
The intra-class correlation coefficient for the two clot length measurements performed by 
XH was 94.8%, with 95% limits of agreement of -6.1 - 7.7 (Figure 6-4) 
 
Figure 6-4. Bland-Altman agreement plot between two measurements for clot 
length (mean[green]±1.96SD[black]). 
The mean clot lengths that resulted in recanalisation were similar between the 
tenecteplase and alteplase groups using a univariate Analysis of Variance (ANOVA) 
(12.8±11.1mm vs 12±13.1mm, p=0.87) (Figure 6-5). In this sample, the length of 
thrombus did not correlate with the baseline stroke severity measured by the NIHSS score 
(p=0.74). 22 out of the 46 patients (46.8%) had confirmed cardioembolic stroke, and the 
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clot length was reversely associated with cardioembolic stroke (p=0.005, 95%CI [-14.6 − -
2.7]). When adjusted with age, OTT and baseline NIHSS, the significance persisted 
(p=0.016, 95%CI [-13.6 − -1.5]). Patients with longer clots were more likely to have 
symptomatic ICH (ECASS 2 definition311) (p=0.033, 95%CI [1-23.2]). When adjusted for 
age, OTT and baseline NIHSS, the significance persisted (p=0.034). No association existed 
between clot length, the change of the NIHSS score at 24 hours (p=0.13), and early 
neurological improvement (p=0.46), mRS 0-1 (p=0.66) or mRS 0-2 (p=0.58) at 90 days; but 
there was an independent association between increased mortality at 90 days and those 
who had longer thrombi on presenting CT scan (p=0.01, OR 1.2, 95%CI [1.1-2]). 
 
 Figure 6-5. The mean length of clot that recanalised by tenecteplase and 
alteplase 
 
No association was found between clot lengths and baseline CTP ischaemic core volumes 
(p=0.25), or the proportion (p=0.54) or the volume (p=0.19) of penumbra salvaged at 24 
hours, but patients with longer clots had a trend towards larger co-registered (p=0.07, B- 
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coefficients 1.7, 95%CI [-0.1-3.5]) and total infarct volumes (p=0.055, B-coefficients 2.8, 
95%CI [-0.1-5.5]). In the subsequent multiple linear regression model, the significances 
did not persist when adjusted with age, OTT and baseline NIHSS scores. 
No association was found between clot length and the likelihood of recanalisation 
(p=0.89) (Figure 6-6).  A trend towards a reduced likelihood of recanalisation was evident 
nevertheless in those who had a thrombus measured longer than 8mm (p=0.071, OR 0.3, 
95%CI [1.3-437.4]). In the multiple regression model, the near-significant trend continued 
(p=0.054, OR 0.2, 95%CI [1.1-735.3]). 
 
 
6.3.2. Collateral flow 
49 (T=22, A=27) patients had retrograde flow on the baseline CT perfusion, and qualified 
for collateral assessment. The proportion of patients who were considered to have good 
collaterals did not differ between the two treatment groups (T=15, A=20, p=0.76). 
In the univariate regression model, good collaterals were associated with less severe 
strokes (p=0.021, OR 0.9, 95%CI [0.5-0.95]), smaller ischaemic core volumes (p=0.001, OR 
0.96, 95%CI [0.9-0.95]), and better ASPECT scores (p=0.002, OR 2.2, 95% CI [2-36.6]). We 
did not find any association between collateral status and other potential predictors 
including penumbra volumes (p=0.82), age (p=0.98), OTT (p=0.69), cardio-embolic stroke 
(p=0.11), history of hypertension (p=0.59), diabetes (p=0.12), hyperlipidaemia (p=0.32), 
the baseline systolic BP (p=0.58), glucose (p=0.92), ipsilateral carotid stenosis (p=0.63) or 
previous use of statin (p=0.72). 
There was a near-significant association between collaterals and mRS 0-2 at 90 days 
(p=0.068, OR 7.3, 95% CI [0.7-13.7]), but not with mRS 0-1 (p=1), early neurological 
improvement at 24 hours (p=0.3), or mortality (p=0.17). Good collaterals were associated 
with a reduced risk of SICH (ECASS 2 definition) (p=0.041, OR 0.1, 95% CI [0.001-0.8]) or 
any ICH (p=0.005, OR 0.1, 95%CI [0.001-0.3]). Significant correlations were found between 
good collaterals, larger proportions of penumbra salvaged (p=0.024, B-coefficients 18.4, 
95% CI [2.9-34.9]) (Figure 6-6), smaller co-registered infarct volumes (p=0.001, B-
coefficients -72.3, 95% CI [-112.2 − - 32.8]) and total infarct volumes (p=0.001, B-
coefficients -115.8,  95% CI [-184- -50.2]), but not with recanalisation (p=0.47). 
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When adjusted for age, OTT and the baseline NIHSS score, collateral flow was 
independently associated with a risk of SICH (ECASS 2 definition), any ICH, co-registered 
and total infarct volumes (Table 6-1). 
Table 6-1. Good collateral status as a prognostic factor in multivariate 
regressions adjusted for age, OTT and baseline NIHSS scores for clinical and 
imaging outcomes 
 B-coefficients or OR (95% CI) P Value 
SICH (ECASS 2 definition) 0.1 (0.02-0.9) 0.044 
Any ICH 0.1 (0.03-0.6) 0.012 
mRS 0-2 at 90 days 1.7 (0.1-22) 0.67 
Early neurological 
improvement at 24 hours 
2 (0.4-9.5) 0.38 
Mortality at 90 days 0.3 (0.07-1.8) 0.2 
Proportion of penumbra 
salvaged 
12.381 (-4.4-29.2) 0.15 
Co-registered infarct volume -48.883 (-87.6- -10.2) 0.015 
Total infarct volume -80.559 (-147.5- -13.6) 0.02 
 
 
 
%
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Figure 6-6. The proportion of penumbra salvaged according to collateral 
circulation 
6.3.3. Cerebral oedema and clinical outcomes 
35 out of 96 patients (36.5%) (Table 6-2) had brain swelling on a 24-hour CT post 
thrombolysis. No difference was found in the distribution of brain swelling severity 
between the two groups (p=0.97). In the univariate logistic regression model, many 
clinical and imaging variables were associated with postthrombolysis brain swelling (Table 
6-4). In the subsequent multiple regression model which included all variables that had a 
significance level <0.3, all associations became insignificant. 
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Table 6-2. Brain swelling in tenecteplase and alteplase treated patients  
Severity of brain swelling n, % Tenecteplase 
N=47 
Alteplase 
N=49 
No swelling 28 (60%) 30 (61%) 
Effacement of adjacent 
lateral ventricle 
11 (23%) 10 (20%) 
Effacement of the lateral and 
the third ventricle  
4 (9%) 4 (8%) 
Midline shift 4 (9%) 3 (6%) 
 
 
Table 6-3. Univariate logistic regression to predict post thrombolysis brain 
swelling 
 
Variables OR (95%CI) P value 
Age 1 (0.97-1) 0.92 
Baseline NIHSS 1.2 (1.1-1.3) <0.001 
OTT 1 (0.99-1) 0.8 
Baseline glucose 0.9 (0.7-1.1) 0.3 
Baseline systolic BP 1 (0.99-1) 0.18 
AF 1.7 (0.7-4) 0.23 
Clot length >8mm 2.9 (0.9-10) 0.085 
Baseline ASPECT 0.6 (0.5-0.8) <0.001 
Core volume 1.05 (1-1.1) <0.001 
Large vessel occlusion (ICA/M1) 4.6 (1.5-13.6) 0.006 
Collateral status 0.2 (0.05-0.6) 0.007 
Hyperdense vessel sign 7 (2.2-22.3) 0.001 
 
In univariate regressions, brain oedema was associated with all clinical and imaging 
outcomes, except for recanalisation (p=0.43) and mRS 0-1 at 90 days (p=0.056) (Table 6-
4). When adjusted for age, OTT and the baseline NIHSS score, brain oedema was still 
associated with a high risk of haemorrhage (Figure 6-7), and poor clinical and imaging 
outcomes as was expected (Table 6-5). The distribution of mRS at 90 days according to 
the severity of cerebral oedema is shown in Figure 6-8. 
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Table 6-4. Univariate regression for cerebral oedema as a poor prognostic 
predictor for clinical and imaging outcomes 
 B-coefficients/OR  (95% CI) P Value 
SICH (ECASS 2 definition) 4.3 (1.9-9.9) 0.001 
Any ICH 4 (2.2-7.6) <0.001 
Early neurological 
improvement at 24 hours 
0.4 (0.2-0.9) 0.017 
mRS 0-1 at day 90 0.5 (0.2-1) 0.056 
mRS 0-2 at day 90 0.3 (0.2-0.7) 0.004 
Mortality at day 90 3.6 (1.9-6.8) <0.001 
Recanalisation 0.8 (0.5-1.4) 0.43 
Proportion of penumbra 
salvaged 
-17.867 (-22.5- -13.2) <0.001 
Co-registered infarct volume 54.561 (46.1-63) <0.001 
Total infarct volume 80.662 (66-95.3) <0.001 
 
 
Table 6-5. Multivariate regression for cerebral oedema as a poor prognostic 
predictor for clinical and imaging outcomes 
 B-coefficients/OR (95% CI) P Value 
SICH (ECASS 2 definition) 11.1 (2.3-54) 0.003 
Any ICH 5.1 (2.2-11.6) <0.001 
Early neurological 
improvement at 24 hours 
0.4 (0.2-0.8) 0.009 
mRS 0-1 at day 90 1.3 (0.5-3.4) 0.6 
mRS 0-2 at day 90 0.6 (0.3-1.3) 0.19 
Mortality at day 90 3.8 (1.6-9.1) 0.002 
Recanalisation 0.7 (0.3-1.3) 0.26 
Proportion of penumbra 
salvaged 
-16.665 (-22- -11.3) <0.001 
Co-registered infarct volume 44.698 (35.1-54.2) <0.001 
Total infarct volume 66.752(50.3-83.2) <0.001 
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Figure 6-7. The distribution of SICH using ECASS 2 definition across the 
different severity of brain swelling 
 
 
Figure 6-8. The distribution of mRS at 90 days according to the severity of 
brain swelling 
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From 104 patients, 38 (36.5%) fulfilled the imaging selection criteria described above; 21 
(55.3%) received alteplase and 17 (44.7%) received tenecteplase. The baseline clinical and 
imaging characteristics were well balanced in the two groups (Table 6-6), but patients 
who received tenecteplase had a significantly higher percentage of the presence of 
hyperdense vessel signs compared with those who received alteplase (p=0.024). 
6.3.4.1. Imaging outcomes (Table 6-7) 
The mean percentage of penumbra salvaged at 24 hours post-thrombolysis (75±26% vs 
70±23%, p=0·62, mean difference [95%CI] 5% [-20-12]) did not differ between 
tenecteplase treated patients and those who received alteplase. Similarly, the mean 
volume of the penumbra salvaged was similar (p=0.1, mean difference [95%CI] 14mL [-29, 
2]) (Figure 6-9). The volumes of infarct growth (p=0.74), co-registered infarct volumes 
(p=0.83) or total infarct volumes (p=0.92) between the two treatment groups were not 
different. The recanalisation rates were 76% in both groups respectively (p=0.48, OR 
[95%CI] 0·5 [0·08-3.3]). 
6.3.4.2. Clinical outcomes (Table 6-7) 
47% and 29% respectively of patients achieved early neurological improvement at 24 
hours (p=0·27, OR [95%CI] 2.2 [0.5-9.3]). The proportion of patients who achieved 
functional independence (mRS 0-1) and mortality rates at 90 days was similar, and the 
mRS ordinal shift test was not significantly different (Figure 6-10) in the two groups. 
6.3.4.3. Safety outcomes (Table 6-7) 
ICH rates of any kind were significantly lower in patients who received tenecteplase (12% 
vs 29%, p=0.048, OR [95%CI] 0.07 [0-1]). The rates of SICH using either the SITS-MOST 
definition318 (p=0·46, OR [95%] 0·3 [0·02-6]) or the ECASS 2 criteria311 (p=0·46, OR [95%] 
0·3 [0·02-6]) were nevertheless similar, probably due to the very small number of events. 
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Table 6-6. Baseline clinical and imaging characteristics of the subgroup of 
patients who fulfilled imaging selection criteria 
 
 
  Tenecteplase 
(n=17) 
Alteplase 
(n=21) 
P Value 
Clinical 
Age years mean(SD*) 77 (9) 72 (13) 0.15 
Male (n, %) 9, 53% 9, 43% 0.75 
Dominant hemisphere stroke (n, %) 6, 35% 13, 62% 0.096 
Baseline NIHSS score (Median, 
IQR)[min-max] 
12 (9-15)[5-21] 12 (10-16)[4-27] 0.79 
Onset-to-treatment 
Time min  
mean(SD) 187 (50) 
 
195 (50) 0.64 
Median 
(IQR) 
197 (145, 218) 197 (153, 235) 0.69 
Previous stroke/TIA (n, %) 5, 29% 4, 19% 0.7 
Hypertension (n, %) 9, 53% 12, 57% 1 
Diabetes (n, %) 4, 24% 4, 19% 1 
Blood glucose mmol/L mean (SD) 7 (2) 7 (3) 0.36 
Atrial Fibrillation (n, %) 10, 59% 9, 43% 0.52 
Hyperlipidaemia (n, %) 12, 71% 10, 48% 0.2 
Smoker (n,% ) 1, 6% 3, 14% 0.61 
Stroke clinical syndrome 
TACS (n, %) 12, 71% 14, 67% 1 
PACS (n, %) 5, 29% 7, 33% 
LACS (n, %) 0, 0% 0, 0% 
POCS (n, %) 0, 0% 0, 0% 
Imaging  
ASPECT score mean (SD) 7 (2) 7 (2) 0.68 
Hperdense sign (n, %) 17, 100% 15, 71% 0.024 
 Penumbra Volume 
mL 
Median (IQR) 53 (38-94) 45 (35-66) 0.28 
Mean (SD) 61 (29) 50 (21) 0.16 
Core Volume mL Median (IQR) 20 (9-40) 19 (12-38) 0.82 
Mean (SD) 26 (20) 25 (19) 0.87 
Mismatch Ratio mean (SD) 5.6 (5) 4.5 (3.4) 0.47 
Occlusion 
M1§ 12, 71% 11, 52% 0.51 
M2§ 5, 29% 9, 43% 
M3§ 0, 0% 1, 5% 
ACA/PCA 0, 0% 0, 0% 
*SD, standard deviation; NIHSS: National Institute of Health Stroke Scale; IQR: Interquartile Range; TIA: Transient 
Ischaemic Attack; TACS; Total Anterior Circulation Syndrome; PACS: Partial Anterior Circulation Syndrome; LACS: 
Lacunar Syndrome; POCS: Posterior Circulation Syndrome; ASPECT score: Alberta Stroke Program Early CT score; 
ICA: Internal Carotid Artery; § Middle Cerebral Artery M1, M2, M3 segment; ACA: Anterior Cerebral Artery; PCA: 
Posterior Cerebral Artery. 
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Table 6-7. Study outcomes in this sub-group of patients who fulfilled imaging 
selection criteria 
 
 
TNK 
(n=17) 
Alteplase 
(n=21) 
p value¢ Mean 
difference 
(95%CI) 
Odds Ratio 
(95%CI) 
Primary outcome  
Percent penumbral salvage at 24-48 h 
mean (SD)* 
75% (26) 70% (23) 0.62 5% (-20-12) - 
Secondary imaging outcomes   
Co-registered final infarct volume at 
24-48 h ml mean (SD )# 
44 (42) 49 (53) 0.83 -5 (-27, 37) - 
Total infarct volume at 24-48 h ml 
mean (SD )║ 
65 (71) 66 (78) 0.92 -1 (-48, 51) - 
Volume of infarct growth at 24-48 h 
ml mean (SD) 
18 (36) 24 (42) 0.74 -6 (-20, 32) - 
Volume of penumbra salvaged at 24-
48 h ml mean (SD) 
48 (29) 34 (18) 0.1 14 (-29, 2) - 
Recanalisation at 24-48 h (n, %)§ 13, 76%¤ 16, 76%¤ 0.48 - 0.5 (0.08-3.3) 
Secondary clinical outcomes  
Early neurological improvement at 24 
h (n, %) ¶ 
8, 47% 6, 29% 0.27 - 2.2 (0.5-9.3) 
Improvement in NIHSS score between 
baseline and 24 h mean (SD) 
4 (6) 2 (8) 0.43 2 (-3-6) - 
mRS 0-1 at 30 days (n, %) 2, 12% 2, 10% 0.84 - 1.3 (0.1-10.8) 
mRS 0-1 at 90 days (n, %) 4, 24% 4, 19% 0.84 - 1.2 (0.2-8.5) 
mRS ordinal shift   0.73  1.2 (-1-1.4) 
Mortality at 90 days (n, %) 3, 18% 2, 10% 0.46 - 3.1 (0.2-64.4) 
Safety outcomes (A=51, T=52)  
Any ICH (n, %) 2, 12% 6, 29% 0.048 - 0.07 (0-1) 
Any parenchymal haemorrhage (n, %) 0, 0% 2, 10% 1   
Parenchymal haemorrhage type 2 (n, 
%) 
0, 0% 1, 5% 1   
Symptomatic ICH (ECASS II
311
 
definition) (n, %) 
1, 6% 2, 10% 0.46 - 0.3 (0.02-6) 
Symptomatic ICH (SITS-MOST
318
 
definition) (n, %) 
1, 6% 2, 10% 0.46 - 0.3 (0.02-6) 
*SD, standard deviation; NIHSS: National Institute of Health Stroke Scale; IQR: Interquartile Range; ICH: 
Intracerebral haemorrhage; mRS: Modified Rankin Scale; 
¢ p-values were calculated from linear of logistic regression models that adjust for stratification variables and are a 
test for difference between groups. 
# Co-registered infarct volume was defined as infarct volume measured on 24-48 h CT slices co-registered to 
baseline CT perfusion; 
║Total infarct volume was defined as total infarct volume measured on follow-up CT at 24-48 h; 
§ Recanalisation was defined as TIMI
371
 2-3; 
¤ The percentages for recanalisation were derived from the number of subjects with an occlusion. 
¶ Early neurological improvement at 24 h was defined as NIHSS reduction ≥ 8 points or 24 h NIHSS 0-1. 
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Figure 6-9. The mean volume of penumbra salvaged at 24 hours post 
thrombolysis in the two groups 
 
 
 
 
 
 
Figure 6-10. mRS in tenecteplase and alteplase treated patients at 90 days 
(expressed as percentage) 
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6.4.  Discussion 
In further imaging analysis, we have assessed the effects of length of thrombi and 
collateral flow. 
No difference was found in the mean clot length that was recanalised in the tenecteplase 
and alteplase groups. 
In this sample, no association between the size of the thrombus and the likelihood of 
recanalisation was found, which is probably due to the small sample size. However, we 
did find that those with a thrombus longer than 8mm had a trend towards reduced odds 
of recanalisation, which is consistent with the finding from Riedel’s group163. 
The size of thrombus was associated with an increased risk of symptomatic ICH, a trend 
towards higher mortality and larger infarct volumes. 
Clot length has been considered to be one of the factors when determining the triage of 
patients for IV or IA recanalisation therapy. However, the methods of measuring thrombi 
using either the single phase CTA or plain CT have their limitations. The measurements on 
thin slice CT derived by Riedel and colleagues have not been reproduced by other groups. 
Using the modified method, we found that the method is easy to apply, but that only 
about 50% of patients had a measurable hyperdense vessel. 
Many methods have been proposed to assess collateral status in acute ischaemic 
strokes229, but without consistency. We used the methods developed by Miteff and 
colleagues81, as this takes into account true retrograde (ie leptomeningeal collateral) flow 
and is easy to use. We have however extended the assessment to M2 occlusions because 
poor collaterals are often present in this population. 
Previous literature has described several factors that may influence the recruitment of 
collaterals including a history of hypertension, the presence of carotid stenosis, 
hyperglacaemia and the previous use of statin. However, we did not demonstrate the 
existence of any association between collateral status and those factors, which may be 
again due to the small sample size. 
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Collateral status is an important predictor for outcomes, and has been used as one of the 
selection criteria for endovascular treatment by some investigators207. In our sample, we 
have demonstrated that similar associations arise with imaging outcomes and ICH risk. 
36.5% of the ATTEST study patients developed cerebral oedema post thrombolytic 
therapy, and approximately 10% had detrimental oedema that was potentially life 
threatening. This overall rate is higher than previously reported401 in the thrombolysed 
population and those who did not receive treatment402 although methods for grading 
brain oedema are not standardised and this findings is reported inconsistently. 
Unfortunately, we did not have an untreated control group with which to make a 
comparison. The proportion of severe brain swelling found was similarly to previous 
findings403. 
Post-thrombolysis brain swelling was associated with a higher risk of ICH and mortality, a 
poor neurological outcome at 24 hours, less penumbra salvage, and larger infarct 
volumes. We did not find any correlation between post-thrombolysis brain swelling and 
recanalisation. As far as we are aware, this is the first study to have explored the 
relationships between post-thrombolysis oedema and imaging outcomes. A larger sample 
is warranted for further investigation. 
Late reperfusion may hypothetically augment BBB permeability, and worsen cerebral 
oedema404,405. However, our study was limited since recanalisation was assessed at 24-48 
hours, and the study did not therefore provide information regarding early recanalisation 
and the development of brain oedema after treatment. 
Some literature has suggested that alteplase neurotoxicity might  induce cerebral oedema 
by increasing neurovascular unit permeability278. No similar finding had been reported for 
tenecteplase. However, given that the structure of tenectplase is rather similar to 
alteplase, except for the three points of modification, we presume that tenecteplase has 
a similar effect on the blood brain barrier caused by an interaction with the low-density 
lipoprotein-receptor-related protein. In our sample, we did not find any difference in the 
proportion of brain oedema in tenecteplase or alteplase treated patients. 
In the comparison of the subgroup of the ATTEST study patients who fulfilled the imaging 
selection criteria used by Parsons and colleagues, with the exception of significantly less 
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ICH in tenecteplase treated patients, no difference was found in other efficacy or safety 
outcomes. 
Compared with the patients in the Parsons study, ours had a larger median core volume 
(19-20mL vs 8-13mL), and a smaller penumbra (45-53mL vs 76-80mL) indicating a 
selection bias. The baseline NIHSS scores (12 vs 14) were similar, but OTTs (187-195 vs 
162-186 minutes) were longer in our patients. The larger cores and smaller penumbras 
may contribute to the neutral results in our sample, but other factors such as clot length 
or collateral flow may also play a role. 
To date, AIS reperfusion studies which have used imaging selection have generated 
heterogeneous results (Tabel 6-8). The studies194,195 which have yielded positive results all 
had a small core (11-18mL) and a large penumbra. On the other hand, MR RESCUE196, the 
only study to date examining the concept of penumbra selection that has failed to 
demonstrate its benefit had a much larger median core of 60mL, although the median 
penumbra volume was 177mL. The main reasons for the neutral result are believed to be 
the selection bias of large core volumes, together with the device (1st generation, 
therefore low efficacy) used, and delayed reperfusion. Our subgroup analysis supported 
the view that selection bias can occur with current tissue selection criteria. Together with 
other unresolved issues in perfusion imaging, the study demonstrated that advanced 
imaging selection requires further refinement of criteria, and ideally validation in a well-
designed RCT. 
In addition, in order to ensure that intra-arterial intervention is beneficial, careful patient 
selection may be necessary. The recent success of the series of endovascular studies is a 
significant progress in AIS management, but the variable selection criteria used in these 
studies makes establishing criteria for clinical application difficult. If the current tissue 
criteria are used, treatment benefits may be smaller than current evidence suggests due 
to the potential selection bias. 
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 Table 6-8. Studies using imaging criteria for patient selection 
 
 
 
 
 
 
 
 
Study Therapy Imaging 
modality 
Inclusion Criteria Core 
(Median, 
mL) 
(treatment 
vs control) 
Penumbra 
(Median, 
mL) 
(treatment 
vs control 
Favourable 
clinical 
outcomes at 
90 days 
(treatment 
vs control) 
Time 
window 
(hour) 
Tissue (mL) Mismatch 
Ratio 
Occlusion Sites 
Core Penumbra 
DIAS
332
 IV vs 
Placebo 
MRI 3-9 <1/3 of MCA 
territory 
>2cm in 
diameter 
involving 
gray matter 
>1.2  17.8 vs 20.4  39% vs 22% 
DEDAS
333
 IV vs 
Placebo 
MRI 3-9  >2cm in 
diameter 
involving 
gray matter 
>1.2 ICA occlusion 
excluded 
22.2 vs 35.1  45% vs 25% 
DIAS2
184
 IV vs 
Placebo 
MRI&CT 3-9 <100  >1.2  11.3 vs 7.9 
vs 12.3 
66.2 vs 51.9 
vs 48.8 
49% vs 54% 
vs 57% 
TNK
194
 TNK vs 
alteplase 
CT <8 <100 >20 >1.2 MCA/ACA/PCA 11 vs 8 vs 13 79 vs 80 
vs76 
72% vs 44% 
EXTEND-IA
198
 IA+IV vs 
IV 
MRI&CT <6 <70 >10 >1.2 ICA/M1/M2 12 vs 18 
 
106 vs 115 71% vs 40% 
SWIFT PRIME
197
 IA+IV vs 
IV 
MRI&CT <6 age18-79: 
MRI<50, 
CT<40 
Age80-85: 
MRI<20, 
CT<15 
>15 >1.8 ICA/M1   60% vs 35% 
ESCAPE
207
 IA+Stand
ard 
care/stan
dard sare 
CT <12 >1/3 of MCA 
territory 
 
  ICA /M1/>2 M2 
occlusions 
  53% vs 29% 
 Trail’s own definition. 
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The analyses carried out in this chapter have limitations. They were secondary analyses 
based on a single centre small phase II study. The sample size was small. The results need 
further verification in a large study. 
6.5. Conclusion 
In secondary analyses, we found patients with a thrombus of more than 8mm in length 
have a trend towards a reduced likelihood of recanalisation. In patients who had achieved 
recanalisation, the size of clot did not differ with tenecteplase or alteplase treatment. 
Good collateral circulation was associated with smaller infarct volumes, and with the 
possibility of more penumbra salvage. 
Post-thrombolysis cerebral oedema is associated with an increased risk of haemorrhage, 
less penumbra salvage, a larger infarct volume and possiblly worse clinical outcomes. 
Further focused analyses using a larger sample size is warranted to establish this. 
In a sub-group of patients who had favourable imaging profiles, no difference was found 
in efficacy between the tenecteplase and alteplase groups. Tenecteplase treated patients 
have a lower risk of ICH post-treatment. Advance imaging based patient selection is 
appealing in conducting studies. However, the method is not verified, requiring further 
examination in RCT. Tissue status criteria require further refinement to avoid selection 
bias. 
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Chapter 7 Analysis of 
coagulation and fibrinolytic 
activity of tenecteplase and 
alteplase in acute ischaemic 
stroke 
7.1. Introduction 
IV thrombolysis with alteplase in acute ischaemic strokes improves clinical outcomes, but 
is associated with a 2.7% risk of fatal ICH (relative risk compared to placebo 6.8%, OR 
[95%CI]7.14 [3.98-12.79])70. The efficacy of alteplase varies depending on the occlusion 
site319, and approximately 15% of those recanalised reoccluded within the first two hours 
of receiving treatment322. 
The potentially beneficial pharmacological properties of tenecteplase have prompted 
investigations of tenecteplase in acute stroke thrombolysis. In chapter 5, we 
demonstrated a trend towards fewer ICH complications among tenecteplase-treated 
patients. This finding is consistent with that of Parsons and colleagues194. Coagulation and 
fibrinolysis assays have been performed in several studies comparing thrombolytic agents 
in MI 306,395, but there are fewer data from acute strokes. Those studies406,407 that have 
examined the fibrinolytic system after IV thrombolysis in strokes have done so to 
investigate mechanisms and predictions of ICH, and have suggested that early fibrinogen 
depletion is relevant, and that significant hypofibrinogaemia (a decrease of 2g/L or 50% 
from baseline) is about one-fifth among patients receiving intravenous alteplase406. 
tPA activates plasminogen to plasmin, which breaks fibrin down to fibrin-degradation 
products. Non-fibrin-selective agents, such as streptokinase or UK significantly affect 
haemostasis by breaking down circulating fibrinogen as well as the fibrin in thrombi242. 
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rtPA has some ability to selectively bond to fibrin on the surface of a clot, and to activate 
mainly fibrin-bound plasminogen, which results in relatively controlled fibrinolysis, and 
hence gives rise to fewer instances of bleeding complication and in more targeted lysis. 
This property of selectively bonding to clot fibrin is termed “fibrin specificity or affinity”, 
and is more prominent in tenecteplase than in alteplase (15-fold)283. The expectation that 
tenecteplase should decrease haemorrhagic incidence without comprising efficacy has 
been evidenced by MI thrombolysis studies290. 
The incidence of spontaneous ICH after thrombolysis in acute MI nevertheless is 
extremely low, and mechanisms are likely to differ from those after acute ischaemic 
stroke. Studies in MI therefore offer limited insight for stroke thrombolysis. Direct 
comparisons using ischaemic stroke patients may be informative. 
As a sub-study of the ATTEST trial, we compared the effects of the two agents on 
coagulation and the fibrinolytic system, and explored associations with ICH and 
recanalisation. 
7.2. Methods 
The study protocol amendment for this sub-study was approved by the ethical committee 
in December 2012, with additional funding awarded from the NHS endowments fund. 
This sub-study was initiated part-way through the main trial. All trial participants were 
approached about the sub-study after it commenced. 
Venous blood samples were collected on citrate (final concentration 0.109 M, Greiner 
Bio-One, Austria) at baseline (pre-thrombolysis) (Time Point [TP] 1), 3-12 hours (TP2) and 
24±3 hours (TP3) after the initiation of thrombolytic drug treatment from each patient. 
Plasma was obtained by centrifugation immediately after sampling and then stored at -80 
°C until analysis. The following assays were performed at the Haematology laboratory in 
Glasgow Royal infirmary; Prothrombin Time (PT), APTT, Fibrin(ogen) Degradation 
Products (FDP), plasminogen, D-Dimer, Factor V, PAI-1 activity and Prothrombin Fragment 
1+2 (F1+2) (Table 7-1). The reference ranges for PT, APTT, fibrinogen and Factor V were 
derived locally, while the others were determined by the kit manufacturer. 
 
 
 179 
Table 7-1. Detailed laboratory methods for coagulation assays 
Analyte Assay method & 
analyser 
Assay Kit Reference 
Limits 
Assay 
CV 
Prothrombin 
Time 
Clot-based [ACL 
TOP700 CTS] 
HemosIL® 
ReCombiPlasTin2G *  
9-13s 1.8-2.6% 
APTT Clot-based [ACL 
TOP700 CTS] 
HemosIL® SynthASil *  27-38s 2.3-2.5% 
Fibrinogen 
[Clauss]408 
Clot-based [ACL 
TOP700 CTS] 
HemosIL® Fibrinogen-C 
XL * 
2.0-4.1 g/L 7.2-8.3% 
Factor V Clot-based [ACL 
TOP700 CTS] 
HemosIL® Factor V 
deficient plasma * 
66-167 iu/dL 6.8% 
Fibrin D-dimer Latex 
immunoassay 
[ACL TOP700 CTS] 
HemosIL® D- Dimer HS * < 243 ng/mL 5-7% 
Fibrin(ogen) 
degredation 
products (FDP) 
Latex 
immunoassay 
[ACL TOP700 CTS] 
HemosIL® FDP * < 2.01 
ug/mL 
3.4% 
Plasminogen 
activity 
Chromogenic 
assay [ACL 
TOP700 CTS] 
HemosIL® Plasminogen 
* 
73-140 u/dL 5% 
PAI-1 activity ELISA ** ZYMUSEST PAI-1 
Activity, HYPHEN 
BioMed 
< 5ng/mL 6.6-
11.2% 
Prothrombin 
Fragment 1+2 
ELISA ** Enzygnost® 1+2 
[monoclonal], SIEMENS 
62-229 
pmol/L 
2.3-
12.5% 
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7.2.1. Statistical analysis 
The baseline value was expressed as the mean ± SD, the changes within groups at TP2 and 
TP3 were expressed as the mean ± SD percentage change from the baseline. Time and 
group interactions were sought using a repeated measure general linear model. 
A related samples Wilcoxon signed rank test was used to examine the within-groups 
differences (TP2 versus TP1, TP3 versus TP1), and any significant global differences 
explored further for between-group effects using an independent Mann-Whitney test. 
A univariate binary logistic regression model was used to explore the potential 
association between coagulation variables, ICH, and recanalisation. 
7.3. Results 
There were 104 participants in the main ATTEST trial, 30 of whom took part in this sub-
study (alteplase = 14, tenecteteplase = 16) (Figure 7-2). The median sampling times did 
not differ significantly between the alteplase and tenecteplase groups for either TP2 (5.3 
vs 4.4 hours, P=0.27) or TP3 (23.8 vs 23.9 hours, P=0.62), nor did the proportion of 
samples acquired in the morning409 (5am-10am) (7% vs 31%, P=0.3). Key baseline 
characteristics were similar between patients who received alteplase and those treated 
with tenecteplase (Table 7-2). The baseline mean values (SD) of all coagulation variables 
and the proportion of their changes at TP2 and TP3 are summarised in Table 7-3. 
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Figure 7-1. Coagulation and fibrinolysis essay sub-study CONSORT chart. 
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Table 7-2. Key demographic and stroke characteristics of the 30 patients 
 Alteplase 
N=14 
Tenecteplase 
N=16 
P value 
Age year (mean±SD) 70±12 69±15 0.95 
Male (n, %) 10 (71%) 10 (63%) 0.71 
OTT mins (mean±SD)  187±52 181±47 0.75 
Baseline NIHSS score 
(median, IQR) 
10 (6-15) 11 (8-17) 0.58 
Cardioembolic stroke 
(n, %) 
8 (57%) 8 (50%) 0.7 
Baseline vessel 
occlusion (n, %) 
9 (64%) 8 (50%) 0.34 
Large vessel occlusion 
(ICA, M1) (n, %) 
6 (43%) 6 (38%) 0.7 
Sampling time for TP2 
hours (median, IQR) 
5.3(4.8-10.1) 4.4(3.9-11.8) 0.27 
Sampling time for TP3 
hours (median, IQR) 
23.8(23.1-24.6) 23.9(23.5-24.6) 0.62 
Diurnal Sampling for 
TP2 (n, %) 
1 (7%) 5 (31%) 0.3 
ICA Internal Carotid Artery; M1 Meddle Cerebral Artery M1 Segment; TP Time point; Frequencies were 
compared using Chi-squared test and Fisher’s test; Mean or median values were compared using 
independent T test and Mann-Whitney U test respectively. 
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Table 7-3. Percentage change of coagulation and fibrinolytic variables in 
alteplase and tenecteplase group within the first 24 hours post thrombolysis 
 Baseline¢ % change TP 2 versus TP1 % change TP3 versus TP1 
 Alteplase TNK 
#
P 
value 
Alteplase 

P value 
TNK 

P value 
#
P 
Value 
Alteplase 

P value 
TNK 

P value 
#
P 
value 
PT 
*9-13 secs 
12±1 12±2 0.47 +13±16% 
0.011 
+1±11% 
0.67 
0.037 +11±14% 
0.005 
+1±10% 
0.86 
0.031 
APTT 
*27-38 secs 
30±3 29±3 0.26 +5±14% 
0.31 
+1±11% 
0.72 
0.16 -2±13% 
0.73 
-3±9% 
0.41 
1 
Fibrinogen 
*2.0-4.1 g/L 
3.1±0.6 3.3±0.7 0.53 -29±26% 
0.002 
- 3 ± 17% 
0.64 
0.002 -18±30% 
0.021 
-8±21% 
0.26 
0.011 
FDPs 
*< 2.01ug/mL 
3.8±3.8 8.3±19.5 0.39 +1048±810% 
0.001 
+908±1204% 
0.003 
0.39 +212±175% 
0.002 
+146±144% 
0.009 
0.29 
Plasminogen 
*73-140 U/dL 
84±16 79±11 0.32 -39±14% 
0.001 
-8±15% 
0.029 
<0.001 -24±13% 
0.001 
-2±16% 
0.62 
0.001 
PAI-1 
activity 
*<5 ng/mL 
1.2±1.3 0.9±0.5 0.49 +600±1191% 
0.093 
+104±314% 
0.87 
0.24 +58±142% 
0.62 
+11±54% 
1 
0.73 
D Dimer 
*<243 ng/mL 
570±631 934±2419 0.59 +716±815% 
0.003 
+1140±1385% 
0.001 
0.59 +107±117% 
0.064 
+148±119% 
0.008 
0.40 
Factor V 
*66-167 IU/dL 
88±21 89±18 0.93 -18±18% 
0.002 
↑4±16% 
0.65 
0.002 +1±29% 
0.45 
+6±20% 
0.48 
0.48 
F1+2 
*62-229 
pmol/L 
308±173 413±518 0.48 +64±87% 
0.087 
+66±89% 
0.074 
0.83 +28±142% 
0.68 
-10±39% 
0.58 
0.91 
Baseline values were expressed as mean±SD, the changes at TP2 and TP3 were expressed as mean ±SD % changes from baseline; 
*laboratory reference value; ¢Baseline values were expressed as mean±SD; 
#
P value between the groups; P value within the 
group; TP Time point; PT Prothrombin time; APTT Activated Partial Thromboplastin Time; FDP Fibrin(ogen) degradation products; 
PAI-1 Plasminogen Activator Inhibitor-1; F1+2 Prothrombin Fragment 1&2. 
 184 
 
7.3.1. Changes in coagulation and fibrinolysis within treatment groups 
(Figure 7-2) 
Alteplase treatment was associated with prolongation of PT, reduced fibrinogen, 
plasminogen levels, elevated FDP and D-Dimer at 3-12 hours post-thrombolysis and at 
24±3 hours. Factor V level also dropped significantly at TP2, but did return to the baseline 
at TP3. The rise of FDP at TP2 was significantly greater than that of D-Dimer (p=0.039). 
In the tenecteplase group, only elevations of FDP and D-Dimer at TP2, TP3, and 
transiently reduced plasminogen at TP2 were seen. The proportion of the FDP rise was 
significantly smaller compared to that of D-Dimer (p=0.005). 
7.3.2. Between-Groups comparison of coagulation and fibrinolytic variables 
(Figure 7-2) 
Alteplase was associated with a significantly greater change from the baseline of PT 
(P=0.037), fibrinogen (P=0.002), plasminogen (P<0.001) and Factor V (P=0.002) at TP2 
compared to tenecteplase, and differences remained significant at 24 hours for PT 
(P=0.031), fibrinogen (P=0.011) and plasminogen (P=0.001). 
7.3.3. Association between ICH, depletion of fibrinogen, Factor V and the 
production of FDP, D-Dimer 
Six out of the 30 patients had a haemorrhage post-thrombolysis, four of which were 
classified as HI1311, one as HI2, and one had a small SAH. None was considered 
symptomatic using either the ECASS 2311 or the SITS-MOST criteria318. 
Fibrinogen levels dropped below 1g/L at TP2 in two patients, both of whom received 
alteplase (2/30, 14%). This low level persisted at TP3 in one, whose follow-up CT revealed 
HI2; The fibrinogen rise to 1.4g/L at TP3 in the other patient who had postthombolysis 
SAH. A binary logistic regression found no association between ICH and the change of 
fibrinogen between TP2 and TP1 (p=0.37), or of D-Dimer (P=0.89). But a near-significant 
association was shown between the magnitude of Factor V drop and ICH (P=0.077).           
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Figure 7-2. The changes of coagulation and fibrinolytic variables in alteplase 
and tenecteplase treated stroke patients from baseline to 24 hours post 
thrombolysis. *Statistical significant difference within or between groups. 
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A rise of FDP of 10-fold or more at TP2 was significantly correlated with the incidence of 
ICH (P=0.046, OR [95% CI] 10.7, [1.05-109.8]); the very wide confidence interval probably 
reflected the very small sample size. 
7.3.4. Recanalisation and the change of FDP, fibrinogen, D-Dimer and PAI-1 
activity 
Within this subset of 30 patients, 17 had a baseline occlusion, of whom 10 recanalised at 
24-48 hours. No association was found between recanalisation status and D-Dimer, FDP 
or PAI-1 activity at TP2 in this sample. The fibrinogen level of the recanalised group was 
non-significantly lower than that of non-recanalised patients (2.2±0.9 vs 2.9±1, P=0.144) 
at TP2. Within the 10 patients who recanalised, 7 received alteplase and 3 had 
tenecteplase; the fibrinogen levels were 2.1±0.9 and 2.7±0.6 respectively (P=0.25). 
7.4. Discussion 
Tenecteplase is reported to have 15-fold higher fibrin specificity, and 80-fold lower 
binding affinity to PAI-1 compared to alteplase282. High fibrin affinity is a desirable 
property of a thrombolytic agent as this ought to translate into greater potency for 
thrombus lysis, while preserving the integrity of systemic coagulation410.  By bonding 
mainly to clot surface fibrin, the fibrin-specific agent ensures that the activation of 
plasminogen is limited to the clot surface. The systemic plasminogen pool is preserved, 
serving a continuous supply to the thrombus surface, leading to a more effective lysis. 
Animal models284 and MI thrombolysis studies289,290 have found fewer bleeding 
complications with tenecteplase while retaining thrombolytic efficacy. Trials in acute 
ischaemic strokes suggest that tenecteplase may also be associated with a lower ICH risk 
with similar or superior recanalization compared to alteplase194 411. In this small sample of 
stroke patients who were treated with standard alteplase or 0.25mg/kg tenecteplase, 
alteplase caused significant fibrinogen depletion and consumption of plasminogen, 
systemic activation of coagulation evidenced by degradation of Factor V412, and activation 
of PAI-1. In contrast, tenecteplase caused minimal disruption to systemic coagulation with 
no hypofibrinogenaemia, while breaking fibrin down at least equally effectivly as 
suggested by the significant rise in FDP and D-Dimer at TP2 and TP3. 
Early degradation of fibrinogen is associated with the occurrence of ICH. Matosevic et 
al406 reported that within six hours post-thrombolysis, a decrease of ≥ 2g/L in fibrinogen 
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levels was an independent predictor for bleeding of all kinds. Significant 
hypofibrinogaemia (a decrease of 2g/L or 50% from baseline) occurs in about one-fifth of 
those receiving IV alteplase, whereas a tenecteplase dose escalation study325 showed no 
severe hypofibrinogenaemia (fibrinogen <1g/dL) in any dose (0.1-0.5mg/kg) tested. 
Similarly, in our sample, tenecteplase treatment did not cause hypofibrinogenaemia using 
either of these criteria. We could not replicate an association between 
hypofibrinogenaemia and ICH, probably due to the small sample, but we found that a 
significant rise in the FDP level at TP 2 (>10 fold) was associated with the incidence of ICH. 
In our sample, the average drop of Factor V was 18% at TP2 for alteplase treated patients, 
but was not severe enough to cause APTT prolongation. The decline of Factor V is a 
marker of systemic fibrinogenolysis and may have a role in the development of bleeding 
complications412, as demonstrated by the near-significant association between the drop 
of Factor V and the occurrence of ICH in our sample. In acute MI413, intravenous alteplase 
caused a much greater drop (average 40%) in circulating Factor V 90 minutes after the 
initiation of treatment, but the co-administration of heparin confounds interpretation. 
Significant disruption of systemic coagulation by alteplase was further evidenced by the 
greater proportion of the rise in FDP than the rise in D-Dimer at TP2. D-Dimer is a specific 
degradation product of cross-linked fibrin, while FDP also includes the degradation 
products of fibrinogen. A greater ratio of FDP to D-Dimer rise suggests degradation of 
fibrinogen (as seen with alteplase), whereas a lower ratio suggests that the majority of 
the FDP were degraded fibrin with minimal fibrinogen breakdown (as seen with 
tenecteplase). 
PAI-1 is the main inhibitor of alteplase, and increased PAI-1 activity post-thrombolysis 
after MI was thought to be one of the main reasons for the limited potency of 
alteplase414. We observed a similar, although non-significant, pattern in the alteplase 
group, and a smaller rise in the tenecteplase group, consistent with greater resistance to 
PAI-1 inhibition. Increased PAI-1 activity was also found to be associated with persistent 
occlusion in acute MI415, but we could not confirm this observation, possibly because of 
the very small sample size, although other factors such as onset-to-treatment time, clot 
burden and collateral flow may have greater relevance than PAI-1 alone on recanalization 
in ischaemic strokes. 
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F1+2 is produced during the process of prothrombin activation by the cleavage of factor 
Xa and the generation of thrombin. The increase of F1+2 during thrombolysis reflects 
thrombin activation. An MI thrombolysis study suggested that the level of F1+2 increase 
can be reduced by concomitant heparin infusion, which implies that the thrombin activity 
during thrombolysis is at least partly due to prothrombin activation416. The level of F1+2 
reflects the procoagulant effect and can serve as a biomarker for monitoring the process 
of reocclusion. In our sample, at TP2, the percent of F1+2 increase was very similar 
between alteplase and tenecteplase. At 24 hours, it returned close to the baseline level in 
the tenecteplase group, but was still elevated in the alteplase group. None of these 
changes was statistically significant. Thrombin activation can also be evaluated by 
measuring the thrombin-antithrombin complex and fibrinopeptide A417, but we did not 
include these variables in our study. No data in a human thrombolysis study comparing 
the procoagulant effect of alteplase and tenecteplase exists to date. It is certainly 
worthwhile investigating whether tenecteplase is less likely to cause reocclusion than 
alteplase in an ischaemic stroke setting, given that concomitant heparin or large dose 
aspirin can be potentially harmful418. 
The significant increase in D-Dimer and FDP post-thrombolysis is well described419,420. One 
early study reported that arterial recanalisation was associated with a greater rise of D-
Dimer post-thrombolysis than with those who had persistent occlusion:421 We could not 
replicate similar results in our small sample. 
Previous investigators413,422 observed that in MI and pulmonary embolism thrombolysis, 
there was more extensive fibrinogenolysis activity in those who had successful 
recanalisation than the non-recanalised group. It was further suggested that some degree 
of firbinogenolysis may be necessary for recanalisation, as it produces adequate amounts 
of FDP in circulation, which inhibits further fibrin production, and therefore prevents the 
ongoing reformation of clots during the thrombolysis process. Therefore when fibrin-
affinity increases beyond a certain limit, the lysis ability cannot rise further410. Whether 
the fibrinogenolysis requirement in recanalisation plays a role in limiting the lysis ability 
of fibrin-specific agents is unknown. However, even if the efficacy does not increase, the 
simplicity of administration and the better safety profile of agents with high fibrin-affinity 
still warrant further investigation in acute ischaemic strokes. 
 189 
Limitations of our study include the small sample size, a variable sampling time at TP2 and 
TP3, and a low incidence of serious ICH (none having parenchymal haemorrhage, or 
clinical deterioration because of the haemorrhage). Since only 17 patients contributed to 
the analysis of recanalization, these findings should also be interpreted with caution. We 
were unable to adjust for known confounding factors such as onset-to-treatment time, 
baseline NIHSS score and age because of the small sample size. Since a repeat CTA was 
undertaken only at approximately 24 hours, we also lack information on the early 
evolution of vessel status, and clot lysis is known to be a dynamic process. Nonetheless, 
we found significant changes in coagulation and fibrinolysis after IV alteplase was 
administered, and significantly less disruption with tenecteplase, consistent with 
potentially a better safety profile for tenecteplase with the retention of fibrinolytic 
efficacy. 
7.5. Conclusions 
In acute ischaemic stroke, tenecteplase caused significantly less disruption to the 
coagulation and fibrinolytic systems compared to alteplase. This finding was consistent 
with the trend towards a reduced incidence of ICH observed in the ATTEST trial. The early 
significant rise of FDP was associated with the occurrence of ICH, and it may have a role in 
predicting ICH. 
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Chapter 8 Tenecteplase 
versus Alteplase in acute 
ischaemic stroke: individual 
patient data meta-analysis of 
randomized controlled trials 
8.1. Introduction 
Intravenous thrombolysis for acute ischaemic strokes with rtPA (alteplase) significantly 
improves functional outcomes if given with 4.5 hours from symptom onset315. Alteplase is 
recognised as having a number of limitations as discussed in previous chapters. In clinical 
use, IV alteplase achieves recanalisation in fewer than 50% of patients319, with especially 
limited efficacy for larger volume occlusions in major cerebral arteries. While much effort 
has been expended on clinical trials to extend the treatment time window or the clinical 
indications for alteplase423-425, better pharmacological revascularisation strategies may 
offer significant benefits for the large proportion of patients who present in the current 
treatment time window. Tenecteplase283 demonstrated improved clot lysis, faster 
recanalisation, and a lower bleeding risk compared with alteplase in a rabbit carotid 
thrombosis model284. In acute myocardial infarctions, tenecteplase290 showed superior 
safety compared to alteplase with no difference in efficacy. 
A small number of preliminary studies have compared tenecteplase and alteplase in 
ischaemic strokes. We undertook a meta-analysis using individual patient data from 
randomised studies to examine the current available evidence for the efficacy and safety 
of tenecteplase compared with alteplase. 
8.2. Methods 
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8.2.1. Search strategy 
A comprehensive internet search was conducted using the MEDLINE, Embase, Cochrane 
databases and clinicaltrials.gov using the term “tenecteplase” (search year 1996-2014). 
The search was then refined by combining these with the terms “stroke”, or 
“cerebrovascular accident”. The latest search was performed in December 2014. By 
reading titles and abstracts, we selected the completed randomised studies. We also 
searched the reference lists of these articles for additional articles. Non-randomised 
studies were not included in analysis. 
8.2.2. Data extraction 
Study principal investigators were contacted to request individual patient data from the 
studies selected. A standardised form was developed for data extraction. Authors were 
contacted for any additional information and clarification. The primary outcome was 
defined as an excellent functional outcome at three months; secondary outcomes 
included a good functional outcome and the mRS shift test at three months, and early 
neurological improvement at 24 hours as efficacy outcomes, as well as safety outcomes 
of ICH, SICH and mortality at three months. 
We defined an excellent functional outcome at three months as an mRS 0-1; a good 
functional outcome as an mRS 0-2; early neurological improvement at 24 hours as an 
improvement on the NIHSS of 8 or more points, or where the NIHSS score was 0 or 1 at 24 
hours post-treatment. ICH was defined as being any intracerebral haemorrhage on 
follow-up CT post-thrombolysis. We defined SICH as being the presence of a PH2 
according to the ECASS 2 radiological classification for ICH311 accompanied by a clinical 
deterioration of four  points or more in the NIHSS score if available, or used the 
investigator-reported SICH if original CT data were not available for review. 
8.2.3. Statistical analyses 
All analyses were performed on an intention-to-treat basis using all randomised patients 
in the selected studies. Since some studies examined more than one dose tier of 
tenecteplase194,327, we compared the effect size in each dose group against the entire 
alteplase control group. We first performed traditional meta-analysis using the 
DerSimonian-Laird test, and used the Breslow-Day test to evaluate the heterogeneity 
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between studies with I² for inconsistency. Random effects models were undertaken to 
account for study heterogeneity. Outcomes were expressed as OR and their 95% CI. 
An individual patient data analysis was then performed using a random effects logistic 
regression model, and an ordinal regression model adjusting for study, age, OTT, and the 
baseline NIHSS score. Group level meta-analysis was performed with StatDirect; 
individual patient data meta-analysis was conducted with SAS 9.3. 
8.3. Results 
8.3.1. Studies and patients 
Seven studies investigating the use of tenecteplase in stroke treatment were identified. 
Five of these were excluded, one being a single arm dose escalation study325, 
three326,328,426 being non- randomised comparisons, and one427 has not started 
recruitment. Three completed randomised studies194,327,411 were included in the analysis, 
with a total of 291 patients. 
8.3.2. Comparative analysis of the studies 
8.3.2.1. Eligibility criteria 
The design features and key characteristics of the study populations are described in 
Table 8-1. Only one trial was double blind; the other two used a PROBE design. Imaging 
methods dictated trial populations, with the ATTEST study including only supratentorial 
strokes due to the limited coverage of CTP, and Parsons and colleagues used imaging 
based selection to identify a responder population. 
None of the three studies applied an upper age limit. Haley et al did not have a minimal 
NIHSS score limit, but did require significant neurological deficits such as language or 
motor deficit if the score was 1 at baseline. No maximum NIHSS score was exclusionary in 
this study. Similarly, the ATTEST study allowed the inclusion of patients with an NIHSS 
score between 1 and 25. Parsons et al required a minimal NIHSS score of 4 or above for 
study entry. The ATTEST study and Parsons et al also required a pre-stroke estimated 
functional independence (mRS 0-2) for study entry. 
While studies varied in the application of guideline or licence contraindications, all three 
shared common exclusion criteria, including ICH on baseline NCCT, contraindications for 
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thrombolysis such as recent surgery, trauma, bleeding disorders, haemostasis problems 
and a high baseline blood pressure. 
8.3.2.2. Study treatment 
All studies used the standard dose of alteplase (0.9mg/kg to a maximum of 90mg, 10% of 
dose as the initial bolus, followed by a one-hour infusion with 90% of dose) as the 
comparator. Haley et al examined three different dose tiers of tenecteplase (0.1mg/kg, 
0.25mg/kg, and 0.4mg/kg) using an adaptive sequential design scoring each dose 
according to the occurrence of early neurological improvement at 24 hours and SICH. The 
0.4mg/kg dose was eliminated early in the study with only 19 patients in this group 
because it met the pre-specified criterion for elimination of unpromising performance (a 
score of six fewer units than the dose group with the leading score). When the study 
terminated prematurely due to slow recruitment, there were 31 patients respectively in 
the 0.1mg/kg, 0.25mg/kg and alteplase groups. Two tier doses of tenecteplase were 
tested in Parsons et al (0.1mg/kg and 0.25mg/kg), while the ATTEST study examined only 
0.25mg/kg. 
8.3.2.3. Outcome measures 
The primary outcome differed in each study. Haley et al terminated prematurely while 
the primary end-point remained the occurrence of early neurological improvement and 
SICH: the original plan to compare three month functional outcomes for the selected 
tenectplase dose did not proceed. The co-primary endpoint of the proportion of 
reperfused perfusion lesion measured by perfusion weighted MRI and the extent of 
neurological improvement at 24 hours in the NIHSS score was used by Parsons et al. The 
ATTEST study compared penumbral salvage at 24-48 hours using the baseline CT 
perfusion, defined as the perfusion lesion minus the final infarct volume on the follow-up 
CT. 
Clinical outcome measures (NIHSS scores at baseline and 24 hours, three month mRS, 
mortality) were common to all three studies. All studies recorded the ICH incidence on 
follow-up CT at 24-54 hours post treatment, but different definitions of SICH were 
applied. Recanalisation status, penumbral salvage and infarct volumes at 24 hours were 
additionally available for two studies. 
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8.3.2.4. Heterogeneity in baseline characteristics 
Consistent with different selection criteria, baseline demographics varied significantly 
across the three studies (Table 8-1), notably for OTT (p<0.001) and the baseline NIHSS 
scores (p<0.001). There were nine subjects with a baseline mRS of 3-4 in Haley et al. No 
differences were found in age and the main co-morbidities, except for the proportion of 
patients with hypertension or previous stroke/TIA. In the two studies with baseline 
perfusion imaging, ischaemic core volumes did not differ, but the median penumbra 
volume was larger in Parsons et al (79ml, IQR 56-100 vs 53ml, IQR 0-110; p=0.008). 
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Table 8-1. Studies included in the meta-analysis and comparison of key baseline characteristics.  
 Haley et al
327
 (2010) Parsons et al
194
 (2012) ATTEST
411
 (2015) Combined 
TNK Alteplase 
Study characteristics 
Treatment arms 
Active vs control 
TNK# 0.1mg/kg vs 0.25mg/kg 
vs 0.4mg/kg vs alteplase 
0.9mg/kg 
TNK 0.1mg/kg vs 0.25mg/kg vs 
alteplase 0.9mg/kg 
TNK 0.25mg/kg vs alteplase 
0.9mg/kg 
  
Double blind Yes Blinded endpoints Blinded endpoints   
Number 31 vs 31vs 19 vs 31 25 vs25 vs 25 52 vs 52 183 108 
Key inclusion criteria NIHSS>0; 
If NIHSS=1, requires 
significant deficit; 
Symptoms onset <3 hours 
First stroke ( not brain stem stroke); 
NIHSS≥4; 
Symptoms onset <6 hours; 
mRS 0-2; 
Core volume< 1/3 of MCA or 1/2 
ACA/PCA territory; 
Perfusion volume > 120% core , and 
≥20mls; 
Occlusion of MAC/ACA/PCA. 
Supertentorial stroke, 
NIHSS 1-25; 
Symptoms onset <4.5 hours; 
mRS 0-2. 
 
  
Key difference in exclusion criteria Stroke in previous 3 months; 
Seizures at the onset of 
stroke. 
Stroke in previous 3 months; 
eGFR<15mls/min; 
Contraindication for MRI. 
Recent stroke on NCCT; 
Hypodensity of >1/3 of the 
MCA territory; 
ASPECT score ≤4; 
Glucose >18mmol/L; 
eGFR<30mls/mins; 
Allergy to Iodinated contrast. 
  
Definition of SICH  Any clinically important 
neurological worsening 
attributable to new 
hemorrhage by independent 
neurology adjudication 
SITS-MOST
318
¤ SITS-MOST; 
ECASS 2
311
§. 
  
Demographics and Clinical Characteristics 
Age Year (mean±SD) 
P=0.69* 
70±17 71±10 70±12 69±14 71±13 
Male n (%) 58 (52) 38 (51) 65 (63) 100 (55) 61 (56) 
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P=0.18* 
Baseline NIHSS (Median, IQR) 
P<0.001* 
10(5-16) 15(12-16) 11(8-18) 12 (7-16) 12 (8-17) 
OTT mins (mean±SD) 
P<0.001* 
141±28 176±46 176±46 167±43 170±50 
Current Smoker n (%) 
P=0.07* 
16 (14) 15 (20) 27 (26) 38(21) 20 (19) 
Hypertension n (%) 
p<0.001* 
89 (80) 47 (63) 50 (48) 121 (66) 65 (60) 
Atrial Fibrillation n (%) 
P=0.22* 
27 (24) 28 (37) 33 (32) 56 (31) 32 (30) 
Hyperlipidaemia n (%) 
p=0.89* 
56 (50) 37 (49) 53 (51) 96 (52) 50 (46) 
Previous Stroke/TIA n (%) 
p<0.001* 
2 (2) 0 25 (24) 16 (9) 11 (10) 
Diabetes n (%) 
p=0.7* 
21 (19) 15 (20) 16 (15) 40 (22) 12 (11) 
Blood Glucose mmol/L (mean±SD) 
P=0.91* 
 6.9±1.7 7±1.9 6.9±1.7 6.9±2 
Imaging Characteristics ( TNK=104, alteplase=79) 
Ischaemic core volume ml 
(median, IQR) 
P=0.5* 
 15(12-16) 15(12-16) 10 (3-23) 13 (4-28) 
Penumbra volume ml 
(median, IQR) 
P=0.008* 
 79(56-100) 53(0-110) 73 (43-
106) 
59 (23-
101) 
Vessel occlusion n (%) 
P<0.001* 
 72 (96) 73 (70) 83 (80) 61 (77) 
Large vessel occlusion n (%) 
P<0.001* 
 58 (77) 49 (47) 66 (63) 41 (52) 
*P values quoted were from ANOVA analysis (continuous variables), and Chi Square test (categorical variables) between studies; OTT=Onset-to-treatment time; 
NIHSS=National Institutes of Health Stroke Scale; TNK=tenecteplase; TIA=Transient Ischaemic Attack; NCCT=Non-Contrast Computed Tomography; eGFR=Estimated 
Glomerular filtration rate; ASPECT score=Alberta Stroke Programme Early CT Score; ¤ PH type 2 or PH remote type 2 on 24-48 hours Non-contrast CT post treatment, 
plus neurological deterioration defined by increase of NIHSS score by 4 or more points; § any ICH on follow-up NCCT with clinical deterioration. 
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8.3.3. Meta-analysis results 
Of 291 patients randomised, 108 were allocated to 0.25mg/kg TNK, 56 to 0.1mg/kg TNK, 
19 to 0.4mg/kg TNK and 108 to standard dose alteplase. 
8.3.3.1. Group level data 
The detailed results for the comparison between alteplase treated patients and those 
who received one of the three dose tiers of tenecteplase respectively are summarised in 
Figure 8-1. 
The 0.25mg/kg TNK group showed a significantly greater odds ratio to achieve early 
neurological improvement at 24 hours with an odds ratio for the combined data of 3.4 
(95% CI, 1.6-7.4, P=0.002). The excellent (OR=1.8, 95% CI, 0.9-3.4, P=0.08) or good (OR=2, 
95% CI, 0.6-6.3, P=0.26) functional outcome at three months, the risk of ICH (OR=0.6, 95% 
CI, 0.3-1.3, P=0.2), SICH (OR=0.6, 95% CI, 0.2-2.1, P=0.39), and the mortality rate at three 
months (OR=0.9, 95% CI, 0.4-2, P=0.89) were not significantly different between patients 
treated with 0.25mg/kg TNK and alteplase. No significant heterogeneity was detected in 
these three studies in all outcomes with I2 for inconsistency ranging from 0-36.1%, except 
for good functional outcomes (p=0.02, I2=73.8%, 95%CI 0-90.1%). 
No significant differences were found in any outcome between 0.1mg/kg TNK and 
alteplase treated patients. 
Only 19 patients received TNK 0.4mg/kg and outcomes did not differ from alteplase
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 Tenecteplase Alteplase  Odds Ratio 
Study Event Total Event Total M-H, 
Random, 95% 
Excellent Functional Outcome (mRS 0-1) at 3 months  
 0.1mg/kg     
Haley 2010 14 31 12 31 1.3 (0.4, 4) 
Parsons 2012 9 25 10 25 0.8 (0.2, 3.1) 
Subtotal (95%CI)  56  56 1.1 (0.5, 2.3) 
 0.25mg/kg     
Haley 2010 15 31 12 31 1.5 (0.5, 4.6) 
Parsons 2012 18 25 10 25 3.9 (1, 15) 
ATTEST 2015 13 52 11 52 1.2 (0.5, 3.5) 
Subtotal (95%CI)  108  108 1.8 (0.9, 3.4) 
 0.4mg/kg     
Haley 2010 6 19 12 31 0.7 (0.2, 2.8) 
Subtotal (95%CI)  19  31 0.7 (0.2, 2.4) 
Good Functional Outcome (mRS 0-2) at 3 months  
 0.1mg/kg     
Haley 2010 17 31 13 31 1.7 (0.6, 5.2) 
Parsons 2012 15 25 11 25 1.9 (0.5, 6.8) 
Subtotal (95%CI)  56  56 1.8 (0.8, 3.8) 
 0.25mg/kg     
Haley 2010 18 31 13 31 1.9 (0.6, 5.9) 
Parsons 2012 21 25 11 25 6.7 (1.5, 33.5) 
ATTEST 2015 17 52 20 52 0.8 (0.3, 1.9) 
Subtotal (95%CI)  108  108 2 (0.6, 6.3) 
 0.4mg/kg     
Haley 2010 9 19 13 31 1.3 (0.3, 4.6) 
Subtotal (95%CI)  19  31 1.3 (0.4, 3.9) 
Early Neurological Improvement  
 0.1mg/kg     
Haley 2010 9 31 7 31 1.4 (0.4, 5.2) 
Parsons 2012 11 25 9 25 1.4 (0.4, 5.1) 
Subtotal (95%CI)  56  56 1.4 (0.6, 3.1) 
 0.25mg/kg     
Haley 2010 14 31 7 31 2.8 (0.8, 10) 
Parsons 2012 21 25 9 25 9.3 (2.1, 47.2) 
ATTEST 2015 21 52 12 52 2.3 (0.9, 5.8) 
Subtotal (95%CI)  108  108 3.4 (1.6, 7.4) 
 0.4mg/kg     
Haley 2010 5 19 7 31 1.2 (0.3, 5.5) 
Subtotal (95%CI)  19  31 1.2 (0.3, 4.6) 
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Figure 8-1. Effect of Tenecteplase (all doses) compared with alteplase in all efficacy and safety outcomes in a traditional meta-analysis. 
SICH       
 0.1mg/kg     
Haley 2010 0 31 2 31 0.2 (0, 5.3) 
Parsons 2012 1 25 3 25 0.3 (0.01, 4.2) 
Subtotal (95%CI)  56  56 0.3 (0.04, 1.6) 
 0.25mg/kg     
Haley 2010 2 31 2 31 1 (0.07, 14.7) 
Parsons 2012 1 25 3 25 0.3 (0.01, 4.2) 
ATTEST 2015 1 52 2 52 0.5 (0.01, 9.8) 
Subtotal (95%CI)  108  108 0.6 (0.2, 2.1) 
 0.4mg/kg     
Haley 2010 3 19 2 31 2.7 (0.3, 35) 
Subtotal (95%CI)  19  31 2.7 (0.4, 18) 
Any ICH  
 0.1mg/kg     
Haley 2010 0 31 4 31 0.1 (0, 1.5) 
Parsons 2012 8 25 12 25 0.5 (0.1, 1.9) 
Subtotal (95%CI)  56  56 0.4 (0.1, 1.3) 
 0.25mg/kg     
Haley 2010 6 31 4 31 1.6 (0.3, 8.7) 
Parsons 2012 7 25 12 25 0.4 (0.1, 1.6) 
ATTEST 2015 7 52 15 52 0.4 (0.1, 1.1) 
Subtotal (95%CI)  108  108 0.6 (0.3, 1.3) 
 0.4mg/kg     
Haley 2010 5 19 4 31 2.4 (0.4, 14) 
Subtotal (95%CI)  19  31 2.4 (0.6, 10.4) 
Mortality at 3 months  
 0.1mg/kg     
Haley 2010 2 31 8 31 0.2 (0.02, 1.2) 
Parsons 2012 3 25 3 25 1 (0.1, 8.3) 
Subtotal (95%CI)  56  56 0.4 (0.09, 2.2) 
 0.25mg/kg     
Haley 2010 7 31 8 31 0.8 (0.2, 3.1) 
Parsons 2012 1 25 3 25 0.3 (0.01, 4.2) 
ATTEST 2015 8 52 6 52 1.4 (0.4, 5.3) 
Subtotal (95%CI)  108  108 0.9 (0.4, 2) 
 0.4mg/kg     
Haley 2010 3 19 8 31 0.5 (0.08, 2.7) 
Subtotal (95%CI)  19  31 
 
0.5 (0.1, 2.4) 
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8.3.4. Individual patient data analysis (Figure 8-2) 
8.3.4.1. Comparison of tenecteplase and alteplase 
We performed pooled analysis using random effects logistic regression and ordinal regression 
models. Individual studies were treated as an independent variable for adjustment, as were other key 
prognostic variables including age, OTT and baseline NIHSS scores. Imaging variables were not 
included, since these were only available in two studies. 
TNK 0.25mg/kg treated patients had greater odds of early neurological improvement (OR [95%CI] 3.3 
[1.5, 7.2], p=0.093). Other outcomes, including mRS shift analysis (Figure 8-3), did not differ 
significantly from alteplase. Other tenecteplase doses did not differ significantly from alteplase for 
any end-point.
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 Figure 8-2. Pooled analysis comparing efficacy and safety outcomes between tenecteplase and alteplase treated patients using random effect logistic 
and ordinal regression models adjusted for studies, baseline NIHSS score, Onset-to-treatment Time and age. 
 Tenecteplase 
(event/total) 
Alteplase 
(event/total) 
 
 
 
 
 
 
 
 
Odds Ratio (95%CI) 
Excellent Functional 
Outcome at 3 months 
0.1 mg/kg (23/56) 33/108 0.7 (0.3, 1.9) 
0.25mg/kg (46/108) 33/108 1.9 (0.8, 4.4) 
0.4 mg/kg (6/19) 33/108 0.4 (0.09. 2.2) 
Good Functional 
Outcome at 3 months 
0.1 mg/kg (32/56) 44/108 1.5 (0.5, 4.7) 
0.25mg/kg (56/108) 44/108 1.9 (0.5, 7.2) 
0.4 mg/kg (9/19) 44/108 1.2 (0.3, 5.3) 
mRS at 3 months 
(Ordinal shift) 
0.1 mg/kg (56) 108 1.2 (0.6, 2.4) 
0.25mg/kg (108) 108 1.4 (0.5, 4.3) 
0.4 mg/kg (19) 108 0.9 (0.3, 2.6) 
Early Neurological 
Improvement 
0.1 mg/kg (20/56) 28/108 1.5 (0.6, 3.4) 
0.25mg/kg (56/108) 28/108 3.3 (1.5, 7.2) 
0.4 mg/kg (5/19) 28/108 1.3 (0.3, 5) 
SICH 0.1 mg/kg (1/56) 7/108 0.2 (0.02, 2) 
0.25mg/kg (4/108) 7/108 0.7 (0.2, 2.5) 
0.4 mg/kg (3/19) 7/108 6.2 (0.7, 56.3) 
Any ICH 0.1 mg/kg (8/56) 31/108 0.2 (0.03, 2.1) 
0.25mg/kg (20/108) 31/108 0.6 (0.2, 1.8) 
0.4 mg/kg (5/19) 31/108 4.6 (0.9, 24.3) 
Mortality at 3 months 
 
0.1 mg/kg (5/56) 17/108 0.5 (0.1, 1.8) 
0.25mg/kg (16/108) 17/108 1.1 (0.5, 2.5) 
0.4 mg/kg (3/19) 17/108 1.1 (0.2, 5.8) 
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Figure 8-3. Distribution of Modified Rankin scale at 90 days for patients treated with tenectepkase 0.25 mg/kg and alteplase. 
 203 
 
Figure 8-4. Pooled analysis comparing efficacy and safety outcomes between tenecteplase 0.25mg/kg and 0.1mg/kg treated patients using random 
effect logistic and ordinal regression models adjusted for studies, baseline NIHSS score, Onset-to-treatment Time and age.
0.1 1 10 
Mortality at 3 months 1.4 (0, 55.7) 
Any ICH 5.6 (0.1, 528.5) 
SICH 3.1 (0.3, 34.5) 
Early Neurological Improvement 3.5 (1, 11.7) 
mRS at 3 months (Ordinal Shift) 1.5 (0.3, 7.5) 
mRS 0-2 at 3 months 2 (0.9, 4.6) 
mRS 0-1 at 3 months 2.5 (0.8, 7.5) 
TNK better Alteplase better 
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8.3.4.2. Comparison of TNK dose 0.25mg/kg and 0.1mg/kg (Figure 8-4) 
We compared the efficacy and safety of TNK 0.1mg/kg and 0.25mg/kg using the same outcomes. We 
did not include 0.4mg/kg TNK in the comparison due to the small sample size. No significant 
differences were observed between these doses, although point estimates of efficacy suggest that 
the 0.25mg/kg dose was associated with a greater probability of improvement at 24 hours (OR 
[95%CI] 3.5 [1, 11.7], P=0.29), and excellent functional outcomes (mRS 0-1) at three months (OR 
[95%CI] 2.5 [0.8, 7.5], P=0.36). 
8.3.5.  Individual patient data analysis using Haley et al and the ATTEST study only 
(Figure 8-5) 
There is no significant difference in all outcomes between patients treated with TNK 0.25mg/kg and 
alteplase, except that TNK 0.25mg/kg has a greater likelihood of achieving early neurological 
improvement compared with alteplase (OR 2.4, 95%CI 1.4-4.7, p=0.24). 
The 0.1mg/kg dose was not analysed, since it was only studied in Haley et al.
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 Figure 8-5. Comparison of TNK 0.25mg/kg and alteplase using Haley et al and ATTEST data only
 Tenecteplase 
(event/total) 
Alteplase 
(event/total) 
 
 
 
 
 
 
 
 
Odds Ratio 
(95%CI) 
Excellent Functional 
Outcome at 3 months 
28/83 23/83 1.3 (0.6, 2.7) 
Good Functional 
Outcome at 3 months 
35/83 33/83 1.0 (0.5, 2) 
mRS at 3 months 
(Ordinal shift) 
83 83 0.9 (0.5, 1.6) 
Early Neurological 
Improvement 
35/83 19/83 2.4 (1.2, 4.7) 
SICH 3/83 4/83 0.9 (0.2, 4.5) 
Any ICH 13/83 19/83 0.8 (0.1, 8.2) 
Mortality at 3 months 
 
15/83 14/83 
 
 
 
1.4 (0.5, 3.4) 
 
 
 
 
 
 
 
 
 
1 
 0.1  1  10 
TNK better Alteplase better 
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8.3.6. Discussion 
Both conventional meta-analysis using group level data and individual patient data analysis showed a 
greater likelihood of early major neurological improvement with tenecteplase 0.25mg/kg, and point 
estimates suggested a potentially greater likelihood of functional independence at 90 days. Point 
estimates for clinical outcomes were, in contrast, neutral for both 0.1mg/kg and 0.4mg/kg doses. 
Experience with tenecteplase in acute stroke remains limited, however, with fewer than 300 patients 
contributing to the randomised controlled trial data. Comparisons of different dose tiers are 
therefore very limited, particularly for the 0.4mg/kg TNK dose group. 
While our analyses support the possible existence of a dose-dependent ICH risk, the small numbers of 
outcome events mean that no analysis achieves statistical significance. The evaluation of the 
0.4mg/kg dose was very limited, with only 19 patients receiving this dose prior to termination of this 
dose level. While the estimated higher ICH risk of 0.4mg/kg TNK compared with alteplase is non-
significant, the unfavourable point estimate likely contributed to the elimination of this dose in the 
relevant trial due to the combination of efficacy and safety factors. Further trial data with this dose 
will be important in order to test this association more rigorously. 
Historically, dose escalation studies in stroke thrombolysis included only small numbers in each 
tier325,332,428,429. The ascending dose design produced a bias towards early dose abandonment on the 
basis of incident ICH since investigators expect greater risk as the trial progressed. Early rtPA 
trials280,310 explored only a narrow range of alteplase doses, and abandoned dose escalation on the 
basis of a small number of ICH events. Efforts to select the optimal tenecteplase dose were 
methodologically rigorous, but premature trial discontinuation limits the reliability of dose 
selection,327 and likely contributes to the variability of doses being investigated in current and 
upcoming tenecteplase studies. Availability of individual patient data allowed us to apply common 
definitions for outcomes (with the exception of SICH) and also to adjust for heterogeneous onset-to-
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treatment time and baseline stroke severity. The selection of patients with an imaging-defined target 
profile (favourable penumbra: core ratio, small core, and intracranial vessel occlusion) in Parsons et 
al, may have resulted in overestimation of the overall ORs for efficacy outcomes, although the 
heterogeneity analysis was not significant across studies. When adjusted for baseline prognostic 
variables including individual study in the pooled analysis of all three studies, or only Haley et al and 
the ATTEST study, the results were similar. 
Advanced imaging characterisation of acute stroke may identify heterogeneity that is not captured 
adequately by clinical variables, and further exploration of imaging-characterised populations in the 
ATTEST study and Parsons studies may be informative. 
Currently three204,330,430ongoing studies are investigating the use of teneteplase in acute ischaemic 
stroke, using either 0.25mg/kg or 0.4mg/kg TNK dose. The ongoing study of tenecteplase versus 
alteplase for thrombolysis in acute ischaemic stroke330 (NOR-TEST) (NCT01949948) (clinicaltrials.gov) 
chose 0.4mg/kg and will thus provide more data for this dose when completed. Other ongoing 
studies have chosen 0.25mg/kg. The TNK–Tissue-Type Plasminogen Activator Evaluation for Minor 
Ischemic Stroke With Proven Occlusion (TEMPO-1)329 trial suggested that both 0.1mg/kg and 
0.25mg/kg TNK were safe in treating minor strokes with intracranial occlusion within 12 hours of 
symptom onset. TEMPO-2430 will randomise patients fulfilling the same criteria to 0.25mg/kg TNK or 
placebo. Similarly, the Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation (TASTE)204 
trial is comparing 0.25mg/kg TNK and alteplase in an imaging-selected group, whereas the ATTEST-2 
study will examine the same dose in all thrombolysis eligible patients on the basis of non-contrast CT 
alone. The data of over 2000 patients will be available when these three studies are complete. Dose 
selection is influenced by the trial populations, since in minor stroke (eg TEMPO-2) safety may be a 
more compelling basis for dose selection than for major stroke where efficacy considerations may 
dominate. 
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8.3.7. Conclusions 
Tenecteplase 0.25mg/kg was associated with greater odds of early major neurological improvement 
and a trend for better functional outcome at three months. Further investigation of tenecteplase in 
acute ischaemic stroke patients is warranted. 
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Chapter 9 Tenecteplase versus 
alteplase in acute ischaemic 
stroke: imaging outcomes – an 
individual patient data meta-
analysis 
9.1. Introduction 
Advance imaging in acute ischaemic stroke plays an important role in providing biomarkers and in 
assisting patient selection in many recent studies. In the ATTEST study411, penumbra salvage was 
used as the primary outcome to reduce the sample size. In the Australian tenecteplase study194, 
advance imaging was utilised for both patient selection and in defining one of the co-primary 
endpoints. The clinical outcomes in tenecteplase- and alteplase-treated ischaemic stroke were 
analysed in the pooled analysis reported in Chapter 8. To investigate whether these two 
thrombolytics yield any difference in imaging outcomes, we performed a pooled analysis of the 
imaging outcomes from the two studies using advanced imaging to determine outcome measures. 
9.2. Methods 
9.2.1. Data acquisition 
Study data of the Australian tenecteplase study was acquired as described in Chapter 8. We used the 
investigator’s own data for the imaging variables including baseline CTP lesion volumes, penumbra 
salvaged at 24 hours, final infarct volumes at 24 hours, and baseline occlusion and recanalisation 
status at 24 hours. To acquire additional imaging variables that were absent from their original data, 
the team was contacted for the transfer of the raw study imaging, which was obtained via a secure 
online file sharing system www.box.com. All imaging had previously been anonymised by the 
investigator and studies were only indentified by study numbers. 
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9.2.2. Imaging acquisition 
The imaging procedure for the ATTEST study was discussed in detail in Chapter 3. 
The Australian tenecteplase study194 was a multicentre study. Its baseline imaging included NCCT, 
CTP and CTA. Imaging was performed with multidetector scanners (16- or 64-slice) before 
randomisation. NCCT was followed by CT perfusion imaging, comprising two 60-second series, each 
performed after an intravenous bolus of 40mL of iodinated contrast agent at a concentration of 370 
mg per millilitre, followed by a 40mL saline flush at a rate of 6mL per second. Each perfusion series 
covered an axial section of 24 to 40mm, acquired as adjacent slices of 5 to 8mm. Subsequently, CTA 
was performed from the carotid bifurcation to the top of the lateral ventricles. 
MRI was performed with the use of 1.5 tesla scanners. Standardized sequences were obtained 24 
hours after treatment and included an axial gradient-echo T2-weighted series, a DWI, a PWI, an 
echoplanar spin-echo sequence, a TOF MRA, and a FLAIR sequence. At 90 days, a FLAIR sequence was 
performed for final infarct volume. 
 
9.2.3. Imaging analysis 
The procedure for volumatic analysis and recanalisation for the ATTEST study was described in 
Chapter 3. 
The software MIStar (Apollo Medical Imaging Technology, Melbourne, Australia)373 was used for all 
imaging analysis in both studies. A slightly different tissue status definition was used in the Australian 
study: ischaemic core was defined as the area with a CBF <40% of the contralesional side194, whereas 
the ATTEST study applied additionally a relative DT>2s. The penumbra tissue imaged by both CTP or 
PWI was defined as the area with MTT>145% on the contralesional side194, but the ATTEST study used 
the relative DT>2s definition. 
Additional imaging variables including clot length and collateral flow were assessed by XH. The 
methods are as detailed in Chapter 6. The clot length was measured with a method modified from 
Riedel et al125; and collateral status was assessed using a method modified from Miteff et al81. 
Analyses were performed twice at separate occasions to minimise the risk of error. An average of the 
continuous variable was taken as the final reading, whereas a third reading was carried out on 
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another occasion for the discrepancy in the categorical reading. The result demonstrated on the two 
agreed readings was used as the final reading. 
9.2.4. Outcome measures 
We defined the primary outcome as the percentage of penumbra salvaged at 24 hours. Secondary 
outcomes were infarct growth, final infarct volumes, and the rate of recanalisation at 24 hours. We 
also assessed the length of clot that was recanalised in the two groups. Recanalisation was defined as 
TIMI2-3225,371 on a 24 hour CTA. Good collateral status was defined as collateral flow of good or 
moderate431. The final infarct volume was defined as the total infarct volume measured on NCCT or 
DWI at 24 hours. The calculations of the percentage of penumbra salvage and infarct growth are as 
described in Chapter 3. 
9.2.5. Statistical analysis 
The analysis was performed on the basis of intention-to-treat. All randomised patients were included 
in the analysis. Traditional meta-analysis was performed first using the Dersimonian-Laird test. The 
heterogeneity of the studies was evaluated with Cochran Q. Inconsistency and bias could not be 
assessed as there were too few strata. 
The individual patient data pooled analysis was subsequently carried out with a random effect 
generalised linear model for continuous variables, and with a random effect binary model for 
categorical variables. The random effect model was used to account for the heterogeneity of the two 
studies. The significance level was set at 0.05. Many confounding factors exist that could potentially 
influence the results. The essential imaging ones include the ischaemic core, the baseline occlusion 
site, collateral status, and clot length, in addition to the clinical variables such as age, OTT and the 
baseline NIHSS score. In this analysis, the study itself is also a potential significant confounder due to 
the obvious difference in the study populations. Considering the small sample size, a univariate 
regression model was used to identify the potential imaging confounders. The variable was 
considered to be a confounder if p<0.4 in the univariate regression model. The final confounders 
included in the random effect model were age, OTT, the baseline NIHSS score, and the study. 
Additionally, the ischaemic core, and collaterals were adjusted for in analyses of the percentage of 
penumbral salvage, infarct growth, and final infarct volumes; baseline occlusion site in recanalisation; 
ischaemic core and baseline occlusion site in clot length. Outcomes were expressed as the effect size 
for continuous variables, the odds ratio for categorical variables, and their 95% confidence intervals. 
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Group level meta-analysis was performed with StatsDirect 2.8. Individual patient data meta-analysis 
was performed with SAS 9.3. 
9.3. Results 
9.3.1. Comparative analysis of the studies 
The extent of the differences in patient selection and baseline characteristics were discussed in detail 
in the last chapter, especially the significant difference in the baseline penumbra volumes in the two 
studies. 
No significant difference in clot length and collateral status at baseline was found between the two 
studies (Table 9-1). 
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Table 9-1. The difference in clot length and collateral status in the two studies according to 
study groups 
 Clot Length n (%) mean (SD) mm Good Collaterals n (%), n (%) 
 Parsons et al ATTEST p value Parsons et al ATTEST p value 
TNK 
0.1mg/kg 
9 (36%) 
10 (8) 
  10 (40%) 
7 (28%) 
  
TNK 
0.25mg/kg 
10 (40%) 
13 (13) 
26 (48%) 
13 (11) 0.95 
12 (48%) 
10 (40%) 
37 (69%) 
29 (54%) 0.53 
Alteplase 7 (28%) 
8 (8) 
21 (39%) 
14 (11) 0.1 
8 (32%) 
8 (32%) 
36 (67%) 
27 (50%) 0.18 
 The number (percentage) of imaging that can be evaluated for clot length or collateral status; n 
(%) the number (percentage) of patients with good collaterals; p value for continuous variables was 
derived with independent t test, and Chi-square test for categorical variables. 
 
9.3.2. Group level data 
Since the TNK 0.1 mg/kg dose was only examined in one study, it was not included in the group level 
meta-analysis. The results for TNK 0.25 mg/kg versus alteplase were shown in Table 9-2 and Figure 9-
1 to 9-4. The primary outcome did not differ in the two groups. There was a significant difference in 
the final infarct volume at 24 hours between the two treatment groups, with a standardised mean 
difference of -0.4 (95%CI -0.8- -0.1, p=0.02). The heterogeneity test for final infarct volumes was not 
significant (p=0.25). No difference was found in other outcomes. 
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Table 9-2. Group level analysis for TNK 0.25 mg/kg vs alteplase 
 n Standardised
Mean 
difference 
95%CI 
TNK Alteplase 
Percent of penumbra salvaged (%) 
Parsons et al 25/25 24/25 1 0.4, 1.6 
ATTEST 36/54 36/54 0.2 -0.3, 0.7 
Total 61/79 60/79 0.6 -0.2, 1.3 
p=0.15 
Cochran Q p=0.042 
Final Infarct Volume (mL) 
Parsons et al 25/25 24/25 -0.6 -1, -0.1 
ATTEST 51/54 46/54 -0.3 -0.7, -0.1 
Total 76/79 70/79 -0.4 -0.8, -0.1 
p=0.022 
Cochran Q: p=0.25 
Infarct Growth (mL) 
Parsons et al 25/25 24/25 -0.7 -1.3, -0.1 
ATTEST 51/54 46/54 -0.1 -0.5, 0.3 
Total 76/79 70/79 -0.4 -1, 0.2 
p=0.17 
Cochran Q: p=0.12 
Recanalisation 
Parsons et al 24/25 15/25 11.2 1.2, 525.2 
ATTEST 22/54 25/54 0.8 0.2, 2.6 
Total 46/79 40/79 2.5 0.2, 34.3 
p=0.49 
Cochran Q: p=0.03 
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Figure 9-1. Forest plot comparing the percentage penumbra salvaged (random effect) 
between TNK 0.25 mg/kg and alteplase treated patients 
 
Figure 9-2. Forest plot for final infarct volume at 24 hours (random effect) between TNK 
0.25 mg/kg and alteplase treated patients 
-0.5 0.5 1.0 1.5 2.0 
ATTEST 
Parsons 
 0 
 Standardised mean difference (%) 
TNK better Alteplase better 
-1.3 -0.8 -0.3 0.2 
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 0 
 Standardised mean difference (mL) 
TNK better Alteplase better 
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Figure 9-3. Forest plot for infarct growth at 24 hours (random effect) between TNK 0.25 
mg/kg and alteplase treated patients 
 
Figure 9-4. Forest plot for recanalisation at 24 hours (random effect) between TNK 0.25 
mg/kg and alteplase treated patients 
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9.3.3. Individual patient data analysis (Figure 9-5) 
Patients who had TNK 0.25 mg/kg had a mean 19% (95%CI -11.8, 49.8, p=0.43) more penumbra 
salvaged at 24 hours compared with alteplase treated patients, but without statistical significance. 
No difference was found in other outcomes in these two groups of patients. 
Between TNK 0.1 mg/kg- and alteplase-treated patients, all outcomes were similar between the two 
groups. 
Between patients who received TNK 0.25 mg/kg and those who had TNK 0.1mg/kg, no difference was 
found in any outcomes. 
9.3.4. Mean difference in clot length in recanalised patients 
Within the total 179 patients, 104 achieved recanalisation at 24 hours, of whom 48 had a visible clot 
on NCCT that could be measured (TNK 0.1 mg/kg 5, TNK 0.25 mg/kg 26, alteplase 17). We assessed 
the mean difference in the length of clot that was recanalised at 24 hours between the TNK 0.25 
mg/kg and alteplase groups using the random effect generalised linear model. A non-significant mean 
difference of 4.2 mm (95%CI -2.8, 11.2, p=0.25) was demonstrated. 
Clot length and recanalisation status was available for 65 out of the 179 patients. In a univariate 
binary logistic regression, clot length more than 8mm was inversely correlated with recanalisation 
(p=0.013) (Figure 9-6). When adjusted with confounders age, the baseline NIHSS score, OTT, the 
study, treatment, baseline core and occlusion sites, the statistical significance remained (p=0.018). 
9.4. Discussion 
In this meta-analysis of imaging outcomes from two thrombolysis studies comparing tenecteplase 
and alteplase in the treatment of acute ischaemic stroke, we found a significant reduction in final 
infarct volumes at 24 hours using group level data. However, in the pooled analysis, when adjusted 
for confounders including study, age, the baseline NIHSS score, OTT, ischaemic core volume and 
collaterals, significance could no longer be demonstrated. Using group level data or IPD analysis, the 
primary outcome of percentage of penumbra salvaged at 24 hours did not differ; neither did other 
outcomes including infarct growth and recanalisation. 
Discussion of the heterogeneity among the three RCTs of tenecteplase was presented in Chapter 8. 
Although differences were found in the baseline NIHSS score, and in OTT across the three studies, the 
heterogeneity test did not show any significant differences. Between the ATTEST study and the 
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Australian study, additional differences in penumbra size and baseline vessel occlusion sites were 
evident. When analysing imaging outcomes, significant heterogeneity was demonstrated by the 
Cochran Q test on two outcomes (percentage of penumbra salvaged and recanalisation). When we 
performed the pooled analysis, the difference in the two studies was taken into account by adjusting 
the cofounding variable study, but the results still need to be interpreted carefully due to the 
differences in the two studies. 
In addition, we explored other imaging characteristics including clot length and collateral status. No 
significant difference was found between the two studies. However, the overall rate of hyperdense 
vessel sign was lower in the Australian study (35% vs 45%). The presence of the hyperdense vessel 
sign is associated with poor clinical outcomes432. The lower prevalence of hyperdense vessels in the 
Australian study, the significantly larger penumbra volumes and the absence of carotid occlusion may 
account for the better outcomes in that study compared to the ATTEST study. 
Tenecteplase is more fibrin selective than alteplase, which should translate into better lysis ability. 
We did not find any difference in the mean length of clot that was lysed between tenecteplase 0.25 
mg/kg and alteplase in a small group of patients who achieved recanalisation and had a measurable 
clot length on NCCT. This result flows from a secondary analysis in a small heterogenic group of 
patients. A large sample is required to examine this further. 
In the secondary analysis of the ATTEST study, we did not find any association between clot length 
and the recanalisation rate. In this larger sample, we demonstrated that those with a clot longer than 
8mm on NCCT have significantly less likelihood of recanalisation by IV thrombolysis. This finding is 
consistent with the results from Riedel’s group163. 
The limitations of this study include the small sample size with a total of 179 patients. Furthermore, 
since the analysis was performed for imaging outcomes, there is sizable missing data due to the 
group of patients who had no perfusion lesion (19%) or no occlusion on the baseline CTA (24%) which 
has had an impact on the results of the intention-to-treat analysis. This group of patients was mainly 
from the ATTEST study. The small sample also limited our ability to adjust for essential cofounding 
imaging variables. 
The other important limitation is, as discussed in detail above, the heterogeneity of the two studies 
included. Unfortunately, the design of the few ongoing phase III studies comparing tenecteplase and 
alteplase in the treatment of acute ischaemic stroke remain heterogenetic. NOR-TEST and TASTE 
have different patient selection methods and use different tenecteplase doses, partly as the result of 
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the uncertainty arising from the previous dose selection studies194,325,327. This also reflects the 
evolution in acute stroke research, and the wish to extend the current treatment window to patients 
with wake-up stroke or to those who present late. Future study design should keep this in mind, and 
collaborate in advance for pre-planned meta-analysis. 
9.5. Conclusions 
In the pooled analysis, there was no difference in the percentage of penumbra salvaged or in other 
imaging outcomes between tenecteplase- and alteplase-treated patients in the two phase II studies 
which applied advance imaging. This analysis was limited by the small sample size, missing data and 
significant heterogeneity in the two studies. When designing future phase III studies, this should be 
taken into account or meta-analysis should be pre-planned to achieve better quality evidence.
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Figure 9-5. IPD results for all outcomes (mean difference [95%CI] for continuous variables, and OR [95%CI] for categorical variables) 
-100 -50 0 50 100 150 
Recanalisation 6.2 (0.6, 60.3) 
Infarct growth -18 (-52.7, 16.7)        0.31 
Final infarct volume -31.6 (-98, 34.8)        0.36 
Percent of penumbra salvaged 15.9 (-9.6, 41.4)        0.23 
Recanalisatio
n 
1.5 (0.4, 6) 
Infarct growth 1.9 (-99.6, 103.4)        0.97 
Final infarct volume -6.5 (-48.3, 35.2)        0.76 
Percent of penumbra salvaged 22.7 (-6.3, 51.7)        0.13 
Recanalisation 2.5 (0.1, 49.4)        0.64 
Infarct growth -12 (-74.7, 50.7)        0.77 
Final infarct volume -15 (-44.4, 14.4)        0.59 
Percent of penumbra salvaged 19 (-11.8, 49.8)        0.43 
TNK 0.1 mg/kg vs alteplase 
TNK 0.25 mg/kg vs 0.1 mg/kg 
Mean difference/OR (95%CI) P Value 
TNK 0.25 mg/kg vs alteplase 
TNK better Alteplase better 
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Figure 9-6. Sigmoid plot of the probability of recanalisation depending on clot length 
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Chapter 10 Conclusions 
Twenty years on since the milestone NINDS study280 was published, the recent success of intra-
arterial studies197,198,206-208 has been another significant step in the development of reperfusion 
therapy in hyperacute stroke. However, endovascular intervention only benefits a small group of 
patients with the right imaging profile. Meanwhile, the remaining majority of acute ischaemic stroke 
patients still only have the option of intravenous alteplase, which is advantageous in approximately 
one-third of the population433 if given within three hours. The treatment is associated with 2-3% risk 
of symptomatic ICH315,318. Looking for alternative thrombolytic agent with better efficacy and safety 
profiles is essential in improving the outcomes in those who are not suitable for, or who do not have 
access to IA therapy. 
Alteplase has a short plasma half-life of 4-9 minutes270,274,275. An hour-long infusion is required 
following the initial bolus to maintain the plasma level in acute ischaemic stroke thrombolysis. In 
practice, delay between the bolus and the subsequent infusion is common, which may affect its 
efficacy. 
Tenecteplase283, an improved tPA with better fibrin specificity, slower plasma clearance, resistance to 
PAI-1, and without a procoagulant effect, has been examined in a small number of phase II studies in 
the treatment of acute ischaemic strokes. In a single centre phase II randomised controlled study 
(ATTEST) that compared tenecteplase 0.25mg/kg and standard alteplase in acute ischaemic stroke 
thrombolysis using imaging biomarkers as endpoints, we demonstrated that tenecteplase 0.25 mg/kg 
has a trend toward a lower risk of ICH compared to alteplase, with no difference in the percentage of 
penumbra salvaged at 24 hours post thrombolysis or in clinical outcomes at 90 days. 
In a subset of patients from the ATTEST study, tenecteplase 0.25 mg/kg was shown to give rise to 
minimal disruption to the coagulation and fibrinolytic systems, whereas alteplase caused significant 
hypofibrinogenaemia. This is consistent with the finding from the main study of a possibly reduced 
risk of ICH with tenecteplase 0.25mg/kg. 
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Using advanced imaging to identify candidates who are likely to respond to reperfusion therapy has 
become increasingly popular among investigators. However, studies using this strategy have 
produced mixed results184,194. Much uncertainty around methodology for analysis persists, especially 
in perfusion imaging, and this has hampered the further application of this method. Criteria for 
optimal imaging characteristics differ in different centres. In further analysis of the imaging data from 
the ATTEST study patients, we found that using different tissue definitions for penumbra and core 
significantly altered the mismatch ratio. This highlighted one of the potential problems that 
multicentre imaging selection studies face where there may be no consensus as to tissue definition, 
and where post processing software may not be in place. 
The uncertainty in imaging selection study was further evidenced by analysing our subgroup of 
patients who fulfilled the selection criteria applied in Parsons et al.194; no difference was 
demonstrated in patients who received tenecteplase or alteplase. 
To date, including the ATTEST study, three phase II randomised controlled studies which have 
compared tenecteplase and alteplase have been completed. The methodologies of the three studies 
are different, which resulted in significant differences in baseline patient characteristics including the 
baseline NIHSS score and OTT. In the two studies which acquired advance imaging, further 
differences in imaging characteristics were demonstrated. However, the individual patient data meta-
analysis suggested that tenecteplase gave rise to potentially better efficacy, especially with the dose 
0.25mg/kg, with a similar SICH risk. In the pooled analysis of the imaging data from the ATTEST study 
and Parsons et al194, no differences in the percentage of penumbra salvaged or recanalisation rates at 
24 hours were found. 
Based on the above information, a phase III study to compare tenecteplase and alteplase in the 
treatment of acute ischaemic strokes is warranted. The design of the future phase III study should 
include all patients who are suitable for thrombolysis based on current guidelines, in order for the 
generalisation of the study results. Since it will be a multicentre study, a NCCT based study is more 
practical and will avoid some potential problems in using advance imaging for recruitment as 
discussed. Similarly, the primary outcome should be clinical outcomes, such as mRS at 90 days. 
However, bias is still possible as patients presenting with severe stroke are likely to undergo 
endovascular intervention in some centres rather than receiving intravenous thrombolysis. Efforts 
should be made to select participating centres carefully, in order to minimise this bias. 
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Appendices 
A.1. National Institute of Health Stroke Scale 
Instructions Scale definition 
1a. Level of consciousness 0=Alert 
1=Not alert, but arousable with minimal 
stimulation 
2=Not alert, requires repeated stimulation 
to attend 
3=Coma 
1b. LOC questions 0=Answers both questions correctly 
1=Answers one question correctly 
2=Answers neither question correctly 
1c. LOC commands 0=Performs both tasks correctly 
1=Performs one task correctly 
2=Performs neither task correctly 
2. Best gaze 0=Normal 
1=Partial gaze palsy 
2=Forced deviation 
3. Visualfield 0=No visual loss 
1=Partial hemianopia 
2=Complete hemianopia 
3=Bilateral hemianopia 
4. Facial Palsy 0=Normal symmetrical movement 
1=Minor paralysis (asymmetry on smiling) 
2=Partial paralysis (total or near total of 
lower face) 
3=Complete paralysis of one or both sides 
5. Motor arm 
5a. Left arm 
5b. Right arm 
0=Normal 
1=Drift 
2=Some effort against gravity 
3=No effort against gravity 
4=No movement 
UN=Untestable 
6. Motor leg 
6a. Left leg 
6b. Right leg 
0=Normal 
1=Drift 
2=Some effort against gravity 
3=No effort against gravity 
4=No movement 
UN=Untestable 
7. Limb ataxia 0=Normal 
1=Present in one limb 
2=Present in two limbs 
UN=Untestable 
8. Sensory 0=Normal 
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1=Mild to moderate decrease in sensation 
2=Severe to total sensory loss 
9. Best language 0=No aphasia 
1=Mild to moderate aphasia 
2=Severe aphasia 
3=Mute, global aphasia  
10. Dysarthria 0=Normal articulation 
1=Mild to moderate slurring of words 
2=Near unintelligible or unable to speak 
UN=Intubated or other physical barrier 
11. Extinction and inattention 0=Normal 
1=Inattention or extinction to bilateral 
simultaneous stimulation in one of the 
sensory modality 
2=Severe hemi-inattention to more than 
one modality 
 
A.2.  Consent forms 
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Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) – Pilot 
Phase 
CONSENT FORM 
         
      Please initial box 
 
I confirm that I have read and understand the information sheet dated 2011 (version 1) for 
the above study and have had the opportunity to ask questions 
 
  
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
  
I understand that sections of any of my medical notes may be looked at by local 
researchers or from regulatory authorities where it is relevant to my taking part in 
research.  I give permission for these individuals to have access to my records. 
 
  
I understand that anonymous data from the study, including CT scans, may be shared with 
other researchers. I give permission for data to be used in this way. 
 
  
I give my permission for the study doctor to contact my GP to inform him/her of my 
participation in this study 
 
 
 
  
I agree to take part in the above study.   
 
 
 
 
________________________ ________________        ____________________ 
Name of Patient (Print name) Date Signature 
 
 
_________________________ ________________       ____________________ 
Name of Person taking consent Date      Signature 
(if different from researcher) 
 
 
_________________________ ________________       ____________________ 
Researcher (Print name) Date Signature 
 
 227 
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) – Pilot Phase   
FORM OF ASSENT for RELATIVES 
Chapter 11 Please initial box 
I confirm that I have read and understand the information sheet dated 2011 (version 1) for 
the above study and have had the opportunity to ask questions 
 
  
I understand that my relative’s participation is voluntary and that I am free to withdraw 
them at any time, without giving any reason, without their medical care or legal rights 
being affected. 
 
  
I understand that sections of any of my relative’s medical notes may be looked at by local 
researchers or from regulatory authorities where it is relevant to their taking part in 
research.  I give permission for these individuals to have access to their records. 
 
  
I understand that anonymous data from the study, including CT scans, may be shared with 
the other researchers. I give permission for my relative’s data to be used in this way. 
 
  
I give my permission for the study doctor to contact my relative’s GP to inform him/her of 
their participation in this study 
 
 
  
I agree that my relative will take part in the above study.   
 
 
I am the nearest relative/ welfare guardian of the patient named below and I can confirm that 
there is neither a nearer relative or welfare guardian to the same said patient.  
 
________________________ ____________________ 
Name of Patient (Print name) Relationship to Patient 
  
________________________ ________________        ____________________ 
Name of Relative (Print name) Date Signature 
 
 
_________________________ ________________       ____________________ 
Name of Person taking consent Date      Signature 
(if different from researcher) 
 
 
_________________________  ________________       ____________________  
Researcher (Print name)  Date    Signature 
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Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) – Pilot Phase  
FORM OF CONSENT to Continuing Participation 
         
      Please initial box 
 
I confirm that I have read and understand the information sheet dated 2011 (version 1) for 
the above study and have had the opportunity to ask questions 
 
  
I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
  
I understand that sections of any of my medical notes may be looked at by local 
researchers or from regulatory authorities where it is relevant to this research study.  I 
give permission for these individuals to have access to my records. 
 
  
I understand that data from the study, including scans, may be shared with the 
international MR Stroke Collaborative Group researchers. I give permission for my data to 
be used in this way. 
 
  
I give my permission for data already collected for this study to be used for all study 
purposes. 
 
 
  
I agree to my continued involvement in the above study.  
 
 
 
  
________________________ ________________        ____________________ 
Name of Patient (Print name) Date Signature 
 
 
_________________________ ________________       ____________________ 
Name of Person taking consent Date      Signature 
(if different from researcher) 
 
 
_________________________  ________________       ____________________  
Researcher (Print name)  Date    Signature 
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